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anatomical orientation of the origin of the fluorescent signal. Overall, important 
factors varying between all produced nir imaging systems are wavelength of the 
excitation light, internal optics, usability and costs. No widely used fluorescence im-
aging standard is yet available resulting in difficulties to compare performance of 
imaging devices in an objective manner9. 
 
clinical indications
Sentinel lymph node mapping  A  The sentinel lymph node (sln) pro-
cedure can be improved by using nir fluorescence igs2. Currently, sln mapping is 
performed by a peritumoral injection of a radiotracer and/or blue dye. The radioac-
tive tracer is injected the day before surgery, after which slns can be detected using 
Single Photon Emission Computed Tomography (spect)/ct or lymphoscintigra-
phy. The radioactive signal can be traced using a handheld gamma probe during sur-
gery. Blue dye is injected peritumorally prior to the first incision and provides visual 
guidance shortly thereafter. However, not all slns stain blue; for example in only 
69% of vulvar cancer patients blue slns could be identified10. Nonetheless, the com-
bined approach results in high sln detection rates and low numbers of false negative 
lymph nodes and is currently standard-of-care in surgery for melanoma, breast and 
vulvar cancer patients11-13. However, high costs of using radioactivity, the risk of ra-
diation exposure, discoloration of the surgical field and long-lasting tattooing of the 
skin by using blue dye, emphasize the need for improvements. 
Indocyanine green (icg) is used as the preferred nir fluorescent dye for sln map-
ping. For decades, icg has been registered and used to determine cardiac output, 
hepatic function and ophthalmic perfusion14. Application of icg as lymphatic tracer 
The diagnostic accuracy of preoperative imaging modalities such as magnetic reso-
nance imaging (mri) and computed tomography (ct)-scan has improved consider-
ably over the last decades, but their ability to detect small sized tumor lesions re-
mains suboptimal1. In addition, translation of these images to the surgical theatre 
is challenging as these images do commonly not depict the actual situation in the 
patient’s body. Image-guided surgery (igs) using near-infrared (nir) fluorescence 
is a promising intraoperative imaging modality that can assist surgeons to identify 
tumor tissue, lymph nodes and vital structures2. This imaging modality gives real-
time information during surgical procedures by revealing the location of targeted 
tissue. Hence it may improve patient outcome, e.g. by reducing the number of posi-
tive resection margins or by decreasing the risk of iatrogenic damage to vital struc-
tures. Here, we describe an overview of the technique, applications and perspectives 
of nir fluorescence igs. 
near-infrared fluorescence imaging
Technique  A  nir fluorescence igs uses fluorophores that emit light after ex-
citation3. Especially fluorophores emitting light in the nir wavelength spectrum 
(700-900nm) are of interest, because autofluorescence and light absorbance of nor-
mal tissue structures, such as blood or fatty tissue, are low at these wavelength spec-
tra4. Consequently, relatively deep tissue penetration can be achieved enabling visu-
alisation of structures up to a depth of 10mm5,6. Furthermore, this light is invisible 
for the human eye and therefore does not alter the surgical field. 
Next to an optimal fluorophore, a fluorescence imaging system consisting of a 
light source that is able to excite fluorophores combined with a camera that can de-
tect the emitted fluorescence is required (fig. 1). Since the introduction of igs in 1998, 
various commercially available nir fluorescence imaging systems have been devel-
oped, either for open, laparoscopic or robotic surgery7. All imaging systems have 
to overcome specific challenges to optimize their utility, such as enabling sufficient 
fluorescence excitation, low-attenuation optics for nir light and enough sensitivity 
to detect low concentrations of nir fluorophores5. High fluence rates of the exci-
tation light would be optimal to achieve deep tissue penetration. However, safety 
of the technique is partly dependent on illumination levels. High power levels can 
burn tissue and photobleach contrast agents8. Therefore, fluence rates are currently 
restricted to the range of 10-25mW/cm2. 
Most fluorescence imaging systems are capable to show normal white light im-
ages next to nir fluorescence images7. Some imaging systems have the ability to dis-
play a real-time overlay of the fluorescence and normal light image, which enhances 
Figure 1 The mechanism of fluorescence igs
After injection of a fluorophore, either intravenously, 
peritumorally or topically, its localization can be 
visualized by nir fluorescence imaging. During 
surgery, the nir light source can be positioned above 
the surgical field with a distance of approximately 
20-30cm, or can be encased within a fiberscope for 
minimally invasive and robotic surgery. Some nir 
fluorescence imaging system can simultaneously 
display color-, nir fluorescence-, and overlay images 
in real-time during surgery and thereby enhance 
anatomical orientation.  
 
Image reprinted by permission from Macmillan 
Publishers Ltd.: Nature medicine2. Copyright © 2013
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Bile duct imaging can be achieved by low dose (2.5-20 mg) intravenous icg injec-
tion prior to surgery32. Since icg is almost exclusively cleared by the liver via biliary 
secretion, it can be used to explore the biliary anatomy with nir fluorescence imag-
ing. Preferably icg is administered 24 hrs before surgery because injection directly 
prior to, or during surgery results in highly fluorescent liver tissue, concealing the 
bile ducts33. The optimal dose of icg and time of dosing is yet to be defined. When 
applied appropriately, icg improves anatomical orientation and may decrease com-
plication rates particularly in patients with an aberrant biliary anatomy, severe adhe-
sions or patients undergoing major liver surgery. 
Another delicate structure that is sensitive to damage is the ureter. In a clinical 
feasibility study, the ureter was successfully visualized with methylene blue (mb) as 
nir fluorophore (fig. 2b)34. mb is fluorescent at 700 nm and is partly cleared by the 
kidneys. Alike icg, mb was first used for its intrinsic blue color35. However, this re-
quires high doses (7.5mg/kg) and may result in serious adverse events, such as toxic 
metabolic encephalopathy36. In strongly diluted concentrations, mb reveals its fluo-
rescent properties37. Intravenous injection of doses of 0.5-1.0 mg/kg mb resulted in 
good visualization of the ureters and no serious adverse events are reported at these 
low dose levels34. However, as mb is a suboptimal fluorophore, improvement can 
be expected when novel 800nm fluorophores, such as zw800-I, will become avail-
able for clinical use. The quantum yield, i.e. brightness of the fluorescent signal, of 
zw800-I is four times higher and zw800-I is cleared exclusively by the kidneys, 
potentially resulting in a much brighter signal in the ureters38. Clinical evaluation of 
this new agent is currently ongoing.
Perfusion angiography  A  Sufficient blood supply is of vital importance 
in the creation of intestinal anastomosis. Although complications such as stricture 
or leakage have multifactorial causes, any means to minimize or avoid these is desir-
able39. A reliable, relatively easy and low-risk method to assess vascularization of 
anastomosis is nir fluorescence angiography. Several studies have shown the feasi-
bility of nir fluorescence angiography during intestinal surgery by using low doses 
of icg40-42. Intravenous injection of 2.5-7.5mg icg led to real-time feedback about 
the perfusion of the organ of interest. A randomized controlled trial to evaluate the 
use of intraoperative fluorescence angiography to prevent anastomotic leakage in 
rectal cancer surgery is currently ongoing43. Objective criteria for insufficient blood 
flow are yet to be determined, because quantification of the fluorescence signal is 
not directly correlated to the actual perfusion. Nonetheless, in the hands of an ex-
perienced surgeon, nir fluorescence angiography may contribute to reduced anas-
tomotic complication rates. Fluorescence angiography has also been proven to be 
was initially based on its intrinsic green color resulting in relatively low contrast and 
consequently low sln detection rates15,16. However, its fluorescent characteristics 
have resulted in superior sln detection rates compared to blue dye alone17. After 
peritumoral injection of a low dose of icg (1.6mL of 500µM), the lymphatic drainage 
could be traced in real-time using a nir fluorescence imaging system. Lymphatic 
vessels and lymph nodes can sometimes even be identified percutaneously, which fa-
cilitates the procedure and may decrease incisional length and postoperative morbid-
ity18. The use of icg as nir fluorescent tracer has been studied in sln procedures in 
head-and-neck, breast, skin, gastro-intestinal, urological and gynaecological cancer 
patients (fig. 2a)10, 19-23. icg emits light with a wavelength of 820 nm, is cleared almost 
exclusively by the liver and has an elimination half-life in blood of approximately 
3 minutes24. Allergic reactions after administration are rare and have been docu-
mented in less than 1:10,000 patients, but only in doses above 0.5mg/kg14. The doses 
used in nir fluorescence imaging are lower: between 0.1-0.5mg/kg25. Although use 
of nir fluorescence light results in deeper tissue penetration (up to 10mm) than use 
of a conventional blue dye (1mm), the relatively superficial tissue penetration still 
remains a problem for sln detection in obese patients. Furthermore, injection of icg 
alone as lymphatic tracer has been shown to result in fluorescent staining of second 
tier nodes. Therefore, icg has been non-covalently absorbed to albumin nanocolloid 
assuming that a larger hydrodynamic diameter would lead to less staining of higher 
tier nodes and a better retention in the sln2,26. In Europe, an albumin-based tracer 
is most commonly used since icg already shows high affinity for albumin, while in 
the usa a sulphur based colloid is commonly used27. A hybrid tracer, combining icg 
and 99mTechnetium nanocolloid (icg:99mTc) has been studied in feasibility trials 
for sln mapping28. Although those studies were intended as feasibility studies, icg 
outperformed blue dye as tracer. Moreover, one combined preoperative injection of 
icg:99mTc resulted in similar sensitivity rates. 
Identification of vital structures  A  Morbidity after surgery de-
pends partly on the extent of damage to vital structures, such as nerves, ureters and 
bile ducts. Although laparoscopic and robotic surgery have decreased morbidity rates, 
iatrogenic damage is sometimes inevitable. One step closer to preservation of vital 
structures is highlighting these structures using nir fluorescence imaging. Currently, 
nerves are identified during surgery by inspection, potentially in combination with 
electromyographic (emg) monitoring. However, nerve damage is still frequently ob-
served, resulting in pain, numbness, weakness or paralysis. Preclinical studies already 
showed accurate identification of nerves as small as 50um using the specific peptide 
np41 and Oxazine 4, but none of these agents are clinically evaluated or approved29-31.
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ovarian cancer lesions could be identified after systemic injection of icg. A possible 
explanation for this failure might be the difference in tumor biology52,55.
mb was initially used to visualize enlarged parathyroid adenomas and neuro-
endocrine tumors; administration of a high dose of mb (up to 7.5mg/kg) resulted 
in macroscopically visible blue staining of the tumor35,36. After dilution, using its 
fluorescent characteristics, nir fluorescence detection of various types of (neuro-)
endocrine tumors by administration of 1mg/kg mb appeared feasible56,57. However, 
the exact mechanism of tracer uptake in these tumors remains unclear. A recent 
study showed visualization of hyperparathyroid adenomas after a single injection of 
0.5mg/kg and mb has also been successfully used for tumor identification in breast 
cancer patients56,58. 
Since the first report of intraoperative use of fluorescein for detection of brain 
tumors in 1948, fluorescence imaging is applied in neurosurgical procedures59. Oral 
administration three hours before surgery of 5-aminolevulinic acid (5-ala), a pre-
cursor of the hemoglobin synthesis pathway, results in accumulation of fluorescing 
protoporphyrine ix (Ppix) in malignant tissue60,61. By using a specifically modified 
neurosurgical microscope, 5-ala can be identified by excitation with violet-blue 
light. In a large phase iii multicentre randomized controlled trial (rct) in 2006, 
Stummer et al. demonstrated the benefit of fluorescence-guided resection of ma-
lignant gliomas using 5-ala compared to conventional white light resection. 5-ala 
resulted in a higher number of complete tumor resections (65% vs. 36%) and signifi-
cantly prolonged 6-month progression-free survival (41% vs. 21%)61. Application of 
5-ala is nowadays approved for resection of high-grade malignant gliomas. 
helpful in reconstructive cancer surgery44. By intraoperative identification of vas-
cular perfusion to free or pedicled flaps, selection of well-vascularized flaps can be 
performed and venous outflow can be monitored45. 
Tumor identification using clinically available fluorophores 
Tumor imaging is already feasible by using the nonspecific dyes icg and mb. Liver 
metastases and hepatocellular carcinoma (hcc) can be identified due to the inherent 
properties of icg. Metastases are identifiable by a fluorescent rim, caused by stasis 
of icg in compressed liver parenchyma. Healthy hepatocytes clear icg within ap-
proximately 24h. Compression by tumor tissue causes obstructed bile canaliculi. In 
addition, compression and inflammation lead to an increased presence of immature 
hepatocytes, in which icg tends to accumulate. As a result, superficially located liver 
metastases, even as small as 1 mm, can be identified by a characteristic fluorescent 
rim pattern surrounding the metastases (fig. 2c). Van der Vorst et al. showed that 
with nir fluorescence imaging, 24 or 48 hours after intravenous injection of either 
10 or 20mg icg, superficial liver metastases that were otherwise undetectable were 
identified in 5 out of 40 patients with colorectal cancer during open surgery46. Also 
in patients with pancreatic cancer additional metastases were identified in 8 out of 
49 patients (16%)47. Especially small, superficially located liver metastases can be 
more readily detected by use of nir fluorescence imaging, since intraoperative ultra-
sound (ious) has more added value in detection of more deeply located metastases 
(>6mm)48. In addition, the resolution of ct is too low to accurately detect lesions 
smaller than 10mm49. 
Ishizawa et al. were the first to demonstrate nir fluorescence detection of hcc 
after a preoperative injection of icg, resulting in a clear fluorescence signal through-
out the tumor50. Currently, three types of fluorescence can be classified in hcc pa-
tients: uniform, partial and rim-type. The type of fluorescence is associated with 
tumor pathology. Well- or moderately differentiated hccs show mostly uniform 
fluorescence, whereas poorly differentiated hccs show partly or rim-type fluores-
cence51. Besides nir fluorescence detection of liver metastases and hccs, tumor im-
aging after an intravenous injection of icg has been investigated in pancreatic can-
cer patients assuming that accumulation of the nir fluorophore in tumorous lesions 
would occur because of the enhanced permeation and retention (epr) effect52. Due 
to a combination of newly formed, porous blood vessels and poorly developed lym-
phatic vessels in tumor tissue, large molecules such as icg retain in the tumor53. The 
epr effect mainly depends on physical characteristics of injected macromolecules 
and therefore leads to non-specific targeting54. Although in breast cancer patients 
the epr effect did result in tumor detection, pancreatic cancer lesions nor metastatic 
Figure 2 Applications of fluorescence igs
Displayed from left to right (a, b, c) are color, nir 
fluorescence and color-nir overlay images.
A Example of sentinel lymph node detection in  
a patient with breast cancer after periareolar- 
injection of 1.6mL 0.5 mM indocyanine green. 
A lymphatic vessel leading to the sln is clearly 
visible. The surgical field is not altered by 
staining of any dye.
B Example of ureter visualisation after intrave-
nous administration of 1mg/kg methylene blue.
c Example of colorectal liver metastasis identi- 
fi cation after preoperative injection (24h before  
surgery) of 10mg indocyanine green. A f luores-
cent rim pattern surrounding the colorectal liver 
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detection. part i, chapter two describes an overview of all clinical studies describing 
different strategies for fluorescence cholangiography and a clinical trial to identify 
the optimal dose and timing of administration of icg for bile duct identification. 
Chapter three explores the use of icg during a (relatively) novel surgical procedure 
as treatment option for patients with initially unresectable liver tumors: associating 
liver partition and portal vein ligation for staged hepatectomy (alpps). Chapter four 
demonstrates the added value of icg during laparoscopic resection of multiple types 
of liver tumors. 
part ii, chapter five describes the expression of Folate Receptor-α (fr-α) in 
breast cancer and non-small cell lung cancer and investigates the concordance be-
tween preoperative biopsies, primary tumor tissues and metastases. Chapter 6 de-
scribes the preclinical development and validation of a novel Epcam-targeted flu-
orescent imaging agent as pluripotent tumor imaging target. In chapter 7, preop-
erative serum cea is compared with the expression of cea on tumor tissue derived 
from patients with pancreatic or rectal cancer. Chapter 8 investigates expression of 
Epcam, cea and c-Met on rectal cancer tissue, derived from patients who did or 
did not receive preoperative (chemo)radiotherapy and compared the differences in 
expression patterns between these groups. 
part iii, chapter 9 demonstrates fr-α expression in tissues derived from high-
risk endometrial cancer patients and shows the first clinical experience with otl-38 
(a folate targeting nir fluorescent agent) in endometrial cancer patients. Chapter 10 
describes the clinical translation of a novel tumor-specific cea-targeted nir fluores-
cent tracer for intraoperative detection of primary, recurrent and metastatic colorec-
tal cancer. 
part iv contains a summary of the thesis and a general discussion on the future 
perspectives of fluorescence-enhanced surgical navigation. 
 
Tumor identification using tumor-targeted fluorescent 
dyes  A  Although broadly applied clinically, 5-ala nor icg or mb are tumor-spe-
cific fluorophores. Identification of novel targets, based on the various hallmarks of 
cancer, have paved the way to develop tumor-specific fluorophores62. To accomplish 
tumor-specific targeting, a tumor recognizing ligand, such as an antibody or nano-
body, has to be conjugated to a (nir) fluorescent dye. Both icg and mb cannot easily 
be conjugated due to their chemical properties, but relatively novel conjugatable nir 
fluorophores include irdye800cw (Li-cor, Biosciences, Lincoln, ne) and zw800-
I (Curadel Surgical Innovations, Wayland, ma). They share favourable characteris-
tics such as emission at a wavelength range of 800nm, small size and low toxicity. 
A milestone in tumor-targeted fluorescence imaging was the first in-human trial 
with Folate-fitc for visualization of metastatic ovarian cancer63. The folate recep-
tor is upregulated in ovarian cancer and targeting of this receptor with Folate-fitc, 
i.e. folate conjugated to a 500nm fluorophore, resulted in intraoperative detection 
of otherwise undetected tumor lesions. Since then, various tumor-targeted imaging 
agents have been tested in first-in-human trials64-67. Vehicles can either be antibod-
ies, but other ligands such as fragments of antibodies, nanobodies, small peptides 
or much larger nanoparticles are currently also evaluated for clinical use. Although 
results are promising, there appears to be substantial variation in the quality of fluo-
rescence tumor detection as shown by the varying fluorescence intensity of tumors 
between patients. This may be due to the heterogeneity of expression of tumor mol-
ecules between patients, heterogeneity in the tumor itself, anatomical location of 
the tumor or combinations thereof. Further, it appears that variability is due to dif-
ferences caused by physico-chemical properties of the ligands and differences be-
tween imaging systems and the machine settings used for imaging. It is therefore of 
utmost importance to identify what patients can benefit most from particular types 
of tumor-specific agents, before these (vulnerable oncological) patients are exposed 
to possibly harmful novel agents. At the mean time, the quest for the optimal tumor 
target to use for igs continues. 
outline of the thesis
This thesis is divided in three parts; part i describes the clinical use of the non-
targeted fluorescent dye icg during hepato-pancreatico-biliary (hpb) surgery, part 
ii focuses on the preclinical development and evaluation of novel tracers for fluo-
rescence-guided surgery and part iii describes the clinical introduction of newly 
developed tumor-specific fluorescent contrast agents for intraoperative tumor 
fluorescence-enhanced surgical navigation 
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introduction
Iatrogenic bile duct injury after laparoscopic cholecystectomy is a rare but serious 
complication with an incidence ranging from 0.08% to 1.5%1-3. Bile duct injuries are 
mostly the result of misidentification of the common bile duct (cbd) or the common 
hepatic duct (chd) for the cystic duct (cd). Transection of the cbd or chd leads 
to severe complications, long-term mortality rates up to 21%, and significant costs4. 
Important contributing factors are the learning curve associated with laparoscopic 
surgery and the presence of (misinterpreted) aberrant bile duct anatomy. Because 
laparoscopic cholecystectomy is currently one of the most performed surgeries 
worldwide, safer approaches are desirable. Use of the critical view of safety – a meth-
od of intraoperative identification of the cd and cystic artery – has been developed 
to minimize the risk of bile duct injury 5. Although this strategy is now implemented 
worldwide, bile duct injuries still occur.
Identification of bile ducts during laparoscopic cholecystectomies can be en-
hanced by intraoperative cholangiography (ioc). This imaging technique requires 
injection of radio-opaque contrast into the cd, whereupon a series of x-rays are 
taken. ioc can accurately depict biliary anatomy and some advocate that it should be 
performed routinely6,7. However, this technique is expensive, time-consuming, and 
exposes patients and health care personnel to radiation. Moreover, bile duct can-
nulation may cause bile duct injury itself and images can be difficult to interpret8,9.
An alternative intraoperative imaging technique that is less invasive, does not 
require radiation, and is not time-consuming, is near-infrared (nir) fluorescence 
cholangiography. Feasibility of real-time nir fluorescence imaging of bile ducts 
using indocyanine green (icg) was first described in 200810. After intravenous ad-
ministration, icg is cleared via the liver, enabling visualization of liver tumors and 
bile duct anatomy11,13. icg has a favorable safety profile; side effects are reported in 
less than 1 out of 40,000 patients14.
Several studies have described fluorescence cholangiography during open, lapa-
roscopic, and robotic cholecystectomy 15-20. However, only few tried to optimize the 
dose and timing of administration15,20. This is important, because if fluorescence im-
aging is performed directly after administration of icg, the liver will be highly fluo-
rescent while bile ducts do not yet contain icg. Optimal would be a high fluorescence 
signal in bile ducts, while liver tissue in the background stains dark. Excretion of icg 
into the bile reaches a peak approximately 2 h after dosing and remains detectable 
long after injection21. Yet, most studies inject icg within the first hour prior to imag-
ing. It is already shown that discrimination between bile ducts and liver is enhanced 
when the time interval between icg injection and fluorescence imaging is prolonged 
abstract
Background " Fluorescence cholangiography using indoycanine green (icg) 
can enhance orientation of bile duct anatomy during laparoscopic cholecystectomy. 
To ensure clear discrimination between bile ducts and liver, the fluorescence ratio 
between both should be sufficient. This ratio is influenced by the icg dose and tim-
ing of fluorescence imaging. We first systematically identified all strategies for fluo-
rescence cholangiography. Second, we aimed to optimize the dose of icg and time in 
a prospective clinical trial.
Methods " PubMed was searched for clinical trials studying fluorescence chol-
angiography. Furthermore, 28 patients planned to undergo laparoscopic cholecys-
tectomy were divided into 7 groups, receiving different intravenous doses (5 or 10mg 
icg) at different time points (0.5, 2, 4, 6 or 24h prior to surgery).
Results " The systematic review revealed 27 trials including 1,057 patients. The 
majority of studies used 2.5mg administered within 1h before imaging. Imaging 3 to 
24h after icg administration was never studied. The clinical trial demonstrated that 
the highest bile duct-to-liver ratio was achieved 3-7h after administration of 5mg 
and 5-25h after administration of 10mg icg. Up to 3h after administration of 5mg 
and up to 5h after administration of 10mg icg, the liver was equally or more fluores-
cent than the cystic duct, resulting in a ratio ≤1.0.
Conclusion " This study shows for the first time that the interval between icg 
administration and intraoperative fluorescence cholangiography should be extend-
ed. Administering 5mg icg at least 3h before imaging is easy to implement in every-
day clinical practice and results in bile duct-to-liver ratios >1.
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scheduled on Tuesday until Friday. Standard-of-care laparoscopic cholecystectomy 
was performed. When the surgeon considered it to be necessary, ioc was performed. 
Fluorescence imaging of bile ducts and adjacent structures was performed at least 3 
times before the critical view of safety was assessed. 
Intraoperative near-infrared fluorescence imaging system 
Laparoscopic imaging was performed using a high definition (hd) fluorescence 
laparoscope (Karl Storz Endoscopes, Germany) through a standard 12 mm 
subumbilical trocar port. The system was equipped with a visible and 760 nm 
(icg modus) light source. No overlay of visible and icg images was possible, but 
anatomical orientation could be maintained due to easy and fast switching between 
both channels using a foot pedal.
Preparation and administration of indocyanine green  A 
Twenty-five mg icg (Pulsion Medical Systems, Munich, Germany) was resus-
pended in 10 cc sterile water to yield a concentration of 2.5 mg/mL. To obtain doses 
of 5 mg and 10 mg icg, respectively 2 and 4 mL of the solution was intravenously 
administered.
Postoperative questionnaire for surgeons  A  After surgery, the 
surgeon completed a questionnaire to score the following statements about fluo-
rescence imaging: (I) it could decrease the number of bile duct complications; (ii) it 
led to better detection of bile ducts; (iii) the technique was of added value for this 
procedure; (iv) it needs to be standard-of-care during laparoscopic cholecystectomy 
(V) it delays surgery. Surgeons scored these statements ranging from totally disagree, 
somewhat disagree, neutral, somewhat agree and totally agree.
Data analysis  A  Data was analyzed using GraphPad Prism Software (Ver-
sion 5.01, La Jolla, ca). Bile duct to liver ratios (blr) were calculated by dividing the 
fluorescence signal of the cd by the fluorescence signal of the liver. Intraoperative 
fluorescence images of 3 different time points were analyzed using Image J (version 
1.49b, National Institutes of Health, Bethesda, md).
results
Systematic review  A  A total of 242 articles were identified (Figure 1). After 
reviewing all titles and subsequently, content of the abstracts, 27 eligible clinical 
studies were reviewed (Table 1)10, 15-20, 22-42. Used icg doses ranged from 0.025 mg 
to 24 h instead of 30 min15. Additionally, a recent study showed that a dose of 0.25 
mg/kg, administered at least 45 min prior to fluorescence imaging facilitates accurate 
bile duct identification20. Although several icg doses were tested (up to 0.25 mg/kg) 
in this study, fluorescence cholangiography was performed only up to 180 min after 
icg administration. The optimal dose for laparoscopic fluorescence cholangiography 
after an extended interval between dosing and imaging as determined by Verbeek et 
al.15, i.e. 10mg icg, was not studied. Moreover, dosing times between 3 h and 6 h prior 
to surgery have never been studied, while these are clinically relevant.
In the current study, we first performed a systematic literature research to identify 
all used strategies for fluorescence cholangiography in clinical studies. Second, we 
optimized the dose of icg and dosing time, ranging from 0.5 h to 24 h prior to sur-
gery, to distinguish bile ducts from adjacent liver tissue.
materials and methods
Systematic review of the literature  A  We systematically searched 
PubMed for clinical trials about fluorescence cholangiography performed during 
open, laparoscopic, or robotic surgery since 2008. Only articles written in English 
and describing 3 or more patients were included. Selection of relevant titles was per-
formed independently by two reviewers. Subsequently, all included articles were 
scanned on the content of the abstract, again by two independent reviewers.
Clinical trial  A  This study was approved by the Medical Ethics Committee 
of the Leiden University Medical Center and performed in accordance with the 
ethical standards of the Helsinki Declaration of 1975 (Netherlands Trial Registry: 
ntr5623). Twenty-eight patients suffering from cholecystolithiasis and/or cholecys-
titis, and planned for laparoscopic cholecystectomy, were included. Exclusion cri-
teria were based on contraindications for icg: renal impairment (egfr <55); allergy 
for iodine, shellfish, or icg; hyperthyroidism and pregnancy. All patients provided 
informed consent.
Patients were first assigned into 2 dose groups receiving either 5 mg or 10 mg icg. 
Patients assigned to the 5 mg group, were planned to receive their icg dose 30 min, 2, 
4, or 6 h prior to surgery (4 patients per time interval). Patients assigned to the 10 mg 
group, were planned to receive their icg dose 4, 6, or 24 h prior to surgery. Patients 
were distributed over the different groups based on their order in the surgical pro-
gram. Patients scheduled early in the morning were allocated in the brief interval 
groups, while patients late in the afternoon were allocated into the longer interval 
groups. Patients were selected for the 24 h interval group if their procedure was 
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fluorescence imaging after icg injection, but it turned out to be difficult to time the 
exact moment between icg administration and surgery due to the unpredictable 
course of the surgical program. In Figure 2, the blr is plotted for every individual 
patient. In the 5 mg dose group, all blrs between 3 to 7 h post dosing were >1, with 
a mean ratio of 1.8 ± 0.5 (video 1). Up to 3 h after dosing, all measurements showed 
equally or more fluorescent liver tissue compared to the cd (blr 0.8 ± 0.2), which 
was significantly lower (p=0.004, Figure 3). In the 10 mg dose group, all blrs be-
tween 5 and 25 h were >1, with mean ratios of 1.4 ± 0.3. Up to 5 h after dosing, the liver 
showed to be equally or more fluorescent than the cd (blr 0.9 ± 0.2, respectively), 
which was again significant (p=0.02, Figure 4). blrs 3 to 7 h post dosing of 5 mg and 
5 to 25 h post dosing of 10 mg were not statistically different (p=0.12) 
Additional finding  A  A patient planned to undergo a laparoscopic chole-
cystectomy and defenestration of a liver cyst received 10 mg icg. Fluorescence chol-
angiography was performed at 3.5 h post dosing. Although bile duct detection was 
hampered by the intense fluorescence of the liver (blr 0.7), the liver cyst could be 
clearly demarcated by the lack of fluorescence inside the cyst (video clip 2). 
Evaluation of fluorescence cholangiography per surgeon 
Results of the questionnaire among all operating surgeons are displayed in Figure 5. 
discussion
Fluorescence cholangiography can improve orientation of bile duct anatomy during 
laparoscopic cholecystectomies and potentially lead to a reduced risk of bile duct 
injury. This study is the first showing that the interval between administration of icg 
and intraoperative fluorescence imaging should be prolonged to 3 to 6 h post dos-
ing of 5 mg, or 5 to 23 h post dosing of 10 mg. By doing so, bile ducts are more fluo-
rescent than liver tissue, resulting in improved discrimination of bile duct anatomy. 
Consequently, also unexpected aberrant bile ducts can be detected43. This may make 
laparoscopic cholecystectomy safer. Large studies focusing on patient outcome 
should demonstrate if fluorescence imaging reduces bile duct injuries. 
In our systematic review, none of the identified manuscripts studied fluorescence 
imaging at the optimal time points. Only two studies focused on optimizing the 
dose of icg and timing of fluorescence imaging. Zarrinpar et al.20 performed a study 
in patients undergoing laparoscopic hepatic or biliary operations and injected doses 
ranging between 0.02 and 0.25 mg/kg, 10 to 180 min prior to fluorescence imaging. 
In this study, the authors also concluded that a prolonged interval appeared optimal 
in total to 0.25 mg/kg. Most studies (17/27) used 2.5 mg administered within 1 h prior 
to fi. Timing of icg administration differed from 0 (intraoperatively) up to 24 h. No 
clinical trial studied fluorescence cholangiography 3 to 24 h after icg administra-
tion. The majority of studies (24/27) performed icg injection 30 to 60 min prior to 
surgery. Successful identification of the cd by fluorescence imaging was achieved in 
98% (range: 48–100%) of all included patients (n=1,057). Two studies investigated 
fluorescence cholangiography using different doses of icg and time of administra-
tion15,20. They studied the doses 5 or 10 mg and 0.025 or 0.25 mg/kg, and time points 
of 10 to 180 min and 30 min or 24 h prior to surgery. 
Patient characteristics  A  A total of 28 patients were included. No ad-
verse events related to icg occurred. Sixteen patients received 5 mg icg and 12 pa-
tients 10 mg icg. Patient characteristics are summarized in Table 2. Three patients 
were excluded: one patient due to failed icg administration, one due to technical 
issues during saving of images, and one patient with a history of Roux-en-Y gastric 
bypass who had a percutaneous drain in situ. In 3 patients, an ioc was performed. 
One patient, with a history of Roux-en-Y gastric bypass, underwent a transgastric 
ercp because of choledocholithiasis. Fluorescence cholangiography, performed 30 
min after injection of 5 mg icg, did not provide an overview of the bile duct anatomy 
(blr 0.3). Another ioc was performed in a patient whose surgery was postponed. 
Fluorescence imaging 10 h post dosing of 5 mg icg was not optimal (blr 0.4). The 
third ioc was performed in a patient who received 10 mg icg 24 h preoperatively. 
Fluorescence imaging showed the cbd (blr 1.1), which was confirmed by ioc. No 
aberrant bile ducts were detected in the current study, but two patients showed ab-
errant arterial structures in close proximity to the gallbladder. Due to the lack of 
fluorescence, these structures could be identified as vasculature instead of bile ducts. 
Optimization of dose and time interval  A  Identification of the 
cd by fluorescence imaging was successful in 24 out of 25 patients (96%). The patient 
with unsuccessful bile duct identification was a patient who suffered from cirrhosis 
and Mirizzi syndrome and previously underwent stent placement and ercp. During 
the laparoscopic surgery, strong adhesions between stomach, duodenum and gall-
bladder were found. No clear overview of bile duct anatomy could be obtained, nei-
ther by normal inspection nor using fluorescence imaging. After conversion, the 
gallbladder appeared completely fused with the proximal duodenum and a fistula 
between gallbladder and duodenum, and a cyst originating from the cbd was found. 
Of the remaining 24 patients, 14 patients received 5 mg icg and 10 patients 10 
mg icg. Patients were intended to be divided in different groups based on time of 
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Intraoperative assessment of biliary anatomy can be improved using several tech-
niques46. ioc, still the most frequent applied technique for bile duct clarification, is 
investigated in large cohort studies. A forest plot of the six largest population-based 
studies showed an odds ratio for bile duct injury of 0.60 (95% confidence interval 
0.52-0.70) when using ioc46. No randomized trial studying the effect of ioc exists 
and is almost impossible to conduct. Still, the association between reduced risk of 
bile duct injury and use of ioc has been shown convincingly47. An important dis-
advantage of ioc is however that obtained radiographic images can be difficult to 
interpret and ioc is a technically challenging procedure48. Moreover, costs of ioc 
are high, caused by prolonged surgery time of 10-23 min, requirement of an addi-
tional medical specialist and use of equipment49. On the other hand, treating pa-
tients with bile duct injuries is a financial burden for the health care system. Some 
physicians state therefore that routinely use of ioc is cost effective47. As indicated by 
our surgeons, fluorescence imaging does not prolong or time. Furthermore, it does 
not require another medical specialist or the use of radiation, and it certainly cannot 
cause bile duct injury35. We therefore advocate that fluorescence imaging should be 
an important part of laparoscopic cholecystectomy. 
A limiting factor of fluorescence cholangiography compared to ioc is the in-
ability to detect cbd stones. Moreover, the cbd is not always identified, due to the 
limited penetration depth of approximately 1 cm of light in the nir spectrum12. 
Structures beneath a layer of (periductal) fat, especially in obese patients, are there-
fore more difficult to identify using nir fluorescence imaging12,42. Fluorescence 
cholangiography can however easily be combined with ioc, as shown in the current 
study. An advantage of fluorescence cholangiography is that it can be performed at 
all time during surgery without significant delay.
Intravenous icg administration can also be valuable to assess intraoperative 
identification of (bile duct) vasculature28,31. Because icg binds to plasma proteins, it 
remains intravascular50. This in combination with its short half-life of approximately 
3 minutes makes it a very useful contrast agent for perfusion angiography. When 
doubt exists about aberrant vasculature or identification of the cystic artery, an ad-
ditional injection of icg can be given. One should however bear in mind that intra-
venous icg administration during surgery will result in intense fluorescence of the 
liver and thus, should only be performed when bile duct anatomy is already clarified.
In conclusion, this study shows that a prolonged interval (at least 3 h) between 
icg injection and intraoperative fluorescence cholangiography results in better con-
trast between bile ducts and liver tissue. Although this study was performed in a 
small group of patients, we believe that when the optimal dose and timing are used, 
fluorescence cholangiography can be of added value for both patients and surgeons. 
for fluorescence cholangiography, but they did not study longer time intervals. Our 
group previously studied fluorescence cholangiography during open and laparo-
scopic surgery 0.5 and 24 h after icg administration15. The latter resulted in much 
better discrimination between bile ducts and liver tissue. However, administrating 
icg 24 h prior to surgery is less feasible in everyday clinical practice; most patients 
arrive in the morning prior to surgery at the hospital. According to our study results, 
we can advise a dose of 5 mg icg, administered 3 to 7 h prior to surgery, which is 
much more practical in everyday clinical practice. Although this study is performed 
with a relatively small group of patients, we believe these results should form the 
basis for larger studies that focus on the added value of fluorescence cholangiog-
raphy. Currently, three large, multicenter, randomized clinical studies are ongo-
ing to assess the potential added value of fluorescence cholangiography (Table 3). 
Unfortunately, probably due to logistical reasons, researchers choose to inject icg 
directly prior to surgery. Prevention of bile duct injuries is a very difficult endpoint 
that requires huge amount of patients, but other useful endpoints could be reduced 
or time, cost effectiveness, less use of radiation for ioc, etc.
A commonly mentioned drawback of fluorescence-guided surgery is the lack of 
standardization of fluorescence imaging systems44. Standardization is important for 
the determination of objective assessments during oncological fluorescence-guided 
surgery trials 45, but differences in fluorescence imaging systems also hinder com-
parison between fluorescence cholangiography studies. Different lasers, leds, filters, 
image sensors, and image processing all make a fair comparison difficult. A recent 
study compared five different fluorescence laparoscopic imaging systems for fluo-
rescence cholangiography: a prototype and an improved version of the Hamamatsu 
Photonics laparoscope, the fluorescence imaging system of Olympus Medical 
Systems, the Karl Storz hd fluorescence laparoscope and the fluorescence imaging 
system of Novadaq19. An important conclusion from this study was that the contrast 
of icg was significantly different among all the used laparoscopic imaging systems. 
Outcomes of studies (e.g., blr) are therefore difficult to compare. The system used 
in the present study, the Karl Storz hd fluorescence laparoscope, showed not to be 
optimal for icg detection and therefore, ratios obtained in the current study are ex-
pected to be even higher when other imaging systems are used.
The intensity of the fluorescence signal depends on several factors, including the 
distance from the tip of the laparoscope to its target and the amount of covering 
tissue. For this reason, we chose in the current study to calculate a ratio between the 
fluorescence signal in the cystic duct and liver, instead of measuring solely fluores-
cence intensity in the bile duct or liver. Moreover, to make the results more accurate, 
we analyzed the blr at 3 different time points during surgery.
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Figure 3 Fluorescence cholangiography over time after administration of 5 mg icg
Shown are images of fluorescence detection of the cystic duct (arrow) and adjacent liver tissue (pyramid) over 
time. Bile duct-to-liver ratios were sufficient (i.e. >1) in patients who received 5 mg icg 3 to 7 h prior to surgery. 
blr was ≤1 when fluorescence imaging was performed less than 3 h after administration.
Figure 1 Flowchart of the literature search
Figure 2 Fluorescence intensity of bile duct compared to adjacent liver tissue for each individual patient
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Figure 5 Results of questionnaire
Shown are all the scores that were given by surgeons after they performed a laparoscopic cholecystectomy with 
use of fluorescence cholangiography. The statements that were scored were respectively (I) it could decrease the 
number of bile duct complications; (ii) it led to better detection of bile ducts; (iii) the technique was of added 
value for this procedure; (iv) it needs to be standard-of-care during laparoscopic cholecystectomy (V) it delays 
surgery. 
Video 1 Fluorescence cholangiography during laparoscopic cholecystectomy, performed 5 hours after 
injection of 5 mg icg (online available)
Video 2 Fluorescence imaging of bile ducts and liver cysts during laparoscopic cholecystectomy and liver 
cyst defenestration (online available)
Figure 4 Fluorescence cholangiography over time after administration of 10 mg icg 
Shown are images of fluorescence detection of cystic duct (arrow) and adjacent liver tissue (pyramid) over time. 




































fluorescence-enhanced surgical navigation 
36 
PART I • chapter 2 • Fluorescence cholangiography: a dose and time optimization study
37
Table 1 Relevant articles about fluorescence cholangiography
Study Year n Procedure Fluorescence imaging system Dose of icg (mg) Timing of injection ir of cd (%)
Mitsuhashi et al.10 2008 5 oc Photo Dynamic Eye 2.5 mg 30min prior to surgery 5/5 (100%)
Ishizawa et al. 22 2009 10 oc Photo Dynamic Eye 2.5 mg 60min prior to surgery / during conversion 10/10 (100%)
Aoki et al. 23 2010 14 lc Hamamatsu laparoscope 12.5 mg 30min prior to surgery 10/14 (71%)
Tagaya et al.25 2010 12 oc (n=4)/lc (n=8) Prototype laparoscope and Photo Dynamic Eye 2.5 mg 60min-120min prior to surgery 12/12 (100%)
Ishizawa et al.24 2010 52 lc Hamamatsu laparoscope 2.5 mg 30min prior to surgery 52/52 (100%)
Hutteman et al.26 2011 8 oc* Mini-flare 5 mg or 10 mg during surgery 8/8 (100%)
Ishizawa et al.17 2011 7 silc Hamamatsu laparoscope 2.5 mg after intubation 7/7 (100%)
Buchs et al.16 2012 12 sirc da Vinci si System (Intuitive Surgical) 2.5 mg 45min prior to surgery 12/12 (100%)
Kaneko et al.28 2012 28 lc Hamamatsu laparoscope 2.5 mg 15min prior to surgery and during surgery*** 27/28 (96%)
Buchs et al.29 2013 23 sirc da Vinci si System (Intuitive Surgical) 2.5 mg after intubation na
Schols et al.31 2013 30 lc Karl Storz hd fluorescence endoscopy system 2.5 mg after intubation and during surgery*** 29/30 (97%)
Schols et al.30 2013 15 lc Karl Storz hd fluorescence endoscopy system 2.5 mg after intubation 15/15 (100%)
Spinoglio et al.32 2013 45 sirc da Vinci si System (Intuitive Surgical) 2.5 mg 30min prior to surgery 44/45 (98%)
Verbeek et al.15 2014 41 oc (n=27)/lc (n=14) Mini-flare / Karl Storz 5 mg or 10 mg 24h or 30min prior to surgery 41/41 (100%)
Prevot et al.33 2014 23 lc Karl Storz hd fluorescence endoscopy system 0.05 mg/kg after intubation 23/23 (100%)
Daskalaki et al.18 2014 184 rc da Vinci si System (Intuitive Surgical) 2.5 mg 45min prior to surgery 184/188 (98%)
Larsen et al.34 2014 35 lc Olympus laparoscopic imaging system 0.3-0.4 mg/mL/kg in 5 mL after intubation 35/35 (100%)
Boni et al.38 2015 52 lc Karl Storz hd fluorescence endoscopy system 0.4 mg/mL/kg 15min prior to surgery and during surgery*** 52/52 (100%)
Dip et al.35 2014 43 lc Karl Storz hd fluorescence endoscopy system 0.05 mg/kg 60min prior to surgery 43/43 (100%)
Kawaguchi et al.39 2015 24 llr Olympus laparoscopic imaging system 0.025 mg after intubation 24/24 (100%)
Osayi et al.40 2015 82 lc Stryker Infrared Fluorescence (irf) Imaging System 2.5 mg 60min prior to surgical incision 78/82 (95%)
Dip et al.36 2015 45 lc Karl Storz hd fluorescence endoscopy system 0.05 mg/kg 60min prior to surgery 45/45 (100%)
van Dam et al.41 2015 30 lc Olympus laparoscopic imaging system 0.05 mg/kg after intubation 29/30 (97%)
Kono et al.19 2015 108 lc 5 fluorescence laparoscopic imaging systems** 2.5 mg 30min prior to surgery and during surgery 99/108 (92%)
Dip et al.37 2015 71 lc Karl Storz hd fluorescence endoscopy system 0.05 mg/kg 60min prior to surgery 100/100 (100%)
Zarrinpar et al.20 2016 37 lc + llr PinPoint 0.025 mg/kg-0.25mg/kg 10 to 180min prior to surgery na
Igami et al.42 2016 21 lc Karl Storz hd fluorescence endoscopy system 2.5 mg After intubation 10/21 (48%)
total   1057         984/1009 (98%)
oc = open cholecystectomy; lc = laparoscopic cholecystectomy; silc = single-incision laparoscopic cholecystectomy;  
sirc = single-incision robotic cholecystectomy; llr = laparoscopic liver resection; ir = identification rate; cd = cystic duct 
* Open cholecystectomy performed during pancreaticoduodenectomy  
** 5 fluorescence laparoscopic imaging systems include (1) prototype and (2) improved version of the Hamamatsu  
 Photonics laparoscope, the fluorescence imaging system of Olympus Medical Systems (3), the Karl Storz hd  
 fluorescence laparoscope (4) and the fluorescence imaging system of Novadaq (5) 
***  An additional icg injection during surgery was given to evaluate fluorescence angiograph
Table 2 Patients’ characteristics
Characteristics 5 mg dose group 10 mg dose group
Number of included patients (n) 16 12 
Age (median, range) 61 (20-75) 61 (40-76)
Gender (n (%))    
 Female 10 (63%) 9 (75%)
 Male 6 (37%) 3 (25%)
Body Mass Index (kg/m2)(median, range) 29 (22-37) 27 (22-36)
asa classification (n (%))    
 asa class I 4 (25%) 3 (25%)
 asa class ii 12 (75%) 9 (75%)
Preoperative diagnosis    
 cholelithiasis 14 11
 choledocholithiasis 5 5
 gallbladder polyp 1 1
 Mirizzi syndrome 1 0
Preoperative imaging technique us 16 12
 mrcp 2 4
 ercp 5 6
us = ultrasound; mrcp = magnetic resonance cholangio- pancreaticography;  
ercp = endoscopic retrograde cholangio- pancreaticography
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lesions could be visualized in the second instance by ious. Frozen section analysis 
was inconclusive, but additional histological staining revealed an adenocarcinoma.
These cases illustrate the added value of fi during alpps. First, it provides real-
time tumor margin assessment during resection (video 1). This in contrast to intra-
operative ligation of vasculature, where discoloration of liver tissue observed by the 
naked eye only represents the ischemic part and not the tumor itself. Secondly, it can 
identify otherwise undetectable lesions and serve as a complimentary intraoperative 
diagnostic modality. fi is an easy, effective, and safe method. The only requirement 
is a nir fluorescence imaging system, several of which are clinically available. Large 
series will have to define if fluorescence imaging truly improves patient outcomes, 
but we believe this technology could become an important component of alpps and 
other liver procedures.
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Associating Liver Partition and Portal vein ligation for Staged hepatectomy (alpps) 
emerged as a novel curative treatment option for patients suffering from initially 
unresectable liver tumors1. The goal of alpps is an R0 resection with maximal pres-
ervation of liver function. The technique remains controversial among hepatobili-
ary surgeons due to high morbidity and mortality rates2. Different adaptations have 
been proposed to reduce these rates. The preferred method at the Leiden University 
Medical Center (lumc) is to perform first only the liver partition, followed by a 
selective percutaneous portal vein embolization when the patient is sufficiently re-
covered, usually after four to five days. We hypothesize that the inflammatory state 
will be decreased after a few days and that this approach therefore results in lower 
complication rates. The international alpps registry showed a 2-year disease-free 
survival rate of 42%3. These data also showed that incomplete resection – usually the 
result of hampered demarcation due to tumor size and location – was accountable 
for only 9% of the recurrent tumors. This may indicate that other small tumors re-
main undetected during surgery. Current pre- and intraoperative imaging modali-
ties all suffer serious drawbacks. ct and mri have low sensitivity for lesions <10 mm 
and intraoperative ultrasonography (ious) has low resolution within the first milli-
meters below the liver surface due to reflection artifacts. In 2009, it was reported that 
intravenous administration of indocyanine green (icg) enables intraoperative iden-
tification of hepatic tumors using near-infrared (nir) fluorescence4. Accumulation 
of icg in liver tissue affected or compressed by invasive growth of tumors results 
in bright signals in and around tumors, while healthy liver tissue clears icg within 
hours. Based on our previous experiences, we currently apply fluorescence imaging 
(fi) routinely during oncologic liver surgery. We believe that fi could become an 
important component of alpps and other liver procedures. In support, we illustrate 
two recent cases. 
Both patients provided informed consent and received an iv administration of 
10 mg icg one day prior to the first stage. Intraoperative fi was performed using 
the Mini-Fluorescence-Assisted Resection and Exploration (Mini-flare®) sys-
tem5. In the first patient, fi was of great value in determining the transection line. 
Contrary to preoperative imaging, the tumor was identified beyond the falciform 
ligament (Fig. 1a). Liver parenchyma was partitioned guided by the fluorescent sig-
nal. Histopathological analysis after the second stage revealed no tumor involve-
ment in the resection margin. The second patient suffered from a large solitary 
tumor in the right liver lobe. Differential diagnosis (based on radiological findings) 
included hcc, fibrolamellar hcc and cholangaiocarcinoma. No biopsy was per-
formed to prevent needle tract metastases. Two lesions of approximately 5 mm in the 
left liver lobe were identified by fi during the procedure (Fig. 1b). Only one of these 
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Figure 1 Near-infrared fluorescence imaging of liver tumors
A Fluorescence-guided transection of the liver; the plane of transection can be marked beyond 
 the falciform ligament (white star) based on f luorescent signal (Patient #1).
B Fluorescence detection of two additional lesions (both arrows) in the left liver lobe (Patient #2).  
Only one lesion could be identified by ious (segment 3; open arrow). This lesion was resected  
and histopathologic examination revealed adenocarcinoma after additional staining.
c Ex vivo f luorescence imaging of resected specimen, 21 days after pre- and intraoperative icg  
administration (Patient #2). Fluorescence is still clearly visible surrounding the tumor (tumor  
is highlighted by black star).
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introduction
Major advances have been achieved in the treatment of patients with liver-only 
metastases and primary liver tumors. Several studies and meta-analyses show im-
proved overall survival after aggressive resection1-3. Recurrence-free survival, how-
ever, is rather low. Up to 69% of patients with colorectal liver metastases develop 
local recurrence or new metastases, with the majority in the first year4. Similar rates 
are reported in patients undergoing resection of hepatocellular carcinoma (hcc)5. 
These numbers are not entirely explained by incomplete resections and support the 
hypothesis that small malignant lesions are missed during resection.
It is well known that preoperative imaging modalities, including computed to-
mography (ct) and magnetic resonance imaging (mri), have relatively low sensi-
tivity for sub-centimeter lesions due to their limited spatial resolution. Moreover, 
altered body position during surgery and time interval between preoperative im-
aging and surgery make translation of preoperative images challenging. Extensive 
intraoperative inspection and palpation of the liver is therefore of vital impor-
tance. Palpation, however, is impossible during minimally invasive procedures. 
Laparoscopic ultrasonography (lus) can assist in detecting tumors, but acoustic re-
flection artifacts can obscure tumors in the first millimeters below the liver capsule6. 
In short, surgeons need a highly-sensitive, real-time intraoperative imaging modal-
ity to identify small superficial tumors in the liver.
Ishizawa and colleagues7 reported in 2009 that an intravenous injection of the safe 
and widely used dye indocyanine green (icg) causes “bullseyes” of fluorescence to be 
formed around primary or metastatic tumors in the liver. Defective biliary clearance 
in the transition area between tumor and normal liver tissue and in primary liver 
tumors results in icg retention, which can be visualized using a near-infrared (nir) 
fluorescence imaging system. Our group showed that this method of detection is fea-
sible during resection of hepatocellular carcinoma (hcc) and hepatic metastases of 
uveal melanoma (umlm) and colorectal cancer (crlm)8,9,10. The added value of fluo-
rescence imaging during oncological liver surgery is twofold: 1) it can demarcate liver 
tumors and provide real-time resection margin assessment, and 2) it can identify oth-
erwise undetectable, i.e., occult, (sub)capsular liver tumors. nir fluorescence imaging 
can be especially valuable during minimally invasive procedures, because surgeons 
are deprived of tactile feedback. Based on previous study results, fluorescence imag-
ing is now routinely performed during laparoscopic liver surgery in our hospital if 
patients provide informed consent. The purpose of the present study was to compare 
sensitivity and positive predictive values of fluorescence imaging with ct, mri, visual 
inspection, and lus during laparoscopic resection of several tumor types in the liver.
abstract
Background " Tumor recurrence after radical resection of hepatic tumors is 
not uncommon, suggesting that malignant lesions are missed during surgery. 
Intraoperative navigation using fluorescence guidance is an innovative technique 
enabling real-time identification of (sub)capsular liver tumors. The objective of the 
current study was to compare fluorescence imaging (fi) and conventional imaging 
modalities for laparoscopic detection of both primary and metastatic tumors in the 
liver.
Methods " Patients undergoing laparoscopic resection of a malignant hepatic 
tumor were eligible for inclusion. Patients received standard-of-care, including pre-
operative ct and/or mri. In addition, 10 mg indocyanine green was intravenwously 
administered one day prior to surgery. After introduction of the laparoscope, inspec-
tion, fi, and laparoscopic ultrasonography (lus) were performed. Histopathological 
examination of resected suspect tissue was considered the gold standard.
Results " Twenty-two patients suspected to have hepatocellular carcinoma 
(n=4), cholangiocarcinoma (n=2) or liver metastases from colorectal carcinoma 
(n=12), uveal melanoma (n=2) and breast cancer (n=2) were included. Two patients 
were excluded because their surgery was unexpectedly postponed several days. 
Twenty-six malignancies were resected in the remaining 20 patients. Sensitivity for 
various modalities was 80% (ct), 84% (mri), 62% (inspection), 86% (lus) and 92% 
(fi), respectively. Three metastases (12%) were identified solely by fi. All 26 malig-
nancies could be detected by combining lus and fi (100% sensitivity).
Conclusion " This study demonstrates added value of fi during laparoscopic 
resections of several hepatic tumors. Although larger series will be needed to con-
firm long-term patient outcome, the technology already aids the surgeon by provid-
ing real-time fluorescence guidance.
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All resected liver lesions were routinely analyzed at the pathology department 
and the method of detection was correlated with histopathological findings. 
Histopathological diagnosis was considered the gold standard. Sensitivity and posi-
tive predictive value of every resected lesion was calculated for all imaging modalities. 
Only malignant lesions were considered true positives. Statistical analysis was per-
formed using spss version 22.0 software (spss, ©ibm Corporation, Somer ny, usa).
results
Patient characteristics  A  Twenty-two patients planned to undergo 
laparoscopic staging (n=4) or resection (n=19) of one or multiple tumors confined to 
the liver were included from April 2013 to November 2015. Patient characteristics are 
shown in Table 1. One patient, with a suspected intrahepatic cholangiocarcinoma, 
was included twice. First, he underwent a diagnostic laparoscopy followed by resec-
tion of the liver tumor 2 months later. 
Preoperative working diagnosis differed from final histopathological diagnosis 
in 4 patients. One patient presented with a large, atypical mass in segments 2 and 3 
was suspected to have (fibrolamellar) hcc by radiological imaging. Final diagnosis 
demonstrated focal nodular hyperplasia (fnh). The second patient, with a history of 
laparoscopic cholecystectomy, presented with abdominal pain and preoperative im-
ages showed a liver lesion suspicious for hcc. This lesion was found to be liver tissue 
herniated through one of the old trocar incisions. The third patient presented with 
a history of breast cancer and a fdg-pet-positive lesion in segment 4b, suspicious 
for metastasis. Instead, the final diagnosis was intrahepatic cholangiocarcinoma. The 
fourth patient was suspected to have an intrahepatic cholangiocarcinoma and si-
multaneous liver metastases of a non-small cell lung carcinoma (nsclc). The large 
liver tumor suspicious for cholangiocarcinoma was not biopsied during the first pro-
cedure. Two other suspect lesions in the liver, either metastases of nsclc or hepatic 
adenomas, were biopsied and diagnosed as hepatic adenomas. The large tumor was 
resected in a second procedure and final histopathological evaluation indeed showed 
an intrahepatic cholangiocarcinoma.
Pre- and intraoperative tumor detection  A  No adverse events 
occurred due to icg administration. Two patients (suffering from umlm and crlm) 
were excluded, because their procedure was postponed 3 and 6 days after icg admin-
istration due to fever and logistical reasons. This delay resulted in intraoperative flu-
orescence signals too weak for sufficient guidance. In all other patients, fluorescence 
imaging of all types of tumors was successful (Figure 1).
materials and methods
Patients   A   The local Medical Ethics Committee and the Departments of 
Surgery and Anesthesiology approved implementation of nir fluorescence imaging 
during oncologic liver surgery as standard-of-care. Informed consent from all patients 
was obtained. icg (25 mg vials, Pulsion Medical Systems, Munich, Germany) was dis-
solved in 10 mL sterile water to yield a 2.5 mg/L (3.2 mM) concentration. Subsequently, 
a bolus of 4 mL containing 10 mg icg was administered intravenously 24 h prior to 
surgery. Dose and time of administration were optimized in our previous study8.
All patients undergoing laparoscopic staging or resection of a liver tumor were 
eligible for inclusion. Exclusion criteria were egfr <55, pregnancy, lactation, and an 
allergy to iodine, shellfish, or icg. Preoperative imaging was performed using com-
puted tomography (ct) with or without positron emission tomography (pet) and in 
most cases also using magnetic resonance imaging (mri), all within 6 weeks prior to 
surgery.
Near-infrared fluorescence imaging  A  Intraoperative imaging 
during surgery was performed using the laparoscopic high definition fluorescence 
imaging system (Karl Storz GmbH & Co. kg, Tuttlingen, Germany). The system 
includes a light source for visible and 760 nm (icg mode) light, a plasma light guide 
and a 30°, 10 mm laparoscope containing optical filters. The system allows easy 
switching between white light and icg modes using a foot pedal. Images were re-
corded using a charge-coupled camera device.
Ex vivo fluorescence imaging of resected tissue specimens was performed at 
the pathology department using the previously described Fluorescence-Assisted 
Resection and Exploration (flare®, Beth Israel Deaconess Medical Center, 
Boston, ma, usa) prototype surgical imaging system11. In addition, the location of 
icg in resected tissue was assessed using fluorescence microscopy. Digital images 
were made using the Leica dm5500B digital microscope (Leica Microsystems b.v., 
Son, The Netherlands) equipped with a Leica dfc365fx camera and las x software 
(version 2.6.0) for image acquisition and processing.
Procedure   A   The procedure started with inspection of the abdominal cav-
ity for presence of extrahepatic metastases. When none were found, the liver cap-
sule was inspected, followed by nir fluorescence imaging. Subsequently, lus was 
performed with a dedicated radiologist. Each suspect lesion detected by inspection, 
fluorescence imaging, and/or lus, was resected when the surgeon considered it to be 
safe and relevant.
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since multiple similar liver lesions were detected during surgery. In one patient, in-
traoperative nir fluorescence imaging after resection showed a fluorescent margin, 
located on the right portal vein. lus and inspection did not show any remaining 
tumor. Based on the latter results, and the goal of preserving as much liver volume 
as possible, it was decided not to extend the resection to a full hemihepatectomy. Ex 
vivo evaluation of the resected tissue showed a tumor positive resection margin, sug-
gesting that a full hemihepatectomy should have been considered.
In the second patient, the positive resection margin was in retrospect visible dur-
ing surgery (Figure 5). The positive resection margin in the third patient, suffering 
from a multinodular hcc, was not visible during surgery.
discussion 
The present study describes the largest series of intra-operative fluorescence im-
aging during minimally-invasive oncological liver surgery. Laparoscopic resec-
tion of liver tumors is believed to have several advantages over open surgery: less 
intraoperative blood loss, lower morbidity rates, and decreased length of hospital 
stay12,13. Importantly, overall and disease-free survival remains similar for patients 
with hcc and crlm. However, implementation of the laparoscopic technique oc-
curs slowly. In France for instance, currently approximately 15% of all liver resec-
tions are performed laparoscopically14. The main concerns include technical feasi-
bility, safety of the technique, and the substantial learning curve15. Indeed, depth 
perception and the range of motion are hampered by a lack of tactile feedback and 
three-dimensional vision, as well as by altered orientation and scale of the surgi-
cal field16. No randomized controlled trials exist, but one can imagine that, com-
pared to open procedures, the more technically demanding laparoscopic approach 
may expose patients to a higher risk of R1 resection. A recent meta-analysis showing 
a significant lower incidence of R1 resections after laparoscopic resection of crlm 
may be the result of a selection bias, as some tumor locations with a higher risk of in-
complete resection, such as the posterior segments, make an open approach prefer-
able17. nir fluorescence guidance during laparoscopic oncologic liver surgery reveals 
the localization of the tumor, enhances demarcation, and hopefully results in fewer 
incomplete resections. The current study showed that no nir fluorescence should 
be visible at the resection margin to ensure a surgical margin of at least 8 mm. The 
radical resection rate was 88% (22 of 25 malignancies) which is comparable with the 
literature18. All 3 incompletely removed tumors were located in the technically more 
demanding segments 6, 7, and/or 8.
A total of 46 lesions, including 26 malignant tumors with a median size of 20 mm, 
were resected in the remaining 20 patients (Table 2). Sensitivity and positive pre-
dictive values of the imaging modalities are shown in Figure 2. Of all resected ma-
lignancies, 20% were missed by ct-scan, 16% by mri-scan, 38% by inspection, 12% 
by lus, and 8% by nir fluorescence imaging. Sensitivity of all imaging modalities 
of lesions sized <10 mm dropped considerably. However, these differences were not 
statistically significant. The lesions missed by lus were all superficially located. The 
lesions missed by intraoperative nir fluorescence imaging (a crlm and umlm) 
were located >8 mm below the liver capsule. During gross examination at the pa-
thology department, the resected crlm did show rim-type fluorescence (Figure 3). 
The other false-negative lesion was located several centimeters below the liver cap-
sule and diagnosis was confirmed after biopsy. A sensitivity of 100% was reached 
when fluorescence imaging and lus were combined.
No additional malignancies were identified only by intraoperative inspection. 
lus alone identified one additional malignant tumor (Figure 3b). nir Fluorescence 
imaging solely identified 3 additional malignancies in 2 patients suffering from 
crlm. The first patient presented with a synchronous, solitary crlm in segment 
6, which partially responded to neo-adjuvant chemotherapy. During laparoscopic 
metastasectomy, 2 additional lesions in segment 3 were visualized by typical rim-
type fluorescence, whereupon resection of these lesions was performed (see Video 
1). Histopathological analysis confirmed the diagnosis of 2 metastatic intestinal type 
adenocarcinomas of 1 and 3 mm respectively. The second patient suffered from mul-
tiple crlm resected by bi-segmentectomy. The additional occult lesion, sized 2 mm, 
was identified within the planned resection area.
Positive predictive values were 71% (ct), 80% (mri), 52% (inspection), 77% (lus), 
75% (nir fluorescence imaging), and 70% (lus combined with nir fluorescence im-
aging). The differences did not reach statistical significance. Lesions that appeared 
suspicious by nir fluorescence imaging included a bile duct hamartoma, steatotic 
liver tissue, necrosis (3 times), cholestatic and inflamed liver tissue, fnh, and a biliary 
adenofibroma (Figure 4). Other benign lesions, such as cysts and fibrosis, were nega-
tive for nir fluorescence. In hindsight, 4 benign lesions were unnecessarily removed 
because inspection alone was positive. One benign lesion was removed because nir 
fluorescence imaging alone was positive.
Fluorescence imaging resulted in clear intra-operative demarcation of tumors. 
Resection could be performed more accurately using fluorescence guidance (see 
Video 2). Prior to resection, the planned margins could be checked again by lus. 
Histopathological evaluation of all resected malignant tumors revealed a radical re-
section rate of 88% (22/25). One large umlm was only biopsied to confirm diagnosis, 
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endoscopic fluorescence imaging system (Novadaq Technologies Inc, Toronto, 
Canada)23 and FireFly fluorescence imaging for the da Vinci Si surgical robot 
(Intuitive Surgical, Inc., Sunnyvale, ca, usa)24. These two systems do possess an 
overlay function, which may improve ease of use.
Near-infrared light (700-900 nm) has the advantage of higher photon penetra-
tion into tissue and lower autofluorescence compared to the visible light spectrum 
(400-700 nm). The reported depth penetration is however limited to a maximum 
of ≈ 8 mm25. In the present study, both lesions missed by fluorescence imaging were 
located >8 mm below the liver surface. Although the missed crlm did show rim-
type fluorescence ex vivo (Figure 3b), these lesions were intraoperatively only vis-
ible using lus. This finding demonstrates that fluorescence imaging must be seen 
as a complementary technique to lus. The combination of lus and fluorescence 
imaging reached a sensitivity of 100%. However, only suspect lesions were resected 
and this value is therefore not accurate, just like specificity and negative predictive 
value. No significant differences were found because this study was not designed and 
powered to do so. Deeper located liver tumors may also be visualized using intra-
operative photoacoustic tomography26. This technique combines the specific uptake 
of icg by some liver tumors with enhanced depth penetration of ultrasonography. 
Although feasible, technical improvements are required to make this technique 
available for clinical use.
Multiple studies illustrated the highly sensitive intraoperative detection of hcc 
and crlm using fluorescence imaging8,21,27,10. However, only 1 small study and 3 
case reports describe this technique during minimally-invasive liver surgery 9,28,29,30. 
Our group previously reported feasibility of umlm detection in 3 patients during 
laparoscopic resection9. Additional metastases were identified in 2 patients. Kudo 
et al. showed fluorescent detection of 12 out of 16 hccs and 11 out of 16 crlm in 17 
patients28. Contrary to our current study, no comparison was made between lesions 
detected by fluorescence imaging and by other imaging modalities. Moreover, no in-
formation was provided about false positive lesions detected by fluorescence imag-
ing. The rather disappointing results of this study may be the result of a less sensitive 
imaging system, a suboptimal icg dose, or variations in timing of icg administra-
tion. To improve homogeneity, we chose to use a fixed icg dose and to administer 
the dose the day before surgery. This strategy allowed visualization of all included 
tumors in vivo or ex vivo. 
Fluorescence imaging can assist in differentiating between benign and malignant 
lesions, such as cysts, fibrosis, and hemangiomas. In the current study, 4 necrotic le-
sions were suspicious using fluorescence imaging. These lesions were resected in 2 
crlm patients who received neoadjuvant therapy. It may be that these lesions were 
Two patients from the current study were excluded because fluorescence imaging 
several days after icg injection resulted in fluorescence signals that were too low. 
Other studies described adequate fluorescence imaging up to 2 weeks after icg ad-
ministration19. Patients included in these studies underwent a standard-of-care icg 
clearance test to assess liver function and received a dose of 0.5 mg/kg icg. In The 
Netherlands, this test is not standard-of-care. Moreover, we have previously opti-
mized dose and timing of administration resulting in a lower dose by a factor of 3 to 
58. The 2 excluded patients demonstrate that if a procedure is postponed, adequate 
fluorescence imaging demands a repeated dose of icg, a higher initial dose of icg, or 
a more sensitive fluorescence imaging system.
The appearance of the fluorescence signal during surgery depends not only on 
icg dose and timing of administration, but also on tumor type and localization. 
Superficial metastases are recognizable by rim-type fluorescence, while deeper lo-
cated metastases are completely surrounded by liver tissue and thus show total stain-
ing. In the current study, ex vivo fluorescence imaging showed rim-type fluores-
cence of all liver metastases and of the intrahepatic cholangiocarcinoma, while hcc 
also showed partial fluorescence. After intravenous administration, icg is rapidly 
eliminated from the blood via the liver with a half-life of 2-3 min. Retention of icg 
around liver tumors is not only due to simple mechanical compression of bile ducts. 
Recent studies revealed an underlying molecular mechanism. The transition zone 
between tumor and healthy liver tissue is composed of dedifferentiated hepatocytes 
with a keratine-7-positive immature phenotype8. These hepatocytes show down-
regulation of anion transporters and are consequently unable to transport icg into 
biliary canaliculi20. icg is thus entrapped around tumors in these immature hepa-
tocytes. Normally differentiated hepatocytes throughout the liver have already ex-
creted their icg and appear dark, just like metastases from extrahepatic tumors and 
poorly differentiated hcc, resulting in high contrast ratios. In differentiated hcc, 
the portal uptake function is preserved, leading to accumulation of icg in the tumor 
itself21. A similar mechanism may play a role in icg retention in fnh and biliary ad-
enofibroma, as shown in this study (Figure 4). Observations in resected liver tumors 
showed that icg is not only preserved in fresh tissue, but also in paraffin-embedded 
tissue22. Ex vivo fluorescence imaging remains possible in samples as old as 3 years.
The laparoscopic imaging system used in this study, i.e. the Karl Storz hd fluo-
rescence laparoscope, allows easy switching between white light modus and fluo-
rescence modus using a foot pedal. A drawback of this system is that no overlay 
of fluorescence and white light images is available. This makes orientation during 
fluorescence imaging sometimes challenging. Several other laparoscopic fluores-
cence imaging systems are available, including the commercially-available Pinpoint 
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Figure 1 Representative images of intraoperative nir fluorescence identification of liver tumors
A well-differentiated hepatocellular carcinoma shows uptake of icg in and around the tumor.  
A cholangiocarcinoma shows a rim-type fluorescence, similar to hepatic metastasis of colorectal and breast 
cancer and uveal melanoma. As the breast cancer and uveal melanoma liver metastases are located below the 
liver surface, the fluorescence does not show a rim. However, ex vivo a distinctive rim-type fluorescence signal 
is visible (data not shown). Of note, the fluorescence laparoscope does not possess an overlay function; the 
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All           < 10 mm        > 10 mm
Figure 2 Sensitivity of all imaging modalities employed
Sensitivity and positive predictive value of computed tomography (ct), magnetic resonance imaging 
(mri), visual inspection, laparoscopic ultrasonography (lus), near-infrared fluorescence imaging (nirf) 
and combination of lus and nirf. nirf has the highest sensitivity rate amongst all imaging modalities. 
Combination of nirf + lus results in detection of all hepatic tumors (100% detection). The graph shows the 
sensitivity for all lesions together and divided into <10 mm and ≥10 mm. Sensitivity of all imaging modalities 
drops considerably for detection of lesions <10 mm. However, all small lesions could still be detected by 
combining nirf and lus. Differences are not statistically.
Figure 3 Ex vivo fluorescence imaging of resected tumors
Rim-type fluorescence surrounding a cholangiocarcinoma (ChC, image A) and a colorectal liver metastasis 
(crlm, image B) imaged using a flare® prototype. The crlm was not visible using fluorescence imaging  
during surgery, because it was located >8 mm below the liver surface. Matching microscopic images (magni-
fication 2X and 40X) of hematoxylin & eosin and dapi staining sections were made of ChC (image C) and 
crlm (image D). Fluorescence shows a sharp demarcation between normal liver tissue and fibrosis or tumor 
tissue. Image D also shows fluorescence in a biliary duct, probably due to mechanic obstruction by the tumor.
t = tumor
f = fibrosis
n = normal liver tissue
b = biliary duct











Figure 4 Fluorescence imaging of benign lesions
A Intraoperative imaging of a cyst (white arrow) and a bile duct hamartoma (dashed arrow). The cyst 
 is not visible using f luorescence imaging, but the bile duct hamartoma is. The weak f luorescence signal 
does not show a distinctive rim-type f luorescence and can thereby be discriminated from a malignancy.
B Benign, large focal nodular hyperplasia also shows nir f luorescence. The mechanism of icg uptake is 
unknown, but potentially its biliary excretion is disturbed.
Figure 5 Intraoperative visualization of a positive resection margin of a colorectal liver metastasis
In vivo fluorescence is visible in the resection margin (white arrow), indicating a tumor-free margin of less than 
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Table 1 Patient characteristics
Total patients, N 22
Age at surgery, median [range] 65 [28 – 76]
Gender, % (n) Female 45 [5]
Male 55 [11]
bmi, median [range] 23.0 [18.8 – 36.6]




Liver cirrhosis, % (n) 14 [15]
Neo-adjuvant therapy, % (n) 27 [31]
asa = American Society of Anesthesiologists
Table 2 Characteristics of resected lesions
  Histopathological  
diagnosis
N Size (mm) Method of detection, n/N*
ct mri Insp lus nirf lus + nirf
Malignant hcc 3 45 [25-58] 3/3 1/1 2/3 3/3 3/3 3/3
ChC 2 32 [30-33] 1/1 1/1 2/2 2/2 2/2 2/2
crlm 18 18 [1-35] 14/18 11/14 10/18 15/18 17/18 18/18
umlm 2 16 [14-18] 2/2 2/2 1/2 2/2 1/2 2/2
bclm 1 11 0/1 1/1 1/1 1/1 1/1 1/1
total 26 20 [1-58] 20/25 16/19 16/26 23/26 24/26 26/26
Benign Adenoma 1 20 1/1 - 1/1 1/1 0/1 1/1
fnh 1 84 1/1 - 1/1 1/1 1/1 1/1
Biliary adenofibroma 1 18 1/1 - 1/1 1/1 1/1 1/1
Bile duct hamartoma 6 4 [2-15] 1/6 1/5 5/6 1/5 1/6 2/6
Necrosis 4 13 [8-37] 2/4 2/4 3/4 2/4 3/4 3/4
No lesion identified** 2 - 1/2 1/2 1/2 0/2 0/2 0/2
Other*** 5 - 1/3 0/4 3/5 1/5 2/5 3/5
Total 20 13 [2-84] 8/18 4/15 15/20 7/19 8/20 11/20
Insp. = inspection; hcc = hepatocellular carcinoma; chc = intrahepatic cholangiocarcinoma;  
crlm = colorectal liver metastasis; umlm = uveal melanoma liver metastasis; bclm = breast cancer liver metastasis; 
fnh = focal nodular hyperplasia. 
* Not all lesions were imaged by all imaging modalities.  
** After gross examination, the pathologist could not identify any abnormal lesion in two specimens. 
*** Includes cholestasis, cirrhotic tissue, fibrosis and steatosis. 
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introduction
The introduction of molecular targeted oncologic therapies has created the need 
to select patients with the right expression patterns to achieve optimal results1. 
Currently, the molecular markup of tumors can be determined using (real-time or 
quantitative reverse transcription) polymerase chain reaction, microrna detec-
tion, or immunohistochemistry (ihc). Immunohistochemical staining of tumor 
tissue is the preferred method, since it provides insight about the expression pat-
tern of specific membrane-bound proteins and, in addition, is a relatively easy and 
inexpensive technique. Immunohistochemical staining of tumor biopsies is already 
implemented in clinical practice and used as an efficient selection method in cancer 
care in, for example, breast cancer patients2. Concordance of biomarker expression 
between biopsy, primary tumor and (distant) metastasis is important for appropri-
ate application of tumor-targeted modalities; e.g. Positron Emission Tomography 
(pet) or Single Photon Emission Computed Tomography (spect)-targeted agents 
or targeted therapies. For example, a biopsy can turn out to be positive for a certain 
biomarker while the distant metastasis showed to be negative in most of the cases, 
resulting in suboptimal applications/results of the targeted approaches. In this study, 
we investigate these concordances in nsclc and breast cancer patients and generate 
insight for the reliable application of frα-targeted agents in these patients.
In the past decades, several membrane-located proteins were discovered that 
could successfully be targeted, i.e. estrogen/progesterone receptor (er/pr) in breast 
cancer patients and epidermal growth factor receptor (egfr) in lung cancer pa-
tients2,3. Another potential target that holds great promise is folate receptor alpha 
(frα). This glycosylphosphatidylinositol (gpi)-anchored cell membrane protein was 
first described on a human ovarian cancer cell line in 1991 and is part of the folate 
receptor (fr) family4,5. Folic acid and 5-methyltetrahydrofolate, the major circulat-
ing form of folate, bind with high affinity to these frs6. Folate, the water-soluble 
vitamin B9, is involved in one-carbon metabolic reactions and is therefore required 
in the biosynthesis of the nucleotide bases thymine and uracil. The essential role of 
folate in growth, proliferation and survival of cells reflects the importance of fo-
late during growth and sustenance of tumor cells7,8. In total, four isoforms of fr 
are described of which frβ and frγ are sited on hematopoietic cells and overex-
pressed on cancer cells of hematopoietic origin7. The isoform frβ is also found on 
activated macrophages, while the function of frδ remains unclear. frα is normal-
ly located on the apical surface of a restricted number of healthy epithelial tissues, 
such as proximal kidney tubules, fallopian tube and type I and ii pneumocytes of the 
lung9. Research on frα has focused on identification of tumor types that show frα 
abstract
Folate receptor alpha (frα) is known to be upregulated in a variety of cancers, in-
cluding non-small-cell lung cancer (nsclc) and breast cancer. To ensure reliable 
implementation of diagnostic- and therapeutic agents, concordance of frα expres-
sion between biopsy, primary tumor and metastases is important. Using immuno-
histochemistry (Mab 26B3.F2) these concordances were investigated in 60 nsclc 
and 40 breast cancer patients. False positivity of frα expression on breast and lung 
cancer biopsies was limited to less than 5%. In nsclc, frα expression was shown 
in 21/34 adenocarcinomas and 4/26 squamous cell carcinomas (scc). Concordance 
of frα expression between biopsy and primary tumor was achieved in respectively 
83% and 91% of adenocarcinomas and sccs. Approximately 80% of all local and dis-
tant metastases of nsclc patients showed concordant frα expression as their cor-
responding primary tumor. In breast cancer, frα positivity was shown in 12/40 biop-
sies, 20/40 lumpectomies and 6/20 ln metastases, with concordance of 68% between 
biopsy and primary tumor and 60% between primary tumor and ln metastases. In 
conclusion, this study shows high concordance rates of frα expression between bi-
opsies and metastases compared to primary nsclc and breast cancers, underscoring 
the applicability of frα-targeted agents in these patients. 
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frα expression and concordance between biopsy, primary 
tumor and metastases in nsclc patients  A  Of all primary tumors 
containing adenocarcinoma (n=34), 21 out of 34 tumors showed frα expression 
of which the majority (>80%) showed overexpression (Figure 1, Table 2). Hetero-
geneity of frα expression was seen in 16 out of 21 frα-expressing adenocarcino-
mas. Of all primary tumors containing scc (n=26), only 4 out of 26 tumors showed 
frα expression. Overexpression was seen in 1 scc and a heterogeneous staining pat-
tern in 3 out of 4 sccs. Of all biopsy specimens (n=23), 8 out of 12 adenocarcinomas 
showed frα expression whereas only 2 out of 11 sccs showed frα expression. Of all 
60 metastatic lns, obtained from 33 patients, 26 out of 42 lns containing adenocar-
cinoma showed frα expression, whereas 3 out of 18 lns containing scc showed frα 
expression. Of all distant metastases (n=23), frα expression was shown in 5 out of 15 
adenocarcinomas but in none of the 8 sccs.
Concordance of frα expression between biopsy and primary tumor was shown 
in 20 out of 23 biopsies (Figure 2, Table 3). Two of the disconcordances (one ad-
enocarcinoma and one scc) were attributed to loss of frα expression in biopsy 
specimens, while primary tumors did show expression. The other disconcordance 
was due to upregulation of frα expression on the biopsy specimen, containing ad-
enocarcinoma. In conclusion, only one biopsy specimen showed false positivity. 
Concordance between local metastasis, e.g. metastatic lns, and primary tumor was 
shown in 31 out of 42 lns containing adenocarcinoma, within 14 of 18 patients. All 
disconcordances could be attributed to loss of frα expression in metastatic lns. In 
scc, concordance of frα expression between metastatic lns and primary tumor was 
achieved in 13 out of 18 lns, within 12 of 15 patients. In 3 lns disconcordance was 
attributed to upregulation of frα expression, while 2 lns showed downregulation 
compared to frα expression in the primary tumor. Concordance between primary 
tumors and corresponding distant metastases was seen in 12 out of 15 adenocarcino-
mas and in 7 out of 8 scc (Figure 3). Disconcordance in 2 of the metastatic adenocar-
cinomas and in the metastasis that contained scc was attributed to downregulation 
of the distant metastases compared to the primary tumor. The other bone metastasis 
containing adenocarcinoma showed upregulation compared to the corresponding 
primary tumor. 
frα expression and concordance between biopsy, primary 
tumor and metastases in breast cancer patients  A  Of the 
total cohort of breast cancer patients in this study (n=40), a positive frα expression 
was seen in 12 of the 40 biopsy specimens, 20 of the 40 lumpectomy specimens and 
6 of the 20 metastatic lns (Figure 1, Table 4). Overexpression of frα was seen in the 
overexpression and a recent study showed that 40% of epithelial tumors show frα 
overexpression, including (non-mucinous) ovarian, kidney, uterine, colon, lung and 
breast cancer10. 
Lung cancer is the number one cause of cancer death worldwide with a poor five-
year survival estimated at 15%. This disease can be divided in non-small cell lung 
cancer (nsclc), contributing to 85% of all lung cancers, and small cell lung cancer 
(sclc). nsclc is further subdivided by histological subtype, of which adenocarci-
noma (40%), squamous cell carcinoma (25-30%) and large-cell carcinoma (10-15%) 
are the most prevalent11. Tumor-targeted therapies have already been extensively 
studied in lung cancer patients, which resulted in implementation of such therapies, 
e.g. bevacizumab, erlotinib and gefitinib, in the treatment guideline of lung cancer 
disease12. Overexpression of frα in lung cancer is mainly restricted to nsclc and 
can therefore be an interesting target for many lung cancer patients13,14. In breast 
cancer, treatment is already personalized by molecular protein expression of the 
tumor2. The outcome of breast cancer patients is significantly improved by targeted 
treatment focused on hormone receptor (hr) positive, or human epidermal growth 
factor receptor 2 (her2) positive tumors. However, 15% of all breast cancers show no 
expression of either er/pr or her2 and are considered triple negative (tn) breast 
cancers. This type of breast cancer has the worst prognosis amongst all breast can-
cers15. Previous studies reported frα overexpression on especially the majority of 
tn breast cancers and therefore, frα could be an interesting target for this specific 
group of patients16. 
The aim of the present study is to determine frα expression on both nsclc and 
breast cancers and to determine concordance between frα expression on biopsy, pri-
mary tumor and corresponding local and distant metastatic tissue. 
results
Patient and tumor characteristics  A  Patient- and histopathologi-
cal characteristics of all nsclc and breast cancer patients are summarized in Table 1. 
In short, mean age of breast and nsclc patients was respectively 56 and 63.5 years at 
diagnosis. The majority of breast cancer patients displayed pT1 or pT2 stage tumors 
and all of them underwent a lumpectomy. The majority of nsclc patients displayed 
pT4 tumors and iascl stage iv. Of both nsclc and breast cancer patients approxi-
mately 70% showed lymph node involvement, i.e. nodal stage N1-2. The cohort of 
breast cancer patients consisted of 15 tn breast cancers with a majority of high-
grade tumors, e.g. 21 out of 40 tumors showed differentiation grade iii. 
fluorescence-enhanced surgical navigation 
66 
PART Ii • chapter 5 • FRα expression in breast- and lung cancer tissues
67
therapeutic agents can be delivered intracellular in through frα-mediated endocy-
tosis18. During this process, an endosome (containing a frα-targeted agent bound 
to frα) is formed which moves to the recycling center, close to the nucleus. Here, 
the folate-agent detaches from its receptor and is released, in contrast to the re-
ceptor that is brought back to the cell surface. This pathway is mainly responsible 
for accumulation of frα-targeted agents in malignant cells. However, absorption 
of folate in normal tissue such as duodenum and jejunum is facilitated by the pro-
ton-coupled folate transporter and the reduced folate carrier (rfc). This anion ex-
changer is responsible for transport of the majority of folate in healthy tissues, while 
folate-coupled agents show no affinity for this rfc nor the proton-coupled folate 
transporter7,19. 
As reported by Hilgenbrink and Low et al.20, folate has been linked to a wide 
variation of substances used in cancer therapy, including protein toxins, enzymes to 
activate prodrugs, chemotherapeutics, immunotherapeutic agents, drug-comprising 
liposomes and nanoparticles. Currently, farletuzumab, vintafolide and imgn853 are 
the three frα-targeting agents that show the most potential in clinical cancer trials, 
among other as treatment strategy for lung cancer10,21. Detection of malignancies 
by frα-targeted imaging approaches is studied broadly using folate linked to radio-
nuclides, pet agents, mri contrast agents and fluorescent dyes. In nsclc, a recent 
study of Okusanya et al. showed feasibility of intraoperative detection of small sub-
pleural lung tumors using a fluorescent frα-targeted molecular agent, e.g. folate-
fitc (Figure 5)22. An excellent sensitivity and specificity was shown, resulting in the 
start of a novel study with the same targeting ligand but optimized fluorophore, e.g. 
otl-38 (clinicaltrial.gov). Analysis of a similar clinical trial in breast cancer patients 
is currently ongoing to determine tumor detection during breast cancer surgery 
using folate-fitc (clinicaltrial.gov). 
In order to efficiently apply both frα-targeted therapeutic and imaging agents, 
adequate patient selection regarding frα expression is required. In addition, 
knowledge about the concordance of frα expression between biopsy, primary tumor 
specimen and (possible) metastasis is pivotal to estimate efficacy and usability of 
these approaches. Based on results from the current study, selection of breast- and 
nsclc patients who might benefit from frα-targeted approaches can be performed 
reliably via biopsy staining. Although the majority of tumor specimens showed 
heterogeneity of frα expression, less than 5% of all biopsies showed false positivity. 
In a clinical setting, this suggests that 1 out of 20 included breast cancer or nsclc 
patients in a frα-targeted trial would show no frα expression in the primary tumor 
while the biopsy stained frα-positive. Regarding the targeting of disseminated 
malignant cells, this study shows high concordance rates of local/distant metastases 
majority of biopsies, lumpectomy specimens and metastatic lns, however, almost 
no homogeneous staining patterns were detected. In total, only 5 of the 20 primary 
tumors showed a homogeneous staining pattern. Of all tissue, the hormone receptor 
(hr) status was known and correlated with frα expression. As described in Table 4, 
the hr status, e.g. er/pr status, showed to correlate negatively with frα expression 
of biopsies (p=0.002) and lumpectomy specimens (p=0.010). Of all the 15 tn breast 
cancers that were included in this study, e.g. er-pr-Her2-, respectively 7 biopsies 
(p=0.091) and 12 primary tumor specimens (p=0.008) showed a positive frα expres-
sion. In addition, 3 out of 7 metastatic lns of tn breast cancers showed frα positiv-
ity (p=0.613). Of all biopsy and lumpectomy tissue, a subdivision of frα expression 
per ln status was made. Of all specimens of patients with ln metastases (n=27), 7 
out of 27 biopsies showed a positive frα expression and 12 out of 27 lumpectomy 
specimens. 
Concordance of frα expression between biopsy and primary tumor was shown 
in 27 out of 40 specimens (Figure 2, Table 3). Disconcordance was attributed to 
downregulation of frα on the biopsy specimens compared to the primary tumor in 
11 of the 13 tissue sections and upregulation in 2 tissue sections. In conclusion, based 
on concordance of biopsy and primary tumor tissue, only 2 of the 40 evaluated tis-
sue specimens showed false positivity. Furthermore, in 50% of all tissues, a similar 
frα expression was shown in biopsy, lumpectomy and metastatic ln. Concordance 
between primary tumor and metastatic ln, in the cohort with ln metastases, was 
seen in 12 out of 20 specimens. Subanalysis showed that 6 out of these 8 disconcor-
dances were attributed to downregulation of frα expression on metastatic lns com-
pared to the primary tumor. The remaining two lns showed a positive frα expres-
sion, whereas the corresponding lumpectomy specimen did not show frα expres-
sion. Separate analysis of the 6 patients that received neoadjuvant therapy showed 
in 4 out of these 6 patients concordant frα expression between primary tumor and 
biopsy specimen. All these 4 patients showed no frα expression in biopsy nor in 
primary tumor. The other two patients both showed a positive frα expression on 
the primary tumor, but no expression on corresponding biopsy. In 5 of the 6 patients 
who received neoadjuvant therapy, metastatic lns were available for evaluation of 
frα expression. Only one metastatic ln showed frα positivity, which was not con-
cordant with the absent frα expression of the primary tumor. 
discussion
Since frα has emerged as target for imaging and treatment purposes, several 
clinical trials have been conducted with promising results10,17. Diagnostic and 
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worse (disease-free) survival16,28. Increased folate storage in frα-expressing tumors 
may cause accelerated growth and consequently, a more aggressive tumor. However, 
a recent study describing frα expression in breast cancer brain metastases was un-
able to show any association between frα expression and survival, possibly due to 
small sample size29. In lung cancer, results from studies investigating survival and 
frα expression also vary. Several ihc studies and a study investigating frα gene ex-
pression using rt-pcr, reported an improved overall survival when frα expression 
is high14,30. However, Nunez et al. could not show any correlation between frα ex-
pression and overall- or recurrence free survival in a cohort of 320 patients13. It still 
remains unclear why high levels of frα are correlated with a favorable prognosis; 
further research is warranted to explain this.
Recent studies showed that frα expressing breast cancers represented a novel 
molecular subtype associated with er-/pr-/Her2Neu- and er- breast cancers16,28. 
The current study endorses these conclusions as 12 out of 15 primary tumors of tn 
breast cancers showed a positive frα expression and a significant correlation be-
tween hr status and frα expression on both biopsy specimens (p=0.002) and pri-
mary tumors (p=0.010) was found. It is known that estrogens are involved in the 
regulation of frα expression and 17β estradiol via the p4 promoter, resulting in 
down-regulation of frα31,32. Positive frα expression was shown in respectively 
30%, 50% and 30% of biopsy-, lumpectomy- and metastatic ln tissue. Although this 
percentage is higher than described in literature, it must be noted that 67.5% of the 
included patients had ln metastases (N1-2) and 37.5% were tn breast cancer pa-
tients. Furthermore, tumors displayed a relatively high tumor grade. In the study of 
Zhang et al.28, a significant association between frα positive expression and high 
histologic grade, high nodal stage and subgroups of er/pr- and tn breast cancers 
was shown. In an extra cohort of metastatic stage iv, Her2 negative breast cancer 
patients, O’Shannessy et al.16 described that the percentage of frα positive tumors 
in early stage disease is retained in late stage metastatic disease, as 36% of samples 
showed frα positive expression of whom 86% were tn breast cancers.
In an additional cohort of nsclc patients (n=23), concordance of frα expression 
between primary tumor and corresponding distant metastases was assessed. In the 
literature, little is known about frα expression on distant metastases. In a study of 
O’Shannessy et al.14, 9 fine needle aspirates comprising ln metastases of lung ad-
enocarcinoma showed 63% frα positivity. Furthermore, Nunez et al.13 reported no 
significant difference in frα expression between 27 nsclc and 15 derived metastatic 
sites. We show concordance rates between primary tumor and distant metastases of 
respectively 80% and 88% for adenocarcinomas and sccs. In addition, all metastatic 
lns showed concordant frα expression with the corresponding distant metastases. 
with corresponding primary tumors. Although concordance rates were relatively 
lower for breast cancer than for nsclc, e.g. 68% vs. >80%, these results still suggest 
that the majority of metastases can be targeted when the primary tumor shows frα 
expression. 
Overall, disconcordance was mainly due to downregulation of frα in biopsy- 
and metastastic tissue compared to primary nsclc and breast cancer, which could 
be a result of tissue sampling or of heterogeneity of frα expression. In this study, 
whole tissue slides were used to overcome the difficulty in evaluating heterogeneity 
as is experienced with the generally used tmas23. Of all 266 evaluated tumor tissue 
specimens, heterogeneity of frα was shown in the majority (>80%) of the stained 
sections. 
Several ihc studies investigated frα expression on primary lung (nsclc) and 
breast cancers. Two lung studies applied the same monoclonal antibody as used in 
this study, i.e. 26B3.F2, and displayed similar expression rates, underscoring the va-
lidity of the used staining: more than 70% of adenocarcinomas expressed frα and 
less than 15% of sccs14,24. In the current study, a significant association between frα 
expression and histological subtype was shown in biopsies (p=0.036), primary tu-
mors (p<0.001) and metastatic lns (p=0.004). The distinction between frα expres-
sion in adenocarcinoma and scc is caused by the type of cancer cell they derive from; 
adenocarcinoma originates from frα-expressing type 1 and 2 pneumocytes and scc 
from more centrally positioned tracheal cells which do not express the receptor14,25. 
Other ihc studies using a different monoclonal antibody (mab343) showed ex-
pression rates in adenocarcinoma and scc ranging from 72% to 87% and 15% to 57% 
respectively13,26. The difference in percentages of positive frα expressing tumors be-
tween studies may be partially contributed to a variation in applied antibodies. For 
example, relatively high percentages of frα expression in patients with scc obtained 
using mab343 may be a result of non-specific binding13,26. Furthermore, cut-off 
values for defining frα positivity and scoring methods are diverse amongst stud-
ies. Nunez et al.13 examined frα expression in nsclc patients (n=320) by using the 
H-score, which offers a separate score for both cytoplasmic and membranous stain-
ing. In breast cancer, cut-off values for defining frα positivity differed from 5-15%. 
Scoring using the M-score has been described in which both membranous tumor 
cell staining and the proportion and staining intensity of frα positive cells are cap-
tured16. Hartmann et al.27 assessed frα expression using mab343 on a tissue micro 
array (tma) containing samples of 63 invasive breast cancers with either poor or 
good outcome. An association between strong frα expression and a poor outcome, 
defined as median time to recurrence of 1.9 years, was shown. These results are in line 
with other studies describing a significant association between frα expression and 
fluorescence-enhanced surgical navigation 
70 
PART Ii • chapter 5 • FRα expression in breast- and lung cancer tissues
71
adenocarcinoma, whereas 8 of them contained scc. Of one patient who suffered 
from adenocarcinoma, tissues from two different metastatic sites were included. 
Metastases originated mostly from the brain (n=10), followed by metastases from 
bone (n=7), liver (n=3), skin (n=1), adrenal gland (n=1) and jejunum (n=1). 
The total cohort of breast cancer patients consisted of 40 patients, who had un-
dergone a breast conserving surgery (lumpectomy) for a cT1 or cT2 stage tumor be-
tween 2000-2014. In total, 6 of the 40 patients received neoadjuvant chemotherapy, 
of whom obtained results are separately described. The first cohort of breast cancer 
patients consisted of 20 patients of whom biopsy specimen and lumpectomy tissue 
was stained. In addition, a second cohort of 20 patients was included to assess con-
cordance of frα expression between biopsy specimen, lumpectomy and metastatic 
lns. Of all patients, the receptor status of the tumor tissue was known, e.g. er, pr 
and her2 status.
Immunohistochemistry  A  ihc was performed using formalin-fixed, 
paraffin-embedded (ffpe) tissue, obtained from the Pathology archive from the 
Leiden University Medical Center, Diakonessen Hospital and Rijnland Hospital. 
All samples were handled in an anonymous fashion according to the national 
ethical guidelines (‘Code for Proper Secondary Use of Human Tissue,’ Dutch 
Federation of Medical Scientific Societies) and approved by the Institutional Ethics 
Committee of the Leiden University Medical Center. Tissue samples were stained 
using the monoclonal antibody (Mab) 26B3.F2 (certified Folate Receptor alpha ihc 
Assay Kit, Biocare Medical) and subsequently scored for staining. The Mab26B3.F2 
is highly specific for frα without cross-reactivity to the other fr, e.g. frβ, frγ or 
frδ. Validation of the staining protocol was performed by using (the recommend-
ed) lung adenocarcinoma as positive control and normal liver as negative control. 
Immunohistochemical staining was performed on 4 um paraffin sections on adhe-
sive slides. Slides were deparaffinized in xylene and rehydrated in decreasing con-
centrations of ethanol. After rinsing in distilled water, endogenous peroxidase was 
blocked with hydrogen peroxide for five minutes. Slides were rinsed in water and 
antigen retrieval was performed in the dako pt Link, Target Retrieval Solution 
pH6.0 at 95°C for 10 minutes. After rinsing in pbs, nonspecific sites were blocked 
with a protein block (Background Punisher) for 5 minutes and the secondary an-
tibody was incubated for 30 minutes on room temperature. As a negative control, 
one control slide was incubated with negative control reagent. After three washes 
the slides were incubated with mach4 Mouse Probe Primary Antibody Enhancer 
(Biocare Medical) for 10 minutes. Again slides were washed in pbs, followed by in-
cubation with mach4 hrp Polymer for 10 minutes. Subsequently, the slides were 
On the contrary, Kikuchi et al.33 showed downregulation of frα gene expression 
in 16 metastatic brain tumors compared to 22 primary lung adenocarcinomas using 
cdna microarray. However, as this study investigated gene expression and non-cor-
responding metastases, results have to be interpreted with caution. 
Finally, normal breast and lung cells showed frα expression (Figure 3). In par-
ticular the luminal border of secretory cells (due to the secretion of folate in milk) 
and the myoepithelial layers of normal epithelial breast tissue stained positive. 
Nonetheless, frα expression on normal breast and lung tissue will not significantly 
interfere when frα-targeted agents are intravenously administered, since the recep-
tor is confined to the luminal side of polarized epithelial cells. The lack of cellular 
polarity on malignant cells on the other hand, will lead to binding of frα-targeted 
agents through the whole tumor18. 
In conclusion, this study shows high concordance rates of frα expression be-
tween primary tumor and corresponding biopsy and metastatic tissue of both breast 
cancer and nsclc patients, underscoring applicability of frα-targeted agents in 
these patients. Moreover, an association between frα expression and histological/
molecular subtype of tumors was shown. Importantly, false positivity of frα expres-
sion on biopsies was limited to less than 5%. Although this study is performed with 
a relatively small amount of tissue specimens, the current results provide rational for 
the use of biopsies to select lung and breast cancer patients for frα-targeted agents, 
eventually leading to optimal personalized medicine. 
material and methods
Tissue samples  A  The total cohort of nsclc patients consisted of 38 patients 
who received curative surgery between 2011-2013 and 22 patients with distant me-
tastases (2000-2013). Of all 60 nsclc patients, 34 primary tumors containing ad-
enocarcinoma and 26 sccs were included as shown in Table 1. To assess the cor-
relation between frα expression on primary tumor and preoperatively obtained 
biopsy tissue, all available biopsy specimens, obtained via mediastinal biopsy, were 
collected. However, in some patients a transesophageal endoscopic ultrasound 
fine needle aspiration (eus-fna) or endobronchial ultrasound transbronchial 
needle aspiration (ebus-tbna) was performed and some patients were referred 
to our academic center, of whom biopsy specimen could not be obtained. In total, 
23 biopsies were collected: 12 biopsies containing adenocarcinoma and 11 biopsies 
containing scc (Table 2). Moreover, 60 metastatic lns of 33 patients were stained 
for frα. Adenocarcinoma was present in 42 of these lns, while scc was present 
in the remaining 18 metastatic lns. Fifteen of the distant metastases contained 
fluorescence-enhanced surgical navigation 
72 
PART Ii • chapter 5 • FRα expression in breast- and lung cancer tissues
73
references
1 Maitland M.L., Schilsky R.L. Clinical trials in 
the era of personalized oncology. CA Cancer J 
Clin;61:365-81;2011
2 Kourea H.P., Zolota V., Scopa C.D. Targeted 
pathways in breast cancer: molecular and protein 
markers guiding therapeutic decisions. Curr Mol 
Pharmacol;7:4-21;2014
3 Roengvoraphoj M., Tsongalis G.J., Dragnev K.H., 
Rigas J.R. Epidermal growth factor receptor tyrosine 
kinase inhibitors as initial therapy for non-small cell 
lung cancer: focus on epidermal growth factor receptor 
mutation testing and mutation-positive patients. 
Cancer Treat Rev;39:839-50;2013
4 Coney L.R., Tomassetti A., Carayannopoulos L., 
Frasca V., Kamen B.A., Colnaghi M.I. et al. Cloning 
of a tumor-associated antigen: MOv18 and MOv19 
antibodies recognize a folate-binding protein. Cancer 
Res;51:6125-32;1991
5 Ross J.F., Chaudhuri P.K., Ratnam M. Differential 
regulation of folate receptor isoforms in normal 
and malignant tissues in vivo and in established 
cell lines. Physiologic and clinical implications. 
Cancer;73:2432-43;1994
6 Della-Longa S., Arcovito A. Structural and functional 
insights on folate receptor alpha (FRalpha) by 
homology modeling, ligand docking and molecular 
dynamics. J Mol Graph Model;44:197-207;2013
7 Elnakat H., Ratnam M. Distribution, functionality 
and gene regulation of folate receptor isoforms: 
implications in targeted therapy. Adv Drug Deliv 
Rev;56:1067-84;2004
8 Gonen N., Assaraf Y.G. Antifolates in cancer therapy: 
structure, activity and mechanisms of drug resistance. 
Drug Resist Updat;15:183-210;2012
9 Weitman S.D., Lark R.H., Coney L.R., Fort D.W., 
Frasca V., Zurawski V.R., Jr. et al. Distribution of the 
folate receptor GP38 in normal and malignant cell lines 
and tissues. Cancer Res;52:3396-401;1992
10 Assaraf Y.G., Leamon C.P., Reddy J.A. The folate 
receptor as a rational therapeutic target for personalized 
cancer treatment. Drug Resist Updat;17:89-95;2014
11 de G.P., Munden R.F. Lung cancer epidemiology, 
risk factors, and prevention. Radiol Clin North 
Am;50:863-76;2012
12 Gadgeel S.M., Ramalingam S.S., Kalemkerian 
G.P. Treatment of lung cancer. Radiol Clin North 
Am;50:961-74;2012
13 Nunez M.I., Behrens C., Woods D.M., Lin H., 
Suraokar M., Kadara H. et al. High expression of 
folate receptor alpha in lung cancer correlates with 
adenocarcinoma histology and EGFR corrected 
mutation. J Thorac Oncol;7:833-40;2012
14 O’Shannessy D.J., Yu G., Smale R., Fu Y.S., Singhal 
S., Thiel R.P. et al. Folate receptor alpha expression in 
lung cancer: diagnostic and prognostic significance. 
Oncotarget;3:414-25;2012
15 Chen L., Linden H.M., Anderson B.O., Li C.I. Trends 
in 5-year survival rates among breast cancer patients by 
hormone receptor status and stage. Breast Cancer Res 
Treat;147:609-16;2014
16 O’Shannessy D.J., Somers E.B., Maltzman J., Smale 
R., Fu Y.S. Folate receptor alpha (FRA) expression 
in breast cancer: identification of a new molecular 
subtype and association with triple negative disease. 
Springerplus;1:22;2012
17 Sega E.I., Low P.S. Tumor detection using folate 
receptor-targeted imaging agents. Cancer Metastasis 
Rev;27:655-64;2008
18 Low P.S., Kularatne S.A. Folate-targeted therapeutic 
and imaging agents for cancer. Curr Opin Chem 
Biol;13:256-62;2009
19 Matherly L.H., Hou Z. Structure and function of the 
reduced folate carrier a paradigm of a major facilitator 
superfamily mammalian nutrient transporter. Vitam 
Horm;79:145-84;2008
20 Hilgenbrink A.R., Low P.S. Folate receptor-mediated 
drug targeting: from therapeutics to diagnostics. J 
Pharm Sci;94:2135-46;2005
21 Shi H., Guo J., Li C., Wang Z. A current review 
of folate receptor alpha as a potential tumor target 
in non-small-cell lung cancer. Drug Des Devel 
Ther;9:4989-96;2015
22 Okusanya O.T., DeJesus E.M., Jiang J.X., Judy R.P., 
Venegas O.G., Deshpande C.G. et al. Intraoperative 
molecular imaging can identify lung adenocarcinomas 
during pulmonary resection. J Thorac Cardiovasc 
Surg;150:28-35;2015
23 Kyndi M., Sorensen F.B., Knudsen H., Overgaard M., 
Nielsen H.M., Andersen J. et al. Tissue microarrays 
compared with whole sections and biochemical 
analyses. A subgroup analysis of DBCG 82 b&c. Acta 
Oncol;47:591-9;2008
24 Bremer R.E., Scoggin T.S., Somers E.B., O’Shannessy 
D.J., Tacha D.E. Interobserver agreement and assay 
rEPRoducibility of folate receptor alpha expression 
in lung adenocarcinoma: a prognostic marker and 
potential therapeutic target. Arch Pathol Lab 
Med;137:1747-52;2013
25 Sutherland K.D., Berns A. Cell of origin of lung cancer. 
Mol Oncol;4:397-403;2010
26 Cagle P.T., Zhai Q.J., Murphy L., Low P.S. Folate 
receptor in adenocarcinoma and squamous cell 
carcinoma of the lung: potential target for folate-
linked therapeutic agents. Arch Pathol Lab 
Med;137:241-4;2013
27 Hartmann L.C., Keeney G.L., Lingle W.L., 
Christianson T.J., Varghese B., Hillman D. et al.  
Folate receptor overexpression is associated with  
poor outcome in breast cancer. Int J Cancer; 
121:938-42;2007
28 Zhang Z., Wang J., Tacha D.E., Li P., Bremer R.E., 
Chen H. et al. Folate receptor alpha associated with 
triple-negative breast cancer and poor prognosis. Arch 
Pathol Lab Med;138:890-5;2014
washed and antibody binding was visualized by using 3,3’-diaminobenzidine (dab, 
dako). Sections were counterstained with haematoxylin, dehydrated and mounted 
with pertex. 
Scoring method  A  frα expression was assessed in both lung and breast can-
cer tissue by using a membranous scoring method with a scale ranging from 0 to 
3+, as described by O’Shannessy et al.14. A score of 0 corresponded with absence of 
staining; 1+ equaled faint staining on luminal borders; 2+ equaled moderate stain-
ing on apical and sometimes lateral borders and 3+ indicated strong circumferen-
tial staining (Figure 1). The tumor was considered positive when more than 10% of 
malignant cells were positively stained (>0). Overexpression of frα was defined as 
a score of 2+ or 3+. Heterogeneity was described when frα expression was detect-
able on all malignant cells. Concordance was achieved when the expression score 
of one of the stained tissues, i.e. biopsy or corresponding ln or distant metastasis, 
matched the score of the primary tumor and both displayed either positive or nega-
tive expression of frα. In general, frα expression of the primary tumor specimen 
was considered as golden standard. Concordance between either biopsy or meta-
static tissue with the primary tumor was described as down- or upregulation of frα. 
False positive expression was determined as positive frα expression on biopsy or 
metastatic tissue without frα expression on the primary tumor. Evaluation of the 
immunohistochemical staining was performed blinded independently by two ob-
servers. Disagreements were resolved by consensus after reviewing the relevant slide 
with the pathologist.
statistical analysis  A  The statistical analysis was performed using spss 
version 22.0 software (spss, ©ibm Corporation, Somer ny, usa). frα expression 
per histopathological subgroup was calculated by the Fishers exact test. A p-value of 
<0.05 was considered statistically significant. 
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Figure 1 Staining intensities of frα in nsclc and breast cancer samples using immunohistochemistry (ihc)
The staining score (0 to 3+) was obtained by assessment of membrane intensity. A score of 0 equals no  
membrane staining, a score of 1+ a faint apical membrane staining, a score of 2+ a moderate apical and  
occasional lateral membrane staining and a score of 3+ equals a strong circumferential membrane staining. 
nsclcfrα expression on biopsy (1A), primary tumor (1B) and metastatic ln tissue (1C) in a nsclc patient, 
containing adenocarcinoma (20x)
1A-d Staining intensity of respectively 0, 1+, 2+ and 3+ in adenocarcinoma samples of nsclc patients (40x).
2A-d Staining intensity of respectively 0, 1+, 2+ and 3+ in breast cancer samples (40x).
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Figure 4 Example of frα-targeted detection of an adenocarcinoma using ec-17, i.e. fluorescent  
frα-targeted molecular agent, in a patient suffering from nsclc. 
In vivo f luorescence imaging was performed using the Artemis imaging system.34
A Prior to pulmonary resection, a tumor of 3 cm in the upper lobe of the left lung is detected  
by ct-and pet-scan
B In vivo f luorescence imaging shows clear tumor delineation
c Ex vivo f luorescence imaging of the tumor in the resected specimen
d After resection, the wound bed was inspected with λex 490 nm and demonstrated no residual 
f luorescence at the surgical margins
e frα upregulation was confirmed by f luorescence microscopy and immunohistochemical staining 
Figure 2 Examples of (dis)concordance in frα staining in biopsy-, primary tumor-, and metastatic ln tissue 
in NSCLC and breast cancer patients
1A-C Example of concordance between positive frα expression on biopsy (1A), primary tumor (1B)  
and metastatic LN tissue (1C) in a NSCLC patient, containing adenocarcinoma (20x)
2A-C Example of disconcordance between frα expression on biopsy (2A), primary tumor (2B) and  
metastatic LN tissue (2C) in a NSCLC patient, containing SCC (20x)
3A-C Example of concordance between positive frα expression on biopsy (3A), primary tumor (3B)  
and metastatic LN tissue (3C) in a breast cancer patient (20x)
Figure 3 frα expression in nsclc and corresponding distant metastases
1A Primary tumor containing adenocarcinoma without frα expression (20x)
1B Corresponding distant metastasis of the bone with positive frα expression (20x) 
2A Primary tumor containing adenocarcinoma with positive frα expression (20x)
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Table 1 Patient and tumor characteristics




Breast cancer  
No. (%)
All patients 34 (57) 26 (43) 40
Mean age at diagnosis (years) 64.5 62.5 56
Sex      
 male 21 (87.5) 20 (77) 0 (0)
 female 13 (12.5) 6 (23) 40 (100)
Tumor size      
 pT1 10 (29) 3 (12) 23 (57.5)
 pT2 5 (15) 6 (23) 16 (40)
 pT3 4 (12) 4 (15) 1 (2.5)
 pT4 15 (44) 13 (50) 0 (0)
Nodal Stage      
 Nx 0 (0) 0 (0) 1 (2.5)
 N0 7 (21) 5 (19) 12 (30)
 N1-2 27 (79) 21 (81) 27 (67.5)
iascl stage      
 ia 4 (12) 1 (4)  
 ib 2 (6) 2 (8)  
 iia 3 (9) 4 (15)  
 iib 2 (6) 0 (0)  
 iiia 7 (20) 10 (38)  
 iiib 1 (3) 1 (4)  
 iv 15 (44) 8 (31)  
Marker status      
 hr status      
 positive     19 (47.5)
 negative     21 (52.5)
 her2 status      
 positive     17 (42.5)
 negative     23 (57.5)
 tn      
 yes     15 (37.5)
 no     25 (62.5)
Histology      
 Ductal     36 (90)
 Lobular     4 (10)
Tumor grade      
 ne      4 (10)
 Grade 1     2 (5)
 Grade 2     13 (32.5)
 Grade 3     21 (52.5)
Neo-adjuvant therapy      
 Yes 14 (41) 8 (31) 6 (15)
 No 20 (59) 18 (69) 34 (85)
nsclc non-small-cell lung cancer; scc squamous cell carcinoma; pT pathological tumor stage, N node status,  
iascl International Association for the Study of Lung Cancer; hr hormone receptor, including progesterone  
and estrogen receptor status; Her2 human epidermal growth factor receptor 2; ne not evaluable;  
Tumor grade, according to Bloom & Richardson scoring method
Figure 5 Examples of frα staining in normal lung and breast tissue
A Staining of frα at the luminal border of normal lung tissue in an adenocarcinoma patient (10x)
B Staining of frα at the luminal border of normal lung tissue in an scc patient (10x)
c Staining of frα in normal breast tissue: staining at the luminal border of secretory cells (10x)
a b c
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Table 4 Folate receptor-α expression in breast cancer patients 





Total   12 28  
 hr status positive 1 (8) 18 (64) 0.002
  negative 11 (92) 10 (36)  
 her2status positive 5 (42) 12 (43) 1.000
  negative 7 (58) 16 (57)  
 tn yes 7 (58) 8 (29) 0.091
  no 5 (42) 20 (72)  
 Node status positive 7 (58) 20 (71) 0.476
  negative 5 (42) 8 (29)  
Lumpectomy specimen        
Total   20 20  
 hr status positive 5 (25) 6 (30) 0.010
  negative 15 (75) 14 (70)  
 her2 status positive 7 (35) 10 (50) 0.523
  negative 13 (65) 10 (50)  
 tn yes 12 (60) 3 (15) 0.008
  no 8 (40) 17 (85)  
 Node status positive 12 (60) 15 (75) 0.501
  negative 8 (40) 5 (25)  
Lymph node metastasis        
Total   6 14  
 hr status positive 2 (33) 7 (50) 0.642
  negative 4 (67) 7 (50)  
 her2 status positive 2 (33) 8 (57) 0.628
  negative 4 (67) 6 (43)  
 tn yes 3 (50) 4 (29) 0.613
  no 3 (50) 10 (71)  
frα Folate receptor α; hr hormone receptor including estrogen- and progesterone receptor; her2 human epidermal 
growth factor receptor 2; tn triple negative








Biopsies        
 Total 23    
 Adenocarcinoma 12 8 (67) 4 (33) 0.036
 SCC 11 2 (18) 9 (82)  
Primary tumor        
 Total 60    
 Adenocarcinoma 34 21 (62) 13 (38) <0.001
 SCC 26 4 (15) 22 (85)  
Lymph node metastases        
 Total 60 (in 33 pts)    
 Adenocarcinoma 42 (in 18 pts) 26 (62) 16 (38) 0.004
 SCC 18 (in 15 pts) 3 (17) 15 (83)  
Distant metastasis        
 Total 23    
 Adenocarcinoma 15 5 (33) 10 (67) 0.122
 SCC 8 0 (0) 8 (100)
SCC squamous cell carcinoma; frα Folate receptor α; pts patients
Table 3 Concordance between biopsy, primary tumor and corresponding disseminated lymph nodes and 
distant metastases in patients with breast cancer and nsclc
Degree of concordance Breast cancer 
patients 
No. (%) 






Concordance of frα status 
 Biopsy = Primary tumor 27 out of 40 (67.5) 10 out of 12 (83) 10 out of 11 (91)
 Primary tumor = Local metastasis 12 out of 20 (60) 31 out of 42 (78)* 13 out of 18 (80)*
 Primary tumor = Distant metastases 12 out of 15 (80) 7 out of 8 (88)
Disconcordance of frα status 
 Biopsy > Primary tumor 2 1 0
 Biopsy < Primary tumor 11 1 1
 Primary tumor > Local metastasis 6 4 2
 Primary tumor < Local metastasis 2 0 3
 Primary tumor > Distant metastasis 2 1
 Primary tumor < Distant metastasis 1 0
SCC squamous cell carcinoma; frα Folate receptor α; pos ln positive lymph node  
* ln expression was assessed in 33 patients, in respectively 18 patients with adenocarcinoma and 15 patients with scc;  
 concordance was seen in 14 out of 18 adenocarcinoma patients (31/42 lns) and 12 out of 15 scc patients (13/18 lns). 
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introduction 
Prognosis after cancer surgery mainly depends on the completeness of the surgi-
cal resection1-4. Accurate detection of tumor margins during surgery can be difficult 
due to the lack of visual distinction between tumor and normal or inflamed/fibrotic 
tissue. This can be problematic especially after neoadjuvant chemo- and/or radio-
therapy (crt), which is frequently used in rectal cancer patients5. Targeted fluo res-
cence-guided surgery (fgs) is an intraoperative imaging technique that allows real-
time tumor identification. fgs is based on (near-infrared, nir) fluorescent dyes in 
combination with a dedicated imaging system and is already widely investigated for 
sentinel lymph node mapping, liver tumor detection and bile duct imaging using 
the non-targeted fluorescent dye indocyanine green6. Conjugating fluorescent dyes 
to specific tumor-recognizing ligands, such as antibodies or peptides, enhances the 
specificity of this technique for tumor imaging considerably.Various tumor-specific 
agents have already shown feasibility in early phase clinical trials7-11. 
Not all tumor-associated biomarkers are suitable targets for imaging purposes; pre-
requisite is expression on the cellular membrane with several fold higher densities 
compared to surrounding normal cells12. The Epithelial Cell Adhesion Molecule 
(Epcam) was among the first human tumor-associated antigens discovered and was 
identified by a number of independently developed monoclonal antibodies (mAb) 
17-1a, 323/A3, and moc3113. Epcam is a 40kD type I transmembrane glycoprotein 
involved in cell-to-cell interactions and adhesions14. The molecule is under physi-
ological conditions minimally expressed on the basolateral surface of epithelial cells 
and in undifferentiated pluripotent stem cells15. However, it is overexpressed in 
virtually all epithelial cancers and expression is conserved with cancer progression 
and metastasis16. Epcam is associated with cellular signaling processes and plays 
a prominent role in tumor cell migration, proliferation and differentiation17. Very 
high overexpression (100-1000 fold) of Epcam has been found in colorectal, gas-
tric, esophageal, head-and-neck, breast and gynecological cancers with cell surface 
copy numbers ranging between 100,000 and 300,00018-20. Consequently, Epcam-
targeting therapeutic antibodies were studied in phase i, ii and iii trials in various 
cancer types including ovarian-, gastric- and head-and-neck cancer and peritonitis 
carcinomatosa21-23. 
In this study, we combined two well-known clinically tested components: 
an antigen binding fragment (Fab) derived from the antibody moc3124 and the 
fluorophore irdye800cw®25,26. The first iteration of the antibody Fab fragment 
has already been tested in preclinical and clinical studies as the immunotoxin vb6-
845, constructed as a recombinant fusion protein27. The fluorophore irdye800cw 
abstract 
Tumor-specific fluorescent imaging agents are moving towards the clinic, support-
ing surgeons with real-time intraoperative feedback about tumor locations. The epi-
thelial cell adhesion molecule (Epcam) is considered as one of the most promising 
tumor-specific proteins due to its high overexpression on epithelial-derived cancers. 
This study describes the development and evaluation of Epcam-F800, a novel fluo-
rescent anti-Epcam antibody fragment, for intraoperative tumor imaging. 
Fab production, conjugation to the fluorophore irdye800cw, and binding ca-
pacities were determined and validated using hplc, spectrophotometry and cell-
based assays. In vivo, dose escalation-, blocking-, pharmacokinetic- and biodistri-
bution studies (using both fluorescence and radioactivity) were performed, next to 
imaging of clinically relevant orthotopic xenografts for breast and colorectal cancer. 
Epcam-F800 targets Epcam with high specificity in vitro, which was validated 
using in vivo blocking experiments with a 10x higher dose of unlabeled Fab. The op-
timal dose range for fluorescence tumor detection in mice was 1-5 nmol (52-260µg), 
which corresponds to a human equivalent dose of 0.2-0.8 mg/kg. Biodistribution 
showed high accumulation of Epcam-F800 in tumors and metabolizing organs. 
Breast and colorectal tumors could clearly be visualized within 8 h post-injection 
and up to 96 h, while the agent already showed homogeneous tumor distribution 
within 4 h. The blood half-life was 4.5 h. 
This study describes the development and evaluation of a novel Epcam-targeting 
agent and the feasibility to visualize breast and colorectal tumors by fluorescence 
imaging during resections. Epcam-F800 will be translated for clinical use, consider-
ing its abundance in a broad range of tumor types. 
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In a 20 L Bioreactor containing 15 L of glycerol minimum media, transformed 
E. coli E104 cells were grown to an od600 of 50 and induced with L-arabinose. 
Following induction, the supernatant was collected by centrifugation, clarified by 
microfiltration, concentrated and diafiltrated prior to loading onto a KappaSelect 
column (ge Healthcare Life Sciences, Mississauga, Canada). After the column was 
washed with equilibration buffer, bound vb5-845d was eluted with 0.1 M Glycine-
hcl, pH 2.5 and neutralized to pH 7.0 with Tris buffer. The fractions containing 
vb5-845d were then flowed-through a Q-sepharose column (ge Healthcare Life 
Sciences, Mississauga, Canada) and the effluent loaded on to an sp-sepharose (ge 
Healthcare Life Sciences, Mississauga, Canada). Bound vb5-845d was eluted, fil-
ter sterilized and frozen at -20°C. Purity and stability was confirmed by Coomassie 
staining and se-hplc and identity by Western blot analysis. Protein concentration 
was determined by bca (Thermo Fisher Scientific, Waltham, ma, usa). 
The 800cw nhs-ester (excitation peak at 773 nm, emission peak at 792 nm) and 
dota were both stored according to manufacturer protocol. Anti-Epcam Fab vb5-
845d was covalently conjugated to 800cw (Epcam-F800) or dota (Epcam-F-dota) 
using N-Hydroxysuccinimide (nhs) ester chemistry against primary amines follow-
ing manufacturer protocol (Thermo Fisher Scientific, ma, usa) and as briefly de-
scribed in the supplementary data. For 800cw, Maldi-tof analyses were performed 
using a Microflex (Bruker) and sinnapinic acid as matrix to evaluate labelling ratios. 
The affinity of anti-Epcam Fab and Epcam-F800 to recombinant His-tagged 
Epcam (Sino Biological) was determined using a Biacore T200 (ge Life Science). 
The Epcam protein was immobilized using the His-tag on the flow cell 2 of the 
nta-Chip to the level of ~150 ru. Fabs were injected in five sequential increasing 
concentration over flow cells 1 and 2 with flow cell 1 used as the binding reference. 
After each experiment the surface of the chip was regenerated from bound Fab and 
immobilized Epcam using sds and edta solutions. The data was fitted according to 
the 1:1 Binding kinetics model using Biacore T200 evaluation software. 
Human cancer cell lines  A  After evaluation of a panel of human cancer 
cell lines for Epcam expression, four human cancer cell lines were selected; two from 
colorectal cancer origin (ht-29 and Colo320) and two from breast cancer origin 
(mcf-7 and mda-mb-231). The latter was a kind gift from drs J. Gostner and G. 
Spizzo, (Medical Universität Innsbruck). All cell lines were free of mycoplasma 
and were cultured in rpmi1640 (paa) supplemented with 10% fetal bovine serum 
(Gibco) and 100 I.U./mL penicillin/streptomycin (paa) in a humidified incubator 
at 37°C and 5% co2. The ht-29-luc2 cell-line was established and validated by our 
own research group28. 
has previously been conjugated to cetuximab and bevacizumab, and showed 
visualization of respectively head-and-neck cancer and breast cancer in early phase 
clinical trials9, 10. 
The aim of this study was to develop and validate a clinical translatable Epcam-
specific nir fluorescent imaging agent that can be used for visualization of multiple 
tumor types. Application of Epcam-F800 during oncological surgeries can poten-
tially aid real-time detection of tumors, assist clinical decision making and improve 
treatment strategies for cancer patients in the near future. 
materials and methods 
Human samples and staining  A  Paraffin-embedded tissue blocks from 
10 patients who underwent surgical resection of rectal cancer between 2014 and 
2015 were obtained at the Pathology Department of the Leiden University Medical 
Center (lumc) to study the effect of neoadjuvant therapy on Epcam expression in 
rectal cancer tissue. Five patients did and five patients did not receive neoadjuvant 
crt. Tissue blocks containing tumor tissue and blocks containing adjacent normal 
rectal tissue were obtained. After sectioning, slides were stained for Epcam using 
mAb moc31 (Millipore Sigma, Saint Louis, mo, usa) in a predetermined optimal 
dilution of 1:10,000. After overnight incubation, dako envision + hrp anti-mouse 
was added for 30 min (K4001; dako Cytomation, Glostrup, Denmark) followed by 
diaminobenzidine solution (dab+; dako Kit) to visualize Epcam expression. All 
sections were counterstained with hematoxylin, dehydrated and finally mounted 
with pertex. All samples were handled in an anonymous fashion according to the 
National Ethical Guidelines (‘Code for Proper Secondary Use of Human Tissue’, 
Dutch Federation of Medical Scientific Societies) and were approved by the 
Institutional Ethics Committee of the lumc. 
Fab production, conjugation and stability  A  vb5-845d 
(Viventia, Winnipeg, Canada) is a T-cell epitope depleted Fab version of the anti-
Epcam Fab deBouganin fusion protein, vb6-845. To express vb5-845d in E. coli 
supernatant, a dicistronic unit was created where the heavy and light chains were 
preceded by a PelB leader sequence. The insert was placed under the control of the 
arabinose promoter and cloned into a ping plasmid. The resulting vb5-845d/ping 
plasmid was then transformed into E.coli strain E1.04. After L-arabinose induc-
tion, the presence of soluble vb5-845d Fab protein in the supernatant was detected 
by western blot using a human anti-Kappa antibody coupled to hrp (Sigma, St 
Louis, mo). 
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In vivo binding characteristics, dose finding and biodis-
tribution  A  When subcutaneous ht-29 colorectal tumors were sized 36 ± 
6 mm2, either 1/16 nmol (3.3 µg), 1/4 nmol (13 µg), 1 nmol (52 µg), 5 nmol (260 µg), 
10 nmol (520 µg) or 20 nmol (1040 µg) Epcam-F800 was intravenously injected 
(n=3 per dose group). At 4, 8, 24, 48, 72 and 96 h post injection, fluorescence was 
measured using the Pearl® and the Artemis imaging system. Biodistribution was 
studied measuring the fluorescence signal in mice bearing ht-29-luc2 tumors 
with either Epcam-mAb800 or Epcam-F800 or control mice without injection of 
Epcam-F800. In total, 6 mice were injected with 1 nmol of Epcam-mAb800 (150µg) 
and sacrificed at 24 (n=3) or 72 h (n=3) post injection. The same experiment was 
performed in mice injected with Epcam-F800 (52 µg, n=6) and control mice (n=6). 
Biodistribution was calculated by measuring the fluorescence intensity of all excised 
organs, as well as of blood, urine and feces29. 
Radiolabeling and biodistribution  A  Radiolabeling was performed 
by dissolving Epcam-Fab-dota in 0.1M hepes buffer (10 µg/100 µL) and add-
ing indium-111 chloride (35 mbq111 InCl3, Covidien-Mallinckrodt, Dublin, Ireland). 
After 30 min of incubation on the shaker, labelling was validated by hplc (jasco, 
Easton, usa). In all cases, labelling efficacy was >90%. To study the biodistribu-
tion, 6 mice were intravenously injected with 1 nmol (50 µg)111 In-Epcam-F-dota. 
Mice were sacrificed 24 (n=3) or 72 h (n=3) post injection and organs were excised, 
weighted, and measured for radioactivity with a gamma counter (Wizard2 2470 au-
tomatic gamma scintillation counter, Perkin Elmer, usa). Activity was divided by 
the weight of each tissue to calculate the percentage injected dose per gram (%id/g). 
Pharmacokinetic analysis  A  Pharmacokinetic analysis was performed 
as previously described30. Briefly, Epcam-F800 was diluted in human whole blood 
to the concentrations 2.0, 1.0, 0.5, 0.25, 0.13, 0.06, 0.03, 0.02, 7.81*10-3, 3.90*10-3, 
1.95*10-3, 9.76*10-4 µM. A calibration curve was created by measuring each concen-
tration in a 75 µl capillary tube using the Pearl® imaging system. Data was plot-
ted in fluorescence intensity over concentration (µM). Subsequently, four mice were 
injected with 5 nmol Epcam-F800 via the lateral tail vein. The contralateral lateral 
tail vein was used to draw blood 5 min before and 1, 30, 60, 90, 120, 180, 240, 360 and 
1440 min post injection. Blood samples were absorbed using 75 µl capillary tubes and 
immediately measured using the Pearl® imaging system. Each measurement was 
extrapolated to its concentration using the calibration curve. Data were plotted in 
logarithmic concentration (µM) over time (min). 
Flowcytometry and fluorescent affinity assays  A  Identical 
protocols for flowcytometry and fluorescent affinity assays were used as recently de-
scribed28 and are described in detail in the supplementary materials. The number of 
Epcam molecules per cell were established using the Qifikit (dako) as described 
before using anti-Epcam monoclonal antibodies 323/A329. 
Animal models  A  The Animal Welfare Committee of the lumc assessed 
all animal experiments for animal health, ethics, and research goals and approved 
the studies. All animals received humane care and maintenance in compliance with 
the ‘Code of Practice Use of Laboratory Animals in Cancer Research’. Similar ani-
mal models were used as previously described30 and are extensively described in the 
supplementary materials. In short, six-week-old, athymic, female mice were either 
injected subcutaneously with ht-29-luc2 cells (5.0 x 105 cells per spot) at 4-sides 
on the back, to induce subcutaneously colorectal tumors, or were inoculated with 
2.5x105 mcf-7-luc2-cgfp cells in two contralateral mam mary fat pads, to induce 
orthotopic breast tumors. For the colorectal orthotopic model, subcutaneously 
growing ht-29-luc2 tumors were harvested, cut in small fragments, and trans-
planted onto the cecal wall. 
nir fluorescence imaging systems A Imaging was performed using 
the Pearl® Impulse small animal imager (li-cor, Lincoln, ne, usa) and the 
Artemis imaging system (Quest Medical Imaging, the Netherlands). Identical im-
aging set-ups were used as previously described30. Detailed information is provided 
in the supplementary material section. 
In vivo specificity  A  The binding specificity of Epcam-F800 was explored 
using an in vivo blocking experiment. Mice bearing subcutaneous colorectal tumors 
(ht-29-luc2) received 4 h prior to iv injection of 1 nmol (52 µg) Epcam-F800 
an intra-peritoneal injection of a 10 times higher dose of unlabeled Fab (10 nmol, 
520 µg, n=4). nir fluorescence images were acquired at 24 and 72 h post-injection 
with both the Pearl and the Artemis imaging system. After the last measurement, 
animals were sacrificed. Tumor-to-background ratios (tbrs) were generated by 
drawing regions of interest (rois) on tumors and surrounding tissue, at the back 
of the mice between the tumors, on fluorescence images. tbrs were calculated by 
dividing the mean fluorescence signals detected in tumor by the mean signals in the 
surrounding tissue. 
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results 
Epcam expression on human rectal (cancer) tissues and 
cell lines  A  Normal rectal tissue showed weak/moderate expression of Epcam, 
which was mostly limited to enterocytes located at the tip of the villi (Figure 1a). 
All rectal cancer tissues showed an intense, homogeneous Epcam expression with 
a circumferential staining pattern (Figure 1b and 1d). Epcam expression on tumor 
tissue and adjacent normal epithelium did not differ between tissues derived from 
patients who were not (Figure 1b and 1c) and who were (Figure 1d and 1e) treated 
with neoadjuvant crt. 
The selection of cell lines for the in vivo studies was based on flow cytometry of 
panels of breast and colon cancer cell lines (for the latter see Suppl. Figure S0). Cell 
lines mcf-7 and ht-29, both with intermediate Epcam expression were selected. 
The number of Epcam molecules per cell, as determined using 2 different mono-
clonal antibodies in combination with Qifikit, confirmed the data obtained by plain 
flow cytometry: The positive colon cancer cell line ht-29 expressed 195,000-197,000 
copies (323/A3 versus moc31) and the breast cancer cell line mcf-7 255,000-265,000 
copies. The control cell lines Colo320 and mda-mb-231 showed numbers under the 
detection limit of the assay (<1,000). 
Fab conjugation, binding capacity and stability  A  Little to no 
expression of Epcam was seen on the control Colo-320 and mda-mb-231 cell lines 
using Fab vb5-845d and positive control moc31, while high expression of Epcam 
was measured on ht-29 and mcf-7 cell lines (Figure 2a). Conjugation was evalu-
ated using sds-page showing epcam-F800 at approximately 45 kDa by silver stain-
ing (Figure 2b-i) and by nir fluorescence imaging (Figure 2b-ii). No degradation 
products were seen. Before conjugation, the Fab showed >98% purity (Figure 2c-i) 
and after conjugation, Maldi-tof analysis indicated that the majority of Fab mol-
ecules were conjugated with an average of 1-4 dye molecules (Figure 2c-ii). Higher 
concentrations of Epcam-F800 resulted in higher signals on the Epcam expressing 
cell lines, while almost no signal was measured in the low expressing control cell lines 
(Figure 2d). The calculated kd of anti-Epcam Fab was with 90 pM comparable to 
those of moc31 and 323/A. Although conjugation with the fluorescent dye 800cw 
diminished the affinity approximately 25 times, this is still considered high affinity. 
In vivo biodistribution  A  At 24 h post injection, the liver, kidneys and 
urine showed higher fluorescence signals than the tumor (Figure 3a). Compared 
to Epcam-F800, injection of Epcam-mAb800 resulted both at 24 and 72 h in a 
Histology and nir fluorescence microscopy  A  Tumor penetra-
tion of Epcam-F800 was assessed in colorectal tumors, obtained from 8 mice bear-
ing subcutaneous ht-29-luc2 tumors. Mice were sacrificed at 1 (n=2), 4 (n=2), 8 
(n=2) or 24 hours (n=2) after injection of either 1 or 10 nmol Epcam-F800. Tumors 
were snap frozen in isopentane and stored at -80ºC. Tissues were sectioned at 10 
µm, stained with dapi and subsequently fluorescence imaging was performed 
using a Leica dm5500B digital microscope (Leica Microsystems b.v., Son, the 
Netherlands). Adjacent slides were hematoxylin-eosin (he) stained. 
Specificity of Epcam targeted fluorescence in ht-29 tumors after injection of 
Epcam-F800 was confirmed by immunohistochemical staining of Epcam using a 
323/A3, an anti-Epcam mAb targeting a different epitope. ht-29 tumors were re-
sected 24 h post injection of 5 nmol Epcam-F800 and snapfrozen in isopentane. 
Subsequently, fluorescence imaging of 5 µm tissue sections on slides was performed 
using the Odyssey imager (li-cor, Lincoln, ne, usa) at 800 nm after which they 
were he-stained. Adjacent slides were used for fluorescence microscopy and im-
munohistochemistry. To confirm the presence of Epcam, slides were stained using 
323/A3-Alexa488 by fixation in acetone for 10 min and incubation with 5 µg/ml of 
the antibody, followed by washing. Slides stained for Epcam, and unstained slides, 
were mounted with Prolong Gold with dapi and analyzed with a Leica dm5500B 
digital microscope using L5 and Y7 filter cubes for detecting Alexa488 and 800cw 
respectively. 
Calculations and statistical analyses  A  Statistical analysis and 
generation of graphs were performed using GraphPad Prism software (version 5.01, 
GraphPad Software Inc, La Jolla, ca, usa). Differences between groups in the in 
vitro binding assays were analyzed using the Mann-Whitney U test. Tumor-to-
background ratios (tbr) were calculated by drawing regions of interest (rois) on 
fluorescence images from the Pearl® small animal imager or Artemis imaging sys-
tem to extract mean signal for tumors and all major organs. Organ-to-blood ratios 
were calculated by dividing each value by the mean fluorescence signal detected in 
the tissue and blood and reported as mean and standard deviation. The two-way 
repeated measurement anova, used to assess the relation between tbrs in differ-
ent dose groups and time points, was corrected for multiple comparisons using the 
Bonferroni correction. 
fluorescence-enhanced surgical navigation 
92 
PART Ii • chapter 6 • Preclinical validation of a novel EpCAM-targeted fluorescent tracer
93
approximately 63 µg*h/mL. Mean systemic clearance was 0.08±0.03mL/min. 
Figure 4d shows examples of images captured with the intraoperative Artemis im-
aging system. Increasing the dose over 5 nmol resulted in higher fluorescence signals 
in both tumors and background, but not in higher tbrs (Figure s5). 
Clinical relevant orthotopic models  A  In the orthotopic breast 
cancer (mcf-7) model tbrs increased significantly up to 48 h (Figure 5a) after in-
jection of 1 nmol Epcam-F800. Due to the relatively short blood half-life, abso-
lute signals in the background decreased faster than signals in the tumor. Figure 5b 
shows an example of in vivo breast tumor detection using the Artemis imaging sys-
tem. Tumors could be recognized at 24 h and 72 h post injection and images from 
all time points are shown in Figure s6. In the colorectal tumor model, mean tbrs 
increased significantly between 24 h and 72 h time-points (4.2±0.2 at 24 h vs. 6.6±0.8 
at 72 h, p<0.05) after injection of 1 nmol of Epcam-F800 (Figure 5c). Similar to the 
breast cancer model, absolute signals in the background decreased faster than the 
signals in the tumors between 24 h and 72 h (46% versus 72%). Figure 5d shows an 
example of images captured by the Artemis imaging system and bioluminescence 
(bli), confirming the presence of tumor tissue. Moreover, millimeter-sized fluores-
cent nodules could be visualized and confirmed by bli. 
Histology and nir fluorescence microscopy  A  Fluorescence 
microscopy revealed a clear difference in penetration pattern and intensity after 1 
and 4 h post injection (Figure 6a). After 1 h fluorescence was mainly present in a 
rim around the tumor cells. After 4 h, fluorescence was seen throughout the whole 
tumor indicating full penetration of Epcam-F800 in tumors between 1 and 4 h after 
injection. Moreover, the level of fluorescence intensity retained in tumors between 4 
and 24 h, possibly due to internalization of the agent. nir fluorescence microscopy 
images of colorectal tumors revealed co-localization of Epcam-F800 and 323/A3-
Alexa488, indicating that Epcam-F800 targets Epcam (Figure 6b). 
discussion 
This study investigates an anti-Epcam Fab fluorescent agent that can demarcate 
multiple tumor types in vivo using real-time fluorescence imaging. Due to the 
generally high overexpression on carcinomas, Epcam is considered as one of the 
most promising generic tumor targets which is also recognized by the National 
Cancer Institute23,31. Highest expression patterns are found in colorectal cancers 
as well as their metastasis19. The reported levels of Epcam overexpression around 
significantly higher signal in the liver (Figure 3a and 3b). Due to the smaller size 
of Epcam-F800 and renal clearance, fluorescence in the kidneys was higher after 
24 h than Epcam-mAb800. In contrast, 72 h after injection of Epcam-mAb800 all 
measured organs showed higher signal intensity compared to Epcam-F800 (Figure 
3b). At 24 h and 72 h post injection of Epcam-mAb800, the intensity of fluorescence 
in blood was respectively 3 and 6 times higher than the fluorescence measured after 
injection of Epcam-F800. Biodistribution of all organs after injection of Epcam-
mAb800, Epcam-F800 and of control mice, without injection of any dye, are shown 
in Figure s1 and S2. tbrs were significantly higher for Epcam-F800 compared to its 
full size variant Epcam-mAb800 at both 24 h and 72 h post-injection (Figure 3c). 
Quantitative measurements of the biodistribution were performed using 111In-
Epcam-F-dota (1 nmol). The total mean activities for the mice sacrificed at 24 h post 
injection were 5.7 ± 0.1%id/g and at 72 h were 5.2 ± 0.3%id/g (mbq, mean ± sd). The 
biodistribution study confirmed accumulation of 111In-Epcam-F-dota in subcuta-
neous colorectal tumors and the kidneys at 24h, with significant lower values at the 
72 h time-point (selection in Figure 3d and full in Figure s3). Compared to the signal 
intensity from the intestine, relatively high intensity signals were observed in the 
skin, thereby influencing tbrs, as also seen with nir fluorescence in this subcutane-
ous model. Mean tumor-to-colon (tc) ratio was 11.5 ± 1.5 at 24 h and 8.9 ± 0.7 at 72 h 
and mean tumor-to-muscle (tm) ratio was 29.6 ± 12.8 at 24 h and 29.0 ± 12.5 at 72 h. 
In vivo blocking and dose optimization study  A  Tumor binding 
of Epcam-F800 was further validated using a blocking experiment by competing 
with the unlabeled Fab fragment. The group with a pre-injection of unlabeled Fab 
showed significant lower tbrs at 24 h post injection compared to the group without 
the pre-injection (2.1 ± 0.4 vs. 6.8 ± 1.7, p<0.05) and the difference increased further 
at 72 h (3.0 ± 0.6 vs. 10.0 ± 3.5, p<0.05) (Figure 4a). 
Dose optimization studies showed increasing tbrs for all doses at 4h post in-
jection (Figure 4b & s4). For the 24 h time-point, a significant difference was ob-
served between 1 nmol versus 1/16 nmol (p<0.05) and no significant differences were 
seen between 1 nmol and higher doses, possibly due to saturation of the receptors 
(Figure 4b). For the 48 h time-point, tbrs measured with 1 nmol only differed sig-
nificant from 1/16 (p<0.05) and 1/4 nmol (p<0.05). Absolute signals in both tumor 
and background decreased significantly within the first 4 h after injection of 1 and 
5 nmol (Figure s4). The maximal concentration of Epcam-F800 in blood measured 
at 1 min post injection was 59 µM (Figure 4c). Decrease of Epcam-F800 blood con-
centrations followed a biphasic pattern with a distribution and elimination phase 
with a mean terminal half-life of 4.5 h, and with an area under the curve (auc) of 
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repeated use in patients undergoing multiple surgeries or participating in tumor 
screening programs. Conjugation with the dye was performed using the gener-
ally accepted nhs-method, with conditions leading to stable dye/protein-label-
ling ratios of around 1.5. Preclinical studies showed that irdye800cw is not im-
munogenic with a no adverse effect level (noael) of 20 mg/kg25. The advantage of 
irdye800cw with respect to other nir fluorescent dyes is its water-solubility in 
combination with high signal intensity. Water-solubility enables conjugation in wa-
ter-based solutions, which simplifies the purification process substantially and sim-
plifies production under current Good Manufacturing Practices (cgmp) conditions. 
The limited effect of the enhanced permeability and retention (epr) effect was 
shown in the in vivo blocking experiment, where a 3-4 times lower tbr was mea-
sured after pre-injection with the unlabeled agent. The stagnating tbrs in the high-
er dose groups (5-20 nmol) clearly show the concentration at which saturation of 
available Epcam binding places occurred. The optimal dose range of Epcam-F800 
for fluorescence tumor detection, i.e. 1-5 nmol in mice (52-260 µg), corresponds with 
a dose of 0.16-0.8 mg/kg in humans, adjusted for body surface area45. 
Biodistribution showed a classical Fab distribution pattern with high tbrs and 
high signals in the tumor and excreting organs. Due to the glomerular-filtration 
cut-off of 60 kDa, most of the agent is excreted via the kidneys. The observed high 
fluorescence signals in the liver may be explained by the lipophilicity and negative 
charge of irdye800cw, which leads to increased albumin binding and adjacent 
liver accumulation. This is underscored by the fact that no significant liver uptake 
could be measured with 111In-Epcam-F-dota46. One should bear in mind that cer-
tain factors influence fluorescence intensity during biodistribution studies, such as 
absorbance of photons by adjacent tissue and scattering properties. 
The half-life time of Epcam-F800 in mice was estimated at 4.5 h, which is in 
concordance with vb6-845 in humans27. Although the total circulation time of 
Epcam-F800 is relatively short (10-20 h), it is sufficient to allow adequate tumor 
penetration; homogeneous signals throughout the tumor were seen at 4 h post 
injection. 
Two clinically relevant orthotopic mouse models were investigated using the 
Artemis imaging system. In this set-up real-time tumor-specific visualization of 
colorectal and breast tumors was shown with high tbrs between 8 and 24 h. Besides 
these tumor types, application of Epcam-F800 may aid detection of multiple other 
epithelial-derived cancers due to overexpression of Epcam. Prior to the clinical in-
troduction of Epcam-F800, toxicology studies need to be performed. Our prelimi-
nary data of a generic single extended dose toxicology study in rats show no test 
item-related mortality, clinical signs and effects on body weight, food consumption, 
200,000-300,000 copies per cell are confirmed for the positive cell lines used in this 
study, reaching the low-end range of the gene-amplification based tumor marker 
her2/Neu (200,000 to 10 million copies per cell).We show that Epcam overexpres-
sion is preserved in rectal cancer tissue after neoadjuvant therapy, a crucial charac-
teristic for a potential candidate oncotarget. Various Epcam specific antibodies are 
clinically tested for their therapeutic effect, with dosages far above the dose suggest-
ed for tumor imaging. Unfortunately, little or no overall survival benefit was shown 
and affinity related side effects were observed hampering their clinical utility32. 
However, this does not make Epcam a useless target for imaging purposes. After all, 
imaging tracers require a much lower dose compared to therapeutic agents, which 
usually avoids potential side effects. 
Epcam has been evaluated as a target for imaging applications utilizing anti-
bodies, antibody fragments and aptamers conjugated to fluorescent dyes, radio-
nuclides or both33-35. Zhu et al. described the use of an Epcam-specific nir fluo-
rescent imaging agent for the recognition of tumor margins in a human prostate 
cancer orthotopic mouse model and showed accurate detection of both primary 
and metastatic lesions35. We recently conjugated the monoclonal antibody 323/A3 
to irdye800cw and showed clear tumor demarcation in breast, head-and-neck 
and colorectal cancer xenograft models at 72h post injection34. Although antibodies 
are believed to possess superior binding characteristics compared to smaller mol-
ecules36,37, their relatively large size (~150kDa) might result in heterogeneous tumor 
distribution, complex pharmacokinetics, and long imaging lead-times (up to 72 h) 
as shown in this and our previous study30. On the other hand, Fab fragments are 
three times smaller and show more homogeneous tumor penetration. Moreover, 
they display shorter half-life times, a decreased immunotoxicity potential 38,39 while 
they are large enough to maintain high plasma levels for optimal (tumor) distribu-
tion40-43. Although smaller vehicles like nanobodies or peptides may result in even 
better pharmacokinetic properties (e.g. faster clearance), they can have lower sta-
bility and affinity (for example, linear peptides vs. scFv fragments), and are more 
compromised by conjugation compared with antibodies or antibody fragments. 
Epcam-F800 is being produced for clinical use and experiments were therefore per-
formed with a clinically validated imaging system and an already clinically tested 
nir fluorescent dye, in order to expedite clinical translation. The antibody fragment 
we specifically developed is a Fab fragment of its full antibody variant, 4D5 moc-
B44. It is deimmunized, to tackle potential immunogenicity. A non-deimmunized 
variant was already used in a first-in-human clinical trial, where it was fused with 
a deimmunized variant of the plant-derived toxin bouganin27. Deimmunization is 
important because it lowers the chance of an immune response. Hence, it allows 
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Figure 1 
A Example of Epcam expression on normal rectal tissue; Epcam expression is confined to the luminal 
 side of the epithelium. 
B Example of Epcam expression on a distal rectal cancer of a patient who was not treated with 
neoadjuvant therapy. 
c Epcam expression on the corresponding normal rectal tissue of the same patient. 
d Epcam expression on a proximal rectal cancer of a patient who has been treated with neoadjuvant 
therapy. 
e Epcam expression on the corresponding normal rectal tissue of the same patient. (5x and 40x 
enlargements). 
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Figure 3 
A Biodistribution of Epcam-mAb800 and Epcam-F800 presented as organ-to-tumor ratio at 24 h post 
 injection of 1 nmol. High fluorescence was seen in metabolizing organs and in the urine. Intensity of the 
fluorescence signal in the liver was significantly higher after injection of Epcam-mAb800 compared to 
Epcam-F800. Higher fluorescence signals in the kidneys after injection of Epcam-F800 are most prob-
ably the result of renal clearance of the Fab fragment. (* = p<0.05). 
B Biodistribution of Epcam-mAb800 and Epcam-F800 presented as organ-to-tumor ratio  
at 72 h post injection of 1 nmol. All organs showed higher fluorescence signals after injection  
of Epcam-mAb800 compared to Epcam-F800. Fluorescence in the liver was significantly higher com-
pared to Epcam-F800. 
c Significant higher tbrs were measured for Epcam-F800 both at 24 h and 72 h post injection compared to 
Epcam-mAb800. The fluorescence signal measured at the back of the mice, between tumors, was consid-
ered as background signal. 
d Biodistribution of 111In-Epcam-F-dota shown as %/id/gram at 24 h and 72 h post injection. 
Figure 2 
A Binding capacity of Fab for Epcam using flow-cytometry. As positive control, the anti-human Epcam 
 monoclonal antibody moc31 was used confirming the high and low expression levels of Epcam on the 
tumor cells. Enhancing the concentration of Fab resulted in an increase in signal on the cells with high 
Epcam expression. 
B Conjugation was evaluated using sds-page gel (4-20%). Unconjugated Fab in lane 1 (10µg) and lane 2 
(1µg) and Epcam-F800 in lane 4 (10 µg), lane 5 (5 µg), lane 6 (5 µg) and lane 7 (5 µg) while lane 3 and lane 8 
are empty. Epcam-F800 was clearly visible at approximately 45kDa both with silver staining  
and fluorescence. 
c I, Maldi-tof analysis of Fab showed one clear peak at 46870 Da with a purity of >98%. ii, extra peaks 
appeared at 47816Da (1), 48795Da (2), 49820Da (3) and 50761Da (4) representing respectively 1, 2, 3 and 4 
irdye800cw labels per Fab. 
d Plate assay analysis showed retained binding capacity of Epcam-F800 on all four cell lines after  
conjugation. Increasing the concentration increased the fluorescent intensity for the high expressing cell 
lines. 
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Figure 5 
A Tumor-to-background ratios and absolute signals of Epcam-F800 in the orthotopic mcf-7 model 
 over time. 
B Examples of images acquired with the Artemis imaging system at 24 and 72 h. In white, the 
background regions are shown used to calculate tbrs. 
c tbrs at 24 and 72 h and mean absolute signals at these time-points of 0.51 ± 0.08 and 0.12 ± 0.02  
at 24 h post injection (shown as 100%) for respectively the tumor and the background, and 0.28 ± 0.07 
and 0.04 ± 0.01 at the 72 h time point are shown. 
d Examples of images taken with the Artemis imaging system and bli showing the co-localization  
of the f luorescent lesions with the colorectal tumors (Organs were slightly altered between f luorescent 
and bli measurements. The background regions used to calculate tbrs are indicated by white stars  
(# tumors of different sizes).
Figure 4 
A Blocking with unlabeled Fab fragments significantly (p<0.05) decreased the tumor-to-background 
 ratios at both the 24 h (6.81 ± 1.65 vs. 2.34 ± 0.42) and 72h (10.01 ± 3.544 vs. 2.96 ± 0.638) time-point. 
B Tumor-to-background ratios (tbr) are shown over time for the 1/16 to 5 nmol dose groups. 
c Pharmacokinetic results, displayed in a logarithmic scale. A mean blood half-life time of 4.5 h was 
measured. 
d Examples of in vivo images of mice bearing subcutaneous tumors acquired at 24 and 72h post injection 
with Epcam-mAb800 or different doses of Epcam-F800. The white regions of interest are used as 
background to calculate tbrs. All images are normalized and acquired with the Artemis imaging 
system. (# tumors of different sizes).  
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Figure 6 
A Fluorescence histology of ht29-tumors, obtained 1 and 4 h after injection of 10 nmol Epcam-F800. 
 Shown are respectively he staining, dapi staining, f luorescence microscopy images and overlay images 
(dapi and f luorescence) of representative tumor slices 1 and 4 h after injection of Epcam-F800. After 
1 h, tumor penetration of Epcam-F800 is limited to the tumor borders, while f luorescence is seen 
throughout the complete tumor after 4 h. 
B Fluorescence histology of a ht-29 tumor, harvested from a mouse injected with 5 nmol Epcam-F800, 
shows co-localization of Epcam-F800 and 323/A3-Alexa488. 
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introduction
Carcinoembryonic antigen (cea) is a glycoprotein produced by gastrointestinal tis-
sue under control of the cell adhesion molecule 5 (ceacam5) gene1. cea is anchored 
on the cellmembrane via glycosylphospatidylinositol (gpi), which makes it vulner-
able for shedding into the lumen, where it is cleared via the faeces. In many cancer 
types, including pancreatic ductal adenocarcinoma (pdac) and (colo)rectal cancer 
(crc), cea is found to be overexpressed, playing a role in cell recognition, adhesion, 
angiogenesis and tumor suppression2-4. A substantial part of cea, shedded from 
tumor cells, derives into the bloodstream and enhanced serum cea is therefore used 
as sensitive biomarker indicating growth or recurrence of crc5. 
Since the recognition of serum cea as a valuable cancer biomarker, multiple cea-
targeted agents have been developed. Therapeutic antibodies directed towards cea-
overexpressing tumors are currently tested in various phase I-iii trials6,7, but also 
anti-cea based radioimmunotherapy and cea-targeted vaccins are investigated8,9. 
In addition to the rapidly expanding field of cea-targeted anticancer therapeutics, 
several imaging agents have become available for clinical testing. These agents can 
be labelled with radioisotopes for pet or spect imaging10,11, with near-infrared 
(nir) fluorescent dyes12,13, or they can provide both molecular imaging and targeted 
therapy of cea-expressing tumors14. 
Especially in early phase clinical trials investigating cea-targeted tumor imaging, 
it would be beneficial to identify patients with homogeneous cea overexpression in 
the tumor prior to inclusion. For example, patient selection is pivotal in the recently 
initiated phase I study (Netherlands Trial Register id: 5673) assessing the safety and 
feasibility of sgm-101, a monoclonal cea-targeted antibody conjugated to a nir 
fluorescent dye, utilized for intraoperative detection of pdac and crc. Selecting eli-
gible pdac and rectal patients for cea-targeted applications might be feasible using 
serum cea levels. Since cea expression on normal epithelium is confined to the api-
cal surface of polarized cells2, it can be hypothesized that cea in serum of cancer pa-
tients originates mostly from shedding by cea-overexpressing malignant cells that 
lose their polarity. The aim of the current study was to investigate if elevated serum 
cea levels can predict overexpression of cea on pancreatic and rectal cancer tissue. 
methods 
This study was approved by the Institutional Ethics Committee of the Leiden 
University Medical Center (lumc) and performed following the Code for Proper 
Secondary Use of Human Tissue, Dutch Federation of Medical Scientific Society. 
abstract 
Carcinoembryonic antigen (cea)-targeted imaging and therapeutic agents are 
being tested in clinical trials. If cea overexpression in malignant tissue corresponds 
with elevated serum cea, serum cea could assist in selecting patients who may ben-
efit from cea-targeted agents. This study aims to assess the relationship between 
serum cea and cea expression in pancreatic (n=20) and rectal cancer tissues (n=35) 
using histopathology. According to local laboratory standards, a serum cea >3ng/
mL was considered elevated. In pancreatic cancer patients a significant correlation 
between serum cea and percentage of cea-expressing tumor cells was observed 
(p=0.04, ρ=0.47). All 6 patients with homogeneous cea expression in the tumor had 
a serum cea >3ng/mL. Most rectal cancer tissues (32/35) showed homogeneous cea 
expression, independent of serum cea levels. This study suggests that selection of 
pancreatic cancer patients for cea-targeted agents via serum cea appears adequate. 
For selection of rectal cancer patients, serum cea levels are not informative. 
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Statistical analysis  A  Statistical analysis was performed using spss ver-
sion 23.0 software (spss, ©ibm Corporation). The concordance of serum cea and 
cea expression on tumor tissue and of pathological T (pT) stage and serum cea was 
assessed using Spearmans’ test, defined as the correlation coefficient. The correlation 
between groups, based on an elevated or normal level of serum cea and between 
smokers and non-smokers, was calculated using the Mann Whitney U test. A χ2 test 
was used to compare homogeneity in pdac tissues. In all tests, results were consid-
ered statistically significant at the level of p < 0.05.
results
Patient and tumor characteristics  A  Patient and tumor character-
istics are summarized in Table 1. In the pancreatic cancer cohort, 3 patients partici-
pated in the preopanc study protocol; 2 of them received preoperative chemora-
diotherapy (crt)15. In the rectal cancer cohort, 8 patients participated in the rapi-
do study protocol16. All serum cea measurements were performed prior to the start 
of crt. Median preoperative serum cea of smoking pdac patients was 3.8 (range 
1.2-6.9), compared to 3.7 (range 0.6-23.8) for non-smokers (p=0.50). For rectal can-
cer patients, median preoperative serum cea of smoking patients was 2.9 (range 1.0-
16.9), compared to 2.7 for non-smokers (range 1.3-9.9; p=0.68). No significant corre-
lation was found between pT stage and preoperative serum cea (p=0.61, ρ=0.09 for 
pdac patients, p=0.95, ρ=0.02 for rectal cancer patients). 
cea expression and correlation to serum cea level
pdac cohort  A  The majority of tumors showed a heterogenous cea expression 
pattern, whereas only 6/20 tumors showed homogeneous cea expression (>80%). 
cea expression was mostly seen on the luminal surface of neoplastic glands and ne-
crotic tissue; low levels of immunoreactivity were seen in the stromal tissue, while 
normal acini did not express cea (Figure 1). A significant correlation was found 
between preoperative serum cea levels and percentage of cea-expressing tumor 
cells (p=0.04, ρ=0.47). This could not be shown for intensity of the staining (p=0.21, 
ρ=0.29). 15/20 tissues showed >50% cea-expressing tumor cells and 16/20 tissues 
showed a high intensity of cea expression (Table 2). When dividing the patients 
in groups of normal (n=6) and elevated serum cea (n=14), no significant correla-
tion between groups and percentage and intensity of stained tumor cells was found 
(p=0.15, p=0.34 respectively). However, all patients with tumors showing homoge-
neous cea expression (n=6) had elevated serum cea levels (χ2 =5.06, p=0.025). 
Tissue samples of twenty patients with pdac and thirthy-five patients with rectal 
adenocarcinoma, undergoing surgery at the lumc between 2013 and 2016, were ret-
rospectively collected. Patients were selected on availability of preoperative serum 
cea values. Based on hematoxylin-eosin-stained (he) slides, a single representa-
tive tumor containing formalin-fixed paraffin-embedded (ffpe) tissue block from 
each patient was chosen by a board certified pathologist (A.F.S.). Serum cea was 
measured using routine methodology (Elecsys, Roche Diagnostics) and according 
to local laboratory standards, serum cea levels >3ng/mL were considered elevated.
Immunohistochemistry  A  Immunohistochemical staining for cea was 
performed on ffpe tissue. Tissue samples were stained using a monoclonal mouse 
antibody against ceacam5 (clone number ci-p83-1, Santa Cruz Biotechnology). 
Validation of the staining protocol was performed by using human colon cancer tis-
sue as a positive control. Sections (thickness 4 µm) were cut from paraffin blocks and 
mounted on adhesive slides (Starfrost). Slides were deparaffinized using xylene and 
rehydrated in decreasing concentrations of ethanol. Subsequently, slides were rinsed 
with distilled water and endogenous peroxidase activity was blocked with 0.3% hy-
drogen peroxide (Merck Millipore) for 20 minutes. Slides were rinsed in distilled 
water and antigen retrieval was performed in dako pt link with target retrieval 
solution pH 6.0 at 95C° for 10 minutes. After rinsing with phosphate buffered saline 
(pbs) the primary antibody was incubated overnight at room temperature and after-
wards rinsed with pbs. Incubation of the secondary antibody (Envision anti-mouse 
hrp (dako)) was performed for 30 minutes at room temperature, followed by rins-
ing with pbs. Antibody binding was then visualized using 3,3’-diaminobenzidine 
(dab, dako). Sections were counterstained with hematoxylin (Klinipath), rinsed in 
tap water, dehydrated and mounted with pertex. All slides were scanned using the 
Philips Ultra Fast Scanner 1.6 ra. 
Scoring system  A  cea expression in cancer tissue was determined by immu-
nohistochemical staining (brown) and scored for staining intensity (0: none, 1: weak, 
2: moderate, 3: strong) and the fraction of positive tumor cells (1: <10%, 2: 10-50%, 
3: 50-80%, 4 >80%). Homogeneity was defined when >80% of tumor cells stained 
positive for cea (=score 4). All tissue specimens were scored by two independent 
observers (A.F.S. and L.B.); disagreements were resolved by consensus after review-
ing the relevant slides. 
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different results compared to this study might be attributable to varying cut-off val-
ues for defining elevated serum cea or differences in the staining or scoring proto-
col. Importantly, no correlation between serum cea and homogeneity of cea ex-
pression in pdac tissues could be studied in this tma study. No strict threshold of 
cea tissue expression to ensure optimal applicability of cea-targeted imaging or 
therapeutic agents has yet been defined. However, patients with homogeneous cea 
expression are expected to benefit most from those agents. 
In contrast to pdac patients, no significant correlation between serum cea and 
cea tissue expression was found in the rectal cancer cohort. A possible cause for this 
finding might be the difference in vasculature and permeability of the two tumor 
types. Rectal tumors are generally well-vascularized and show a relatively good re-
sponse to chemo(radio)therapy23. pdac shows poor blood supply and high amounts 
of stroma, possibly explaining the disappointing response to chemotherapy and the 
low 5-year survival rates of less than 5%24. It can be hypothesized that cea derived 
from rectal tumors accesses the bloodstream easier than cea from pdac, leading to 
higher cea serum levels. However, no significant correlation between preoperative 
serum cea and pT stage of tumors was found in the current study. Previous reports 
have indicated that several other factors, including tumor necrosis, smoking, benign 
liver disease and the location of the cea receptor on the cell membrane, could also 
affect serum cea levels25,26. 
Park et al 27 showed that cea serum concentrations were significantly higher in 
patients with cea-positive tumors than cea-negative tumors, but this correlation 
could not be reproduced in other studies28-30. It is nowadays accepted that rectal and 
colon cancer should be categorized as two different types of malignancies and treat-
ed differently. The current study differs from others as only rectal cancer patients 
were included. Nearly all tissues showed an intense and homogeneous expression 
compared to low expression on normal epithelium, independently of the neoadju-
vant therapy given nor the preoperative serum cea level. Although a relatively low 
number of rectal cancer patients was included, serum cea levels, assessed prior to 
the start of preoperative crt, are concordant with literature31. Thus, all rectal can-
cer patients, independent of their serum cea level, might benefit from cea-targeted 
agents. 
A limitation of this small, retrospective study is that different intervals elapsed 
between measurement of the cea serum concentrations and resection. Over- or 
underrating serum cea levels, as a consequence of the timing of cea measure-
ment, could have influenced the outcome of the study. Moreover, it is possible that 
selection bias has occurred because not all serum cea levels were measured in all 
subsequent patients between 2013-2016. Both of these issues could be avoided by 
Rectal cancer cohort  A  Almost all tumors (32/35, 91%) showed homoge-
neous cea expression. cea expression was found on luminal sides of malignant cells 
and in the majority of tumors, circumferential cea staining was shown. Normal epi-
thelium showed low levels of cea immunostaining, which was far less than the cea 
expression in cancer cells (Figure 2). No significant correlation was found between 
preoperative serum cea and percentage and intensity of cea-expressing tumor cells 
(p=0.58, ρ=0.10 and p=0.17, ρ=0.24 respectively). When dividing patients in groups 
of normal (n=20) and elevated serum cea (n=15), again no significant correlation 
between groups and the percentage and intensity of cea-expressing tumor cells was 
found (Table 2). 
discussion
This study shows a significant correlation between serum cea and the percentage 
of cea-expressing tumor cells in pdac tissue. Moreover, serum cea levels were el-
evated in all pdac patients with homogeneous cea expression in the tumor (>3 ng/
mL, χ2 =5.06, p=0.025). These results suggest therefore that especially patients with 
elevated serum cea levels could benefit from cea-targeted agents. Importantly, nor-
mal acini did not show any expression of cea. Personalized oncological care, to en-
sure that cancer patients benefit from targeted imaging and therapeutics, is already 
performed for other targets. For example, her2-targeted drugs (i.e. trastuzumab) 
are recommended when >30% of tumor cells show a complete, circumferential and 
intense membrane staining17. 
pdac patient selection is justified as not all tissues express cea. In the current 
study, only 6/20 tissues showed homogeneous cea expression and 15/20 tissues 
showed expression in >50% of neoplastic pancreatic cells. Previous studies reported 
cea expression in approximately 60-75% of pdac tissues3,18. Serum cea measure-
ments were performed using the Elecsys cea assay (Roche Diagnostics), which is 
previously described to be specific for ceacam5 as well as for nca-2, the nonspe-
cific cross reacting antigen-219. nca-2 is a truncated form of ceacam5 with identi-
cal amino acid sequence, and therefore ceacam5 was used as immunohistochemical 
tissue marker in this study20. Several other ceacam molecules have been previously 
described, each with a slightly different function21,22. Gebauer et al.3 investigated 
ceacam1, ceacam5 and ceacam6 as suitable biomarkers for pdac in a tissue 
micro array (tma; n=252). No significant correlation between elevated serum levels, 
e.g. >4.7ng/mL, and tissue expression of one of these ceacam subtypes could be 
shown. Yet, a significant correlation between ceacam5 and ceacam6 tissue expres-
sion and decreased overall and disease-free survival was demonstrated. The partly 
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designing a prospective study in which serum cea is measured directly prior to sur-
gery. In addition, the effect of neoadjuvant therapy on serum cea level and cea ex-
pression on rectal and pancreatic cancer tissue should be studied further. 
In conclusion, a significant correlation between serum cea levels and percentage 
of cea-expressing tumor cells in pdac tissue was shown. pdac patients that might 
benefit from cea-targeted imaging or therapeutic agents can adequatly be selected 
using serum cea levels (>3 ng/mL). This finding can be used in the process of per-
sonalized cancer care. Selection based on serum cea levels seems not useful in rectal 
cancer patients, as almost all show an intense, homogeneous cea expression. 
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Figure 1 Representative example of he and cea staining of pancreatic cancer tissue 
cea expression of tumor (T) tissue compared to adjacent normal (N) pancreatic tissue, derived from a patient 
with a preoperative serum cea level <3ng/mL (A) and >3ng/mL (B; magnification 1x and 10x). The magnified 
image in A shows moderate cea expression on the luminal side of neoplastic glands, while tumor tissue in 
image B shows an intense, circumferential cea expression. The adjacent normal acini do not stain positive. 
Figure 2 Representative example of he and cea staining of rectal cancer tissue 
cea expression of tumor tissue (T) compared to adjacent normal (N) rectal tissue, derived from a patient with 
a preoperative serum cea level <3ng/mL (A) and >3ng/mL (B; magnification 1x and 10x). Both tumor tissues 
(A and B) show an intense, circumferential cea expression, independent of the preoperative serum cea level. 
Normal epithelium shows weak expression. 
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Table 2 Percentage and intensity of stained tumor cells
Pancreatic cancer (n=20) CEA serum level  
Percentage of stained tumor cells <3ng/mL >3ng/mL Total 
1 (<10%) 1 2 3
2 (10% - 50%) 1 1 2
3 (50% - 80%) 4 5 9
4 (>80%) 0 6 6
Intensity of staining    
0 (none) 0 0 0
1 (weak) 0 0 0
2 (moderate) 2 2 4
3 (strong) 4 12 16
Rectal cancer (n=35) cea serum levels  
Percentage of stained tumor cells <3ng/mL >3ng/mL Total
1 (<10%) 0 0 0
2 (10% - 50%) 0 0 0
3 (50% - 80%) 1 1 2
4 (>80%) 19 14 33
Intensity of staining      
0 (none) 0 0 0
1 (weak) 0 0 0
2 (moderate) 2 1 3
3 (strong) 18 14 32
crt = chemo- and radiotherapy; cea = carcinoembryonic antigen; ln = lymph node;  
epcam = epithelial cell adhesion molecule; c-Met = tyrosine kinase protein Met
Table 1 Patient and tumor characteristics
Pancreatic Rectal
cancer cancer
Included patients   n=20 n=35
Gender Male 11 (55%) 22 (63%)
Female 9 (45%) 13 (37%)
Age at diagnosis Median age in years (range) 71 (51-86) 67 (42-78)
pT stage 1 2 (10%) 1 (3%)
2 2 (10%) 13 (37%)
3 7 (35%) 21 (60%)
4 0 (0%)  0 (0%) 
Unknown 9 (45%) 0 (0%)
pN stage 0 8 (40%) 21 (60%)
1 11 (55%) 13 (37%)
2 1 (5%) 1 (3%)
pM stage 0 20 (100%) 35 (100%)
1 0 (0%) 0 (0%)
Angioinvasion Yes 7 (35%) 0 (0%)
None 9 (45%) 27 (77%)
Unknown 4 (20%) 8 (23%)
Neoadjuvant therapy None 17 (85%) 18 (51%)
preopanc study protocol 3 (15%) n.a.
Radiation therapy (25 x 2 Gray) n.a. 7 (20%)
rapido study protocol n.a. 8 (23%)
Chemoradiation therapy n.a. 2 (6%)
Smoking Yes 7 (35%) 7 (20%)
None 13 (65%) 11 (31%)
Unknown 0 (0%) 17 (49%)
Tumor diameter (cm) Median (range) 3 (0.9-6.1) 2.5 (1.2-6.0)
Differentiation grade Well/moderate 3 (15%) 3 (9%)
Moderate/poorly 14 (70%) 28 (80%)
Unknown  3 (15%)  4 (11%)
p=pathological, n=number, crt=chemo- and radiotherapy, n.a.=not applicable
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introduction
The cornerstone of rectal cancer (rc) treatment is surgical resection, performed 
via total mesorectal excision1. Completeness of the surgical resection is pivotal for 
the prognosis of rc patients. A positive circumferential resection margin is asso-
ciated with a high rate of local and distant recurrences, high morbidity and mor-
tality2,3. The introduction of neoadjuvant chemo- and radiotherapy (crt) led to a 
significant decrease in the rate of irradical resections4. Still, a recent meta-analysis 
reported a positive resection margin rate of 14.7% after abdominoperineal excision 
and 27% after pelvic exenteration5, stressing the need for novel diagnostic imaging 
tools that can enhance contrast between cancer and adjacent normal/fibrotic tissue 
during surgery. An imaging modality that can fulfil this need is tumor-targeted fluo-
rescence imaging6. This innovative technique can provide real-time intraoperative 
tumor visualization by selectively highlighting tumor cells. 
Selection of tumor targets for imaging purposes depends on various character-
istics including the expression pattern, localization of the biomarker in the cell and 
the tumor-to-normal (T/N) expression ratio7,8. Prerequisite is a low or absent ex-
pression of a protein in normal tissue in combination with enhanced expression in 
cancer lesions. Promising targets for detection of rc are carcinoembryonic antigen 
(cea), epithelial cell adhesion molecule (Epcam) and the tyrosine-kinase receptor 
c-Met9,11. The glycoprotein cea is overexpressed in the vast majority of colorectal 
cancers (crc) and has already been used for therapeutic and imaging purposes12,13. 
Recently, an early phase clinical trial has been initiated utilizing a cea-targeted flu-
orescent tracer for intraoperative detection of crc (Netherlands Trial Register id: 
5673). Epcam is a transmembrane glycoprotein, involved in cell-cell interactions and 
cell-stroma adhesion, and overexpressed in nearly all epithelial malignancies14. The 
recognition of Epcam as one of the most promising, pluri-potent tumor markers has 
resulted in (pre)clinical testing of several Epcam-targeted agents10,15,16. First-in-
human studies with an Epcam-specific fluorescent agent to visualize various tumors 
during surgery are planned to start soon in our institution. c-Met, the receptor of 
hepatocyte growth factor (hgf), is involved in tumor cell proliferation and invasion, 
and its enhanced expression is associated with a poorer survival17. The upregulation 
of c-Met in (pre)malignant colorectal lesions supported the successful clinical test-
ing of a c-Met targeted fluorescent peptide, i.e. ge-137, for better endoscopic detec-
tion of colorectal adenomas11,18. 
Although several studies showed overexpression of cea, Epcam and c-Met 
in crc tissues18-20, the effect of crt on protein expression is still unknown. This 
issue is however important for the reliable applicability of cea-, Epcam- and 
abstract
Purpose " Intraoperative identification of rectal cancer (rc) can be challenging, 
especially because of fibrosis after treatment with preoperative chemo- and radio-
therapy (crt). Tumor-targeted fluorescence imaging can enhance contrast between 
tumor and normal tissue during surgery. Promising targets for rc imaging are car-
cinoembryonic antigen (cea), epithelial cell adhesion molecule (Epcam) and the 
tyrosine-kinase receptor c-Met. The effect of crt on their expression determines 
their applicability for imaging. Therefore, we investigated whether crt modifies 
expression patterns in tumors, lymph nodes (ln) metastases and adjacent normal 
rectal tissues. 
Procedures " Preoperative biopsies, primary tumor specimens and metastatic 
lns were collected from 38 rc patients who did not receive crt (cohort 1) and 34 pa-
tients who did (cohort 2). cea, Epcam and c-Met expression was determined using 
immunohistochemical staining and semi-quantified by a total immunostaining 
score, consisting of the percentage and intensity of stained tumor cells (tis, range 
0-12). 
Results " In both cohorts cea, Epcam and c-Met were significantly higher 
expressed in more than 60% of tumor tissues compared with adjacent normal epi-
thelium (T/N ratio, p<0.01). Epcam showed the most homogeneous expression in 
tumors, whereas cea showed the highest T/N ratio. Most importantly, cea and 
Epcam expression did not significantly change in normal or neoplastic rc tissue 
after crt, whereas c-Met levels changed (p=0.02). Tissues of eight patients with a 
pathological complete response after crt showed expression of all biomarkers with 
tis close to normal epithelium. 
Conclusion " Histological evaluation shows that cea, Epcam and c-Met are 
suitable targets for rc imaging, because all three are significantly enhanced in cancer 
tissue from primary tumors or ln metastases compared with normal adjacent tis-
sue. Furthermore, the expression of cea and Epcam is not significantly changed 
after crt. These data underscore the applicability of c-Met and especially cea, and 
Epcam as targets for image-guided rc surgery, both before and after crt. 
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the ffpe blocks in 4 µm slides, these were mounted on adhesive slides (Starfrost), 
deparaffinized using xylene and rehydrated in decreasing concentrations of etha-
nol. Subsequently, slides were rinsed with distilled (di) water and endogenous per-
oxidase was blocked with hydrogen peroxidase 0.3% hydrogen peroxidase (Merck 
Millipore) for 20 minutes. Slides were rinsed in di water and antigen retrieval was 
performed in the dako pt link, Target Retrieval Solution pH6.0 at 95ºC for 10 
minutes. After rinsing with phosphate buffered saline (pbs), slides were stained with 
predetermined dilutions using monoclonal antibodies (mAb) against ceacam5 
(clone ci-p83-1:, sc-23928 from Santa Cruz Biotechnology, 0,2 µg/m, dilution 
1:2500), Epcam (clone moc-31 Acris Antibodies, dilution 1:10,000) and a polyclonal 
antibody against c-Met (polyclonal rabbit, Santa Cruz sc-10, 1 µg/ml, dilution 
1:100). After overnight incubation with the primary antibodies, slides were incu-
bated with the secondary antibody (Envision anti-mouse hrp (dako)) for 30 min, 
followed by diaminobenzidine solution (dab+; dako Kit). All slides were counter-
stained with hematoxylin, dehydrated and finally mounted with pertex.
Scoring method  A  All tumor tissues, metastatic lns, normal appearing mu-
cosae and fibrotic rectal tissues from patients who had a pcr after crt were scored 
for expression of cea, Epcam and c-Met. The total immunostaining score (tis) was 
calculated by multiplying the proportion score (ps) and intensity score (is), as pre-
viously described20. The ps represented the percentage of positively stained tumor 
cells and ranged between 0-4 (0=none; 1 <10%; 2=10-50%; 3=51-80%; 4>80%). The 
is represented the intensity of the stained tumor cells and could range between 0-3 
(0=no staining; 1=weak; 2=moderate; 3=strong). Subgroups were defined based on 
the calculated tis: 0, no expression; 1-4, weak expression; 6-8, moderate expres-
sion; 9-12, intense expression. Homogeneous expression was defined when >80% of 
tumor cells, with a staining intensity of ≥1, showed expression of one of the biomark-
ers (ps=4). Evaluation of the ihc stainings was performed independently by two 
observers (A.F.S. and L.B.). All the sections with interobserver disagreement were 
discussed with a board certified pathologist until agreement was reached. 
Statistical analysis  A  Statistical analyses were performed using spss 
version 23.0 software (spss, © ibm Corporation, Somer ny, usa) and GraphPad 
Prism 6 (GraphPad, Software, Inc., La Jolla). For each patient, biomarker expres-
sion on biopsies, resected primary tumors and metastatic lns was compared using 
the Mann-Whitney test. Differences in expression levels between cohort 1 (no crt) 
and cohort 2 (crt) were calculated using the Wilcoxon rank test. This test was also 
used to calculate differences in expression levels between tumor and adjacent normal 
c-Met-targeted fluorescent contrast agents for rc imaging, as the majority of rc 
patients receive neoadjuvant crt. In addition, this knowledge can be utilized for 
application of cea-, Epcam or c-Met-targeted tracers for other imaging purposes, 
such as pet- or spect imaging. The aim of this study was to investigate whether 
crt modifies expression of cea, Epcam and c-Met in rc tissues and in adjacent 
normal epithelium. Therefore we first studied the concordance in protein expression 
between diagnostic biopsies and tissue from primary resected adenocarcinomas and 
ln metastases of patients who did not receive neoadjuvant crt, in order to establish 
that there are no significant differences between biomarker levels. Subsequently, the 
effect of crt was studied in an additional cohort by correlating cea, Epcam and 
c-Met expression between biopsies, obtained prior to the start of crt, versus pri-
mary tumors and metastatic lns. 
methods
Tissue samples  A  Formalin-fixed paraffin-embedded (ffpe) tissue blocks 
from 72 patients, who underwent surgical resection of rc or polypectomy between 
2000-2015, were obtained from the Pathology Department of the Leiden University 
Medical Center (lumc) (Table 1). Medical records and pathology samples were ret-
rospectively reviewed. Patients were divided into two cohorts based on their ther-
apy: cohort 1 was defined by patients without neoadjuvant crt whereas cohort 2 
comprised the neoadjuvantly treated patients (Figure 1). crt consisted of a combi-
nation of chemo- and radiotherapy, e.g. 25x2 Gray and Capecitabine with/without 
Avastin or 5x5 Gray with Capecitabine plus Oxaliplatin (rapido study design)21. 
Available ffpe tissue blocks of diagnostic biopsy specimens, tumor resection mate-
rial and metastatic lns were collected. All biopsies from patients treated with neo-
adjuvant crt were obtained via endoscopic procedures, prior to the start of crt. 
Multiple biopsy specimens of individual patients were incorporated on one slide. 
Eight patients showed a pathological complete response (pcr) after crt. These tis-
sues were also included in the study to assess the expression of biomarkers on nor-
mal/fibrotic epithelium. All samples were handled in an anonymous fashion accord-
ing to the national ethics guidelines (‘Code for Proper Secondary Use of Human 
Tissue,’ Dutch Federation of Medical Scientific Societies) and approved by the 
Institutional Ethics Committee of the Leiden University Medical Center. 
Immunohistochemistry A Based on hematoxylin-eosin-stained (he) 
slides, a representative ffpe tissue block containing tumor and normal tissue from 
each patient was chosen by a board-certified pathologist (A.F.S.). After sectioning 
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three biomarkers between endoscopically obtained biopsy specimens and resection 
specimens per individual patient (p=0.43 for cea, p=0.10 for Epcam and p=0.41 for 
c-Met). These data suggest that differences found between stainings in biopsies and 
resected material in cohort 2 are exclusively induced by crt. 
Also in cohort 2, the majority (>61%) of cases showed a concordant expression pat-
tern when comparing biopsies and resection material, despite the fact that biopsies 
were obtained prior to the start of neoadjuvant crt and primary tumors after crt. 
The concordance between biopsies is shown in Table 2 and graphically displayed in 
Figure 4. No significant difference in cea and Epcam expression was found between 
the various tumor tissues per patient (p=0.52 for cea, p=0.11 for Epcam). However, 
c-Met expression appeared significantly different between biopsies and resected tu-
mors (p=0.02). Again, most discordant expression scores between biopsies and pri-
mary tumors were due to minor differences in tis between intense vs. moderate; 4/7 
(57%) disconcordant scores for cea, 5/6 (83%) for Epcam and 7/9 (78%) for c-Met. 
Finally, when comparing all tumor tissues from patients who did not receive crt with 
patients who did, no significant differences were found between expression in primary 
tumors and between expression in metastatic lns (all p-values>0.05). cea, Epcam 
and c-Met expression did not significantly differ between tumor tissues that showed 
no response after crt and tissues that showed a partial pathological response.
Comparison of biomarker expression between carcinoma 
and adjacent normal tissue  A  Figure 5 shows the distribution of cea, 
Epcam and c-Met tis in tumor tissues compared with normal adjacent epithelial 
tissues, from both patient cohorts together. All three biomarkers were significantly 
upregulated in cancer tissue compared to normal tissue of the same patient (p<0.01 
for cea, Epcam and c-Met). Median tis expression in normal epithelium were re-
spectively 4 (range 0-12) for cea, 12 (range 0-12) for Epcam and 8.5 (range 0-12) 
for c-Met. A significant difference between biomarkers was found using a Kruskal-
Wallis test with the highest mean rank for cea, followed by equal mean ranks for 
Epcam and c-Met (p<0.01). 
Expression on tissue with complete pathological response 
Median biomarker expression scores (tis) in the tumor bed of resected tissue from 
patients with a pcr after neoadjuvant crt were respectively 5 (range 1-12) for cea, 
10.5 (range 4-12) for Epcam and 8.5 (range 4-12) for c-Met. cea expression was seen 
on the surface of normal epithelium and alike Epcam and c-Met, in mucin produc-
ing cells. The muscularis propria showed some expression of c-Met (probably non-
specific binding). 
tissue per patient. Additionally, a Mann-Whitney test was performed to compare 
these analyses between patients of cohort 1 and 2. A Kruskal Wallis test was used to 
determine the differences in T/N ratio between all three biomarkers. In all tests, re-
sults were considered statistically significant at the level of p<0.05. 
results
Patient and tumor characteristics are summarized in Table 1. Briefly, thirty-eight 
patients did not receive neoadjuvant crt (cohort 1). Of these patients, available bi-
opsy specimens (n=36), primary tumor specimens (n=38) and metastatic lns (n=10) 
were collected (Figure 1). In cohort 2, 34 patients treated with neoadjuvant crt were 
included. Available biopsy specimens (n=31), obtained prior to the start of crt, pri-
mary tumor specimens (n=34) and metastatic lns (n=7) were collected. Eight out of 
34 patients had a pcr after neoadjuvant crt.
cea, Epcam and c-Met expression  A  Representative examples of cea, 
Epcam and c-Met staining in tumor tissue derived from a patient from cohort 1 
are shown in Figure 2. cea was mainly expressed on the apical side of cancer cells, 
while Epcam and c-Met showed a more circumferential, membranous staining. 
Moreover, lymphoid cells, histiocytes and necrotic areas stained also positive for 
c-Met. Figure 3 shows similar representative staining’s in a patient from cohort 2. 
All biomarkers showed some positivity in non-cancerous mucin producing cells in 
neoadjuvantly treated tissues. cea, Epcam and c-Met expression scores of all tumor 
tissues are shown in Table 2. The median tis of all biomarkers in all tumor tissues 
was 12. In cohort 1, homogeneous expression of cea, Epcam and c-Met was found 
in respectively 28/38 (74%), 34/38 (89%) and 31/38 (82%) of the malignancies in resec-
tion material, which was significantly similar to the expression of cea, Epcam and 
c-Met in malignancies in resection material in cohort two, found in respectively 
19/26 (73%), 24/26 (92%) and 22/26 (85%) of samples. 
Comparison between biomarker expression before and 
after crt  A  The degree of concordance of cea, Epcam and c-Met expres-
sion between the various tumor tissues, i.e. biopsy, tumor in resection material and 
metastatic ln, is shown in Table 3. In cohort 1, >61% of biopsies showed concor-
dant expression with their corresponding resected tumor. The majority of discordant 
scores were due to a difference in intense vs. moderate expression between the tumor 
tissues, i.e. 10/14 (71%) discordant scores for cea and Epcam, and 6/7 (86%) discor-
dant scores for c-Met. There was no significant difference in expression of any of the 
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seem a disadvantage for Epcam as a target. However, when analysing these data, 
one should take the limitations of ihc scorings into consideration when quantify-
ing protein expression. For instance, a difference between 10,000 Epcam molecules 
on a regular cell and 400,000 on a neoplastic cells would probably not be noticed by 
conventional ihc, but would be enough to discriminate tumor from normal tissue 
using fluorescence imaging. On the other hand, cea has the disadvantage of being 
anchored to the cell membrane via a gpi-anchor, making it vulnerable for shedding 
in the bloodstream27. As a result, high levels of soluble cea could scavenge the intra-
venously administered targeting agent, being a disadvantage for cea-based imaging. 
Our group previously described the preclinical evaluation of respectively a fluo-
rescent labelled Epcam-specific mAb and a cea-specific single-chain antibody frag-
ment and showed successful fluorescent delineation of several tumor models, in-
cluding crc and peritonitis carcinomatosis9,10. As already indicated in the previous 
paragraph, preclinical models can only partly mimic the human situation. The most 
important factor that influences the tumor-to-background ratio during clinical ap-
plication of tumor-targeted agents will be the presence of the targeted receptor on 
adjacent normal cells. Both Epcam and cea expression are described to be confined 
to the basolateral surface of normal polarized epithelial cells, where these recep-
tors might be less accessible for targeting by intravenous administered agents26,28,29. 
When epithelial cells dedifferentiate into tumor cells, polarity is lost and cea and 
Epcam become expressed throughout the entire membrane. This phenomenon 
would be advantageous for tumor imaging. Especially for normal enterocytes, with 
a lifespan of 1-2 days, the continuous shedding of these cells into the bowel lumen 
would result in relatively low background fluorescence in normal mucosa, especially 
when imaging occurs a few days after tracer administration. 
The main drawbacks of this study are the relatively low numbers of tissue sets 
and the use of semi-quantitative ihc. The collection of tumor tissue before and after 
crt implies that both endoscopic diagnostic biopsy material and resection material 
of the same patient are available at the same institution. Our hospital is a reference 
hospital for some regional hospitals and therefore many of the diagnostic biopsies 
are taken elsewhere. Collecting the material is tedious and time consuming. Our ap-
proach of studying two cohorts of patients showed that the differences of expression 
of the three selected biomarkers before and after crt were limited. ihc is relatively 
easy to perform, available at low costs compared to other diagnostic techniques, and 
provides information about the expression patterns of certain proteins in various cell 
types, which is pivotal information for imaging purposes. Although it is nowadays 
routinely used, ihc in most cases lacks standardization (pre-test variability) and 
variance in interpretation of the staining (post-test variability)20. To minimize these 
discussion
Tumor-targeted fluorescence imaging has the potential to revolutionize the cur-
rent practice of oncologic surgery by selectively highlighting neoplastic cells. This 
technique may be particularly useful during rc surgery, as clear tumor visualization 
is sometimes impaired by anatomic constrains such as a narrow pelvis. The present 
data confirm the results of previous studies that expression of the studied biomark-
ers cea, Epcam and c-Met is increased in tumor tissue as compared with normal 
mucosa from the same patient, and hence in principle could be used as targets for 
image-guided assistance during surgery. However, a substantial part of rc patients 
are nowadays treated with neoadjuvant crt to induce down staging and to achieve 
local control22. Although the addition of crt leads to a decrease in recurrence rates, 
it also causes massive tissue fibrosis which in turn hinders intraoperative tumor lo-
calization23. The data presented here demonstrate that the expression of cea and 
Epcam does not significantly differ between endoscopically obtained diagnostic bi-
opsies, resected primary tumors and ln metastases, in patients treated with or with-
out neoadjuvant crt. These results demonstrate the usability of these biomarkers for 
rc imaging. c-Met expression differed significantly between biopsies and resected 
tumors in cohort 2, which might reflect an effect of the crt on protein expression, 
but could also be the result of a small sample size. 
In the current study we showed that all three proteins are abundantly expressed 
in the vast majority of rc tissues, confirming previous studies with larger co-
horts18-20. Although ihc is not a fully quantitative technique, and results might de-
pend on the selected antibodies and tissue fixation, the representative figures show 
that cea and Epcam seem to outperform c-Met with respect to staining intensity 
in tumors. Unlike cea and Epcam, which are involved in cell adhesion, c-Met is 
a tyrosine kinase receptor that becomes activated after binding of the hepatocyte 
growth factor. Due to the pivotal role of c-Met in cancer biology and overexpres-
sion in several cancer types, it is regarded as a promising target for molecular tumor 
imaging, including colorectal neoplasia11,24. Still, the numbers of this receptor per 
tumor cell might be lower compared to adhesion molecules like cea and Epcam, as 
reflected in the expression scores within this study8. 
A prerequisite for appropriate tumor targets in image-guided surgery is en-
hanced expression on tumor cells compared to adjacent normal tissue7. cea and 
Epcam are cell adhesion molecules and are both moderately expressed on normal 
cilindric epithelium and goblet cells25,26. Although Epcam showed the highest 
amount of homogeneous tumor expression among all three biomarkers, the dif-
ference in the tis between tumor and normal tissue was relatively low. This could 
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limitations, we performed ihc staining with validated antibodies and used a scor-
ing method that was previously evaluated20. Nevertheless, differences in expression 
could be observed by using various antibodies against the same target. Especially for 
c-Met, the use of a polyclonal antibody might difficult the comparison with other 
studies. 
A promising application of cea, Epcam, or c-Met-targeted fluorescent agents 
might be the implementation during (endoscopic) surveillance of patients eli-
gible for the Watch-and-Wait strategy (W&W), or during Transanal Endoscopic 
Microsurgery (tem)30,31. Over the last years, organ-preserving approaches for rc 
patients, such as the W&W strategy for patients with a complete clinical response 
(ccr) and tem, are gaining interest31. As recent studies show a local regrowth rate 
up to 38% in patients selected for W&W, it seems that conventional imaging modali-
ties are not able to select patients sufficiently32. Therefore, tumor-targeted fluores-
cence imaging during colonoscopies may assist in identification of a ccr, or residual 
tumor cells. This application would however only be valuable when markers are sen-
sitive and specific enough to distinguish between normal tissue, fibrotic tissue and 
scattered tumor cells. In the eight tissues derived from patients with a pcr all bio-
markers showed some expression in the resected fibrotic tumor bed, but consider-
ably less than in the tumors. Larger studies are needed to confirm these findings and 
assess the expression of these and other biomarkers in patients with a pcr, both for 
primary and recurrent rc patients. 
conclusion
In conclusion, this study shows that cea, Epcam and c-Met are abundantly ex-
pressed in rc and ln metastases, and that modifications of protein expression by 
crt in tumor or adjacent normal tissue are limited. Homogeneous expression in rc 
tissues of primary tumors and metastatic lns was highest for Epcam. But, based on 
staining of normal adjacent epithelium, cea appeared the most distinctive biomark-
er. The data of the present study underscore a reliable applicability of cea-, Epcam- 
and c-Met-targeted imaging agents, which have recently been or will soon be used 
in clinical practice. A firm conclusion about which biomarker has the highest po-
tential cannot be drawn based only on ihc or on animal models. Only comparative 
clinical trials can answer this question. 
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Figure 2 Representative images of cea, epcam and c-Met expression on rc tissues of a patient who was 
not treated with crt
A Biopsy specimen (magnification 5x). All cancer cells show expression of all three biomarkers.
B Primary tumor specimen (magnification 5x). The dotted arrow indicates normal epithelium and the 
other arrow indicates cancer tissue. A difference in intensity between tumor and normal tissue can be 
seen for all three biomarkers. This difference appears the highest for cea, followed by Epcam and c-Met
c Metastatic lymph node (magnification 5x). The arrow indicates the location of cancer cells, which are 
clearly visualized by Epcam and cea staining.
Figure 1 Overview of included tumor tissues
Described are the number of included specimens derived from patients who received no neoadjuvant crt 
(cohort 1, n=38) and patients who did (cohort 2, n=34). In the primary tumor specimens, expression of 
biomarkers on normal epithelium was assessed when applicable. Biopsies were endoscopically obtained, prior 
to crt (cohort 2). In cohort 1, 36 tumor sets were included consisting of biopsy material and primary resection 
specimens. Of these 36 patients, 10 tissues of ln metastases were included. In cohort 2, 31 sets were included 
consisting of biopsy material and primary resection specimens, including 4 with ln metastases. One patient 
with a ln metastasis had a cpr. Two ln metastases could only be correlated with expression in primary 
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Figure 4 Difference in cea, Epcam and c-Met expression between biopsies, obtained prior to the start of 
crt, and primary tumors
A horizontal line indicates the same level of expression between biopsy and primary tumor. For all biomarkers, 
the majority of tissues showed an intense expression (tis of 12) in biopsies and corresponding primary 
tumor. The number of biopsy and tumor tissues with a certain expression score (tis) are indicated next to the 
corresponding line. 
Figure 5 Tumor-to-normal tissue ratio for cea, Epcam and c-Met on primary resected tumors
Shown are correlations between tumor tissue and adjacent normal tissue in the same sample, per patient and 
per biomarker (both cohort 1 and cohort 2). All biomarkers were significantly upregulated in tumor tissue 
compared to adjacent normal epithelium. The T/N ratio was highest for cea. The arrows indicate the number 
of tumor tissues that show an enhanced or decreased expression compared to adjacent normal epithelium; = 
refers to equal expression scores. 
Figure 3 Representative images of cea, Epcam and c-Met expression on rc tissues of a patient who was 
treated with neoadjuvant crt
A Biopsy specimen (magnification 5x), obtained prior to the start of crt, showing expression of all three 
 biomarkers. 
B Primary tumor specimen (magnification 5x). The dotted arrow indicates normal epithelium and the 
other arrow indicates tumor tissue. A difference in intensity between tumor and normal tissue can be 
seen for all three biomarkers. This difference appears the highest for cea.
c Metastatic lymph node (magnification 5x). The arrow indicates the location of cancer cells, which are 
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Table 2 Total immunostaining scores of all stained tumor tissues, derived from patients who did not (-) and 
patients who did (+) receive neoadjuvant crt 
Total Immunostaining Score (tis) on tumor tissue n (%)















































































































Table 1 Patient and tumor characteristics
  No crt (n=38) crt (n=34)
Age at diagnosis, median years (range) 67 (36 - 87) 64 (26 - 76)
Gender, n
 male 25 21
 female 13 13
Previous radiotherapy in area of rectum, n 3 2
Type of surgery performed
 low anterior resection 32 30
 abdominoperineal resection 4 14
 subtotal colectomy 1 0
 polypectomy 1 0
Tumor size, median mm (range) 35 (5 - 120) 25 (1 - 70)
Primary tumor stage, n 
 pT0 0 8
 pT1 5 2
 pT2 13 10
 pT3 17 11
 pT4 3 3
Nodal stage, n
 pN0 24 24
 pN1 8 6
 pN2 6 4
Metastatic stage, n
 pM0 32 32
 pM1 6 2
Pathological response, n
 none n.a. 9
 partial n.a. 17
 complete n.a. 8
p=pathological, n=number of patients, crt = chemoradiotherapy
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Table 3 Degree of concordance of biomarker expression between various tumor tissues per patient
No crt cea Epcam c-Met
biopsy = tumor 22/36 (61%) 22/36 (61%) 28/36 (78%)
 biopsy > tumor 5/36 (14%) 2/36 (6%) 2/36 (6%)
 biopsy < tumor 9/36 (25%) 12/36 (33%) 6/36 (17%)
ln metastasis = tumor 9/10 (90%) 9/10 (90%) 7/10 (70%)
 ln metastasis > tumor 1/10 (10%) 1/10 (10%) 1/10 (10%)
 ln metastasis < tumor 0/10 (0%) 0/10 (0%) 2/10 (10%)
crt
biopsy = tumor 16/23 (70%) 17/23 (74%) 14/23 (61%)
 biopsy > tumor 2/23 (9%) 1/23 (4%) 1/23 (4%)
 biopsy < tumor 5/23 (22%) 5/23 (22%) 8/23 (35%)
ln metastasis = tumor 6/7 (86%) 7/7 (100%) 4/7 (57%)
 ln metastasis > tumor 1/7 (14%) 0/7 (0%) 0/7 (0%)
 ln metastasis < tumor 0/7 (0%) 0/7 (0%) 3/7 (43%)
crt chemo- and radiotherapy, = indicates a concordant expression between the two tissues, > indicates up regulation of 
expression, < indicates down regulation of expression
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introduction
Endometrial cancer (ec) can be categorized in type 1 and type 2, based on etiol-
ogy and clinicopathologic features1. Type 1 ec are commonly estrogen-dependent, 
low-grade, endometrioid adenocarcinomas, accounting for 80% of all ec. Type 2 ec 
account for the remaining 20% and represent a more aggressive, high-grade tumor 
type with a poorer prognosis2,3. These tumors are generally non-endometrioid, i.e. 
serous or clear cell, and unrelated to estrogen exposure. High-risk ec is defined as 
a combination of several factors including non-endometrioid ec, more advanced 
disease stages/age, high-grade and lymphovascular space invasion4. Although ec 
is conventionally categorized in type I and ii, improved understanding of the mo-
lecular landscape of ec has resulted in subdivision of ec in four molecular subtypes 
with improved prognostic significance, among others p53 mutant ec5. Each type 
and risk group of ec requires a different surgical approach because of distinctive 
tumor characteristics. For type I, low-grade ec the extent of pelvic organ resection 
and lymphadenectomy depends on the tumor stage, whereas a complete staging is 
recommended for clinically early stage serous and clear cell carcinomas, due to high-
er rates of metastatic disease6. A complete surgical staging includes a total hyster-
ectomy with bilateral salpingo-oophorectomy (bso), pelvic and para-aortic lymph 
node sampling, omentectomy, and several peritoneal biopsies of predefined spots7. 
Depending on the presence of metastases during surgical staging, patients will ei-
ther be monitored via follow-up or treated with adjuvant therapy1. 
Both during staging and cytoreductive surgery (crs) of ec it is of utmost im-
portance to identify tumor lesions with high accuracy. Surgeons are dependent on 
inspection and palpation (in case of open surgery) for intraoperative distinction 
between tumor and normal tissue. Histopathological analysis on frozen specimens 
obtained during the procedure can provide additional information, but is only per-
formed on clinically suspicious lesions. Furthermore, non-suspect, but malignant le-
sions can easily be missed when visual inspection and palpation are the sole means 
for identification. An innovative technique that can assist in real-time intraopera-
tive tumor detection is near-infrared (nir) fluorescence imaging8. This technique 
is based on administration of a fluorescent agent and real-time detection of fluores-
cence using a dedicated nir imaging system. A new era in the field of nir fluores-
cence imaging has emerged with the clinical testing of tumor-targeted fluorescent 
contrast agents9. These agents consist of a tumor-targeting ligand, e.g. a peptide, an-
tibody, nanobody etc., conjugated to a nir fluorescent dye. One of the most prom-
ising agents currently available for clinical testing is otl-38, a nir fluorescent-la-
belled peptide targeting the Folate Receptor-α (frα)10. The frα, an isoform of the 
abstract
Objective " Detection and resection of all malignant lesions is pivotal in stag-
ing and cytoreductive surgery (crs) of endometrial cancer (ec). Intraoperative ec 
detection could be enhanced using otl-38, a fluorescent-labelled folate receptor-α 
(frα) targeted imaging agent. The objectives of this study were to investigate which 
subgroups of high-risk ec patients express frα and assess feasibility of intraopera-
tive ec detection using otl-38. 
Methods " Immunohistochemical (ihc) staining of frα expression was per-
formed on tissue micro arrays (tma) of 116 patients with high-risk ec features. 
Patients with either serous or clear cell ec, planned for staging or crs, were eligible 
for inclusion in the clinical study and received an intravenous dose of 0.0125 mg/kg 
otl-38, 2-3 hours prior to surgery. Resected lesions, identified by standard-of-care 
and/or fluorescence imaging, were histopathologically assessed for frα and tumor 
status.
Results " frα expression on tma was significantly correlated with tumor type 
(p<0.01). Eighty-two percent of serous and clear cell carcinomas showed frα ex-
pression. Four patients were enrolled in the clinical study. Using fluorescence im-
aging all omental (n=3) and lymph node (ln) metastases (n=16) could be clearly 
identified, including one otherwise undetected omental metastasis. However, false-
positive fluorescence was identified in 17/50 non-metastatic lns, caused by otl-38 
targeting of frβ, expressed by (tumor-associated) activated macrophages. 
Conclusion " This study describes high frα expression in serous and clear cell 
ec and demonstrates the first experience of intraoperative frα-targeted tumor 
detection in patients with these subtypes of ec. Although all metastases could be 
clearly identified using otl-38, the role of tumor-associated macrophages should be 
further evaluated.
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Clinical study
Patient characteristics  A  Four patients with ec (serous carcinoma; n=3 
and clear cell carcinoma; n=1) were included in the clinical study (Table 2). Three pa-
tients underwent a staging procedure and one patient crs. The patient undergoing 
crs (patient #4) was diagnosed with a large mass in the fundus uteri (5.5cm) and two 
suspect peritoneal depositions in the omentum (respectively 1.3cm and 2.8cm) on 
preoperative computed tomography imaging. crs consisted of uterus extirpation, 
bso and omentectomy. 
Safety and pharmacokinetics  A  All patients received 0.0125mg/kg 
otl-38 over 1 hour and no infusion was stopped or intermitted. Two patients ex-
perienced possibly related aes: one patient experienced a mild muscle spasm and 
another patient mild pruritus. Both aes were self-limiting. No clinically relevant 
changes in blood pressure or pulse rate were observed. The maximal concentration 
for each dose was obtained directly after the end of the infusion. The elimination 
half-life was approximately 86 min. 
Intraoperative fluorescence imaging  A  Intraoperative fluores-
cence imaging allowed clear detection of tumor lesions using an exposure time of 
less than 60 ms. During surgery a fluorescent signal arising from the uterus could be 
detected in all patients with the primary tumor still in situ, with a mean tumor-to-
background ratio (tbr) of 6.4 (sd=4.7; range: 2.9-13, Table 3). However, after slicing 
of the resected specimen, adjacent uterine tissue without tumor (#1 and #2) appeared 
more fluorescent than the signal arising from the tumor (Figure 2). In patient #4, 
almost no normal uterine tissue was present because of the bulky size of the tumor. 
The intraoperative fluorescence signal therefore probably originated from the pri-
mary tumor, instead of from normal uterine tissue. 
In two of four patients (#1 and #4) metastases were found in respectively 16/22 
lns and in three omental lesions. In the remaining two patients, no metastases were 
found during staging procedures. All histologically proven metastatic malignant le-
sions (19/19) could be identified by fluorescence imaging, with a mean tbr of 6.3 
(sd=4.5; range 3.2 – 14.1) in metastatic lns (16/19) and a mean tbr of 2.3 (sd=0.2; 
range 2.1 – 2.5) in omental metastases (3/19). Importantly, one omental lesion was 
not seen during visual inspection and only identified by fluorescence imaging. 
Histopathological analysis of this lesion revealed a small deposit of clear cell car-
cinoma. Fluorescence imaging enabled clear detection of all histologically proven 
metastatic lns, even when these were located beneath a layer of peritoneum or other 
overlying tissue (Figure 2). 
folate receptor, is anchored on the cell membrane and binds folic acid with high 
affinity. Expression of frα on normal tissue is restricted to the apical surface of few 
epithelial tissues. However, marked overexpression in several tumor types, including 
ec, makes the frα an attractive candidate for targeted imaging and therapy11,12. 
Safety and feasibility of frα-targeted tumor detection using otl-38 have been 
demonstrated in ovarian and lung cancer10,13. Application of otl-38 in ec surgery 
could be especially valuable in high-risk ec patients, who have a high likelihood of 
extra-uterine disease7. In these high-risk ec patients, real-time fluorescence guid-
ance with otl-38 during staging and crs may provide enhanced visualization and 
detection of more metastatic lesions. The aim of this study was to assess which high-
risk ec patients could benefit from frα-targeted imaging. Although general overex-
pression of frα in ec was previously described12,14, specific frα expression in only 
high-risk ec patients, including both non-endometrioid and endometrioid ec, has 
not been demonstrated. Therefore, expression of frα was assessed on a tissue micro 
array (tma), consisting of 116 tissues derived from ec patients with high-risk fea-
tures. Based on these results, feasibility of nir fluorescence intraoperative tumor de-
tection using otl-38 was studied in patients with serous or clear cell ec, scheduled 
for staging or crs. 
results
tma-study 
Tissue cores of 101 patients were suitable for assessment of frα expression. 
Clinicopathological characteristics and expression scores are shown in Table 1. 
Figure 1 shows representative examples of weak, moderate and strong intensity of 
frα expression, in both endometrioid and non-endometrioid cancer. frα expression 
was found in 63% of endometrioid cancers and in 82% of non-endometrioid can-
cers. Strong frα expression was found in 38% of all endometrioid cancers compared 
to 46% of non-endometrioid cancers. A significant correlation (p<0.01) between 
the pattern of frα expression, i.e. homogeneous vs. heterogenous, and tumor type 
was found. The majority of serous endometrial carcinomas (73%) showed homo-
geneous frα expression, while clear cell carcinomas showed a more heterogenous 
frα expression pattern (65%). Endometrioid cancers showed both homogeneous 
and heterogenous frα expression in respectively 33% and 30% of all scored cases. 
Furthermore, a significant association between p53 status, i.e. wildtype or mutant, 
and frα expression was found (p=0.01). All (11/11) homogeneous frα-expressing 
non-endometrioid cancers showed a mutant p53 status. 
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systems and quality of antibodies. Notwithstanding, results of the current study cor-
roborated results of the tma study by Brown Jones et al.14, who also showed a sig-
nificant association between frα overexpression and high-risk ec. Our study differs 
because frα expression was evaluated among a subset of ec patients with high-risk 
features. Additionally, this is the first study to show a significant association be-
tween homogeneous frα expression and a mutant p53 status in non-endometrioid 
ec. Routinely performed evaluation of the p53 status may therefore assist in patient 
selection for frα-targeted agents. We did not perform a frβ staining on the tma, 
because previous literature describes that frβ is more prevalent on stromal cells than 
on cancer cells16,17. Yet, a systematic comparison between frα and frβ expression 
on endometrial cancer tissues with enough stromal tissue may be interesting.
The most important prognostic factor for ec survival is the presence of ln me-
tastases. Therefore, pelvic and para-aortic lymph node sampling is recommended as 
an integral part of a surgical staging procedure for a subset of ec patients with a high 
likelihood of metastatic disease, such as non-endometrioid ec patients6. The goal is 
to identify patients with nodal disease who will most likely benefit from adjuvant 
therapy18. The morbidity and mortality, costs and importantly, impact on patient 
survival associated with this procedure are however all subject to debate, especially 
in early stage ec patients19. In an attempt to better match the extent of the surgical 
staging procedure with the risk of ln metastasis, a surgical algorithm has recently 
been adopted for early stage ec patients20. Another method that has been advocated 
as alternative staging procedure is sentinel lymph node (sln) mapping. Recently 
published results of a large multicenter sln study suggest high accuracy of sln de-
tection in 340 early ec patients using indocyanine green (icg) as fluorescent tracer21. 
Cervical injection of icg led to successful mapping of at least one sln in 86% of 
patients and nodal metastases were correctly identified in 35 of 36 patients (97%). icg 
is a safe and relatively inexpensive fluorescent dye, that has been extensively studied 
for sln mapping in multiple tumor types, such as vulvar and cervical cancer22,23. 
Although icg proved its suitability as lymphatic tracer, it is not tumor-specific and 
does not bind to tumor cells. The use of icg during gynecologic cancer surgery is 
therefore limited to the detection of slns. otl-38 is an example of a tumor-targeted 
fluorescent tracer, that can selectively highlight tumor cells that express frα10. otl-
38 has therefore the potential to aid gynecologists in real-time detection of distant 
metastases, i.e. peritoneal metastases, as well as more reliable removal of metastatic 
pelvic and para-aortic lns. 
In the current study, all metastatic lns were detected using fluorescence imag-
ing with otl-38. Importantly, lns located below a layer of ± 1cm of tissue, such as 
para-aortic lns, could be clearly identified. Nevertheless, three out of four patients 
Furthermore, a total of 50 lns were resected that did not contain tumor cells. 
Seventeen out of these 50 lns were detected by fluorescence imaging (patient #1, #2 
and #3). Mean tbr of these false-positive lns was 2.5 (sd=1.3; range 1.5 – 6.2). No 
other false-positive lesions were identified, i.e. no fluorescence was detected in biop-
sies of the bladder, the diagraphm and recto-uterine (Douglas) pouch. Sensitivity, 
specificity and positive predictive value of fluorescence detection of lns was 100% 
(16/16), 70% (39/56) and 48% (16/33) respectively. 
Histopathology  A  Histopathological analysis of ec lesions showed a cir-
cumferential staining pattern of frα in malignant cells of both clear cell and serous 
cancer origin (Figure 3). frα expression was also found in adjacent normal uterine 
epithelial cells and in adenomyosis tissue (patient #2, Figure 2), possibly explaining 
the weakened fluorescence intensity of uterine tumors compared to adjacent ‘nor-
mal’ uterine tissue. 
In all metastatic lns, an intense frα expression was seen in lymph node follicles, 
while expression in sinuses was weak (Figure 3). In contrast, frα expression was ab-
sent in all (fluorescent) false-positive lns. Additional staining experiments however 
showed frβ expression in the sinuses of these lns which explained the false-posi-
tive fluorescence signal. The frβ is expressed by activated macrophages and is also 
targeted by otl-38 (Figure 4). 
discussion
Prior to the clinical study, we first performed a tma study with tissue of ec patients 
with high-risk clinical features to select those ec patients who may benefit most 
from frα-targeted tumor imaging4. Optimally, selection of ec patients with homo-
geneous frα expression would result in targeting of all frα-expressing tumor cells 
and consequently, low chances to miss tumor lesions in the clinical setting. A signifi-
cant association between frα expression and tumor type was shown, with positive 
expression in the majority of non-endometrioid cancers (82%). Remarkably, 73% of 
serous type ec showed homogeneous frα expression, which makes particularly this 
group of patients suitable for frα imaging. Although a substantial part of high-risk 
ec patients (63%) also showed frα expression, we chose to include only non-endo-
metrioid cancer patients in this clinical proof-of-concept study. Non-endometrioid 
ec is by definition high-grade and all these patients require staging or crs. Several 
other studies support our findings and show upregulation of frα in non-endometri-
oid ec and a correlation with tumor grade12,14,15. Limitations of the tma part of this 
study are inherent to ihc analysis, such as variation in staining techniques, scoring 
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Specimen of 116 patients were included in this tissue micro array (tma) study, and 
tissue microarrays contained 1-mm tumor and tumor/stroma cores in triplicate. 
Clinicopathological characteristics, including tumor type, stage, grade and p53 sta-
tus of all cases have been described previously4.
Immunohistochemical staining and evaluation  A  Immuno-
histochemistry was performed as described previously using the monoclonal an-
tibody (mab) 26B3.F2 (certified Folate Receptor alpha ihc Assay Kit, biocare 
Medical)29. The mab26B3.F2 is highly specific for frα without cross-reactivity to 
the other fr, e.g. frβ, frγ or frδ. For validation of the staining protocol lung ad-
enocarcinoma was used as positive control and normal liver as negative control. 
Blinded, independent evaluation of ihc staining was performed by two observers 
(L.B. and C.H.). Discrepancies were resolved by reviewing the relevant scores with 
a board certified pathologist (T.B.). A tumor core was rejected and not included in 
the analysis if it was missing or if >75% of the core was insufficient for evaluation. 
Staining was scored as absent/weak (0), moderate (1+) or strong (2+). A positive frα 
expression was defined when >5% of tumor cells showed a moderate or strong frα 
expression. A core was considered negative when none or <5% of tumor cells showed 
frα expression. The overall intensity of staining of a case was recorded for the inten-
sity that was seen in the majority of cores. Homogeneity was defined when all three 
cores showed similar intensity of frα expression. 
Clinical study  A  This trial was approved by the Medical Ethics Committee 
of the Leiden University Medical Center and was performed in accordance with 
the ethical standards of the Helsinki Declaration. Four patients with a high suspi-
cion of primary serous or clear cell carcinoma, planned for either staging or crs by 
laparotomy or laparoscopy, were included. Main exclusion criteria were pregnancy, 
history of anaphylactic reactions and impaired renal function (defined by egfr<50 
ml/min/1.73m2) or liver function (defined as values greater than 3x the upper limit of 
normal (uln) for alt, ast, or total bilirubin). 
Tracer administration and surgical procedure  A  Patients 
received a 1 hour intravenous infusion of 0.0125 mg/kg otl-38, 2-3 hours before 
the start of surgery. The investigational product, otl-38, has been extensively de-
scribed10. Tolerability assessments (blood pressure, pulse, peripheral oxygen satura-
tion, respiratory rate, ecg, temperature and skin assessments) and blood collection 
for pharmacokinetics and routine laboratory tests were performed regularly from 
just before administration up to 24 hours post-dosing. Adverse events (aes) and use 
of concomitant medication were recorded. All surgical procedures were performed 
showed false-positive lns during staging procedures. The fluorescence signal arising 
in those lns appeared related to expression of frβ, which is also targeted by otl-
38 as shown by histopathology evaluation. frβ is selectively expressed on activated 
macrophages and is therefore explored as imaging target to detect lesions of inflam-
matory conditions24. Recently the role of frβ in tumor tissues has been elucidated 
showing frβ expression in tumor-associated macrophages25. In a study of thousand 
tumor sections, Shen et al. showed that frβ is mainly expressed on tumor-associated 
macrophages in stromal cells17. Importantly, the percentage of positively stained 
cells correlated with tumor stage and ln involvement, suggesting that expression of 
frβ might be an indication of the metastatic potential of a tumor. Further research 
is needed to clarify whether the apparently non-malignant lns identified with fluo-
rescence imaging are involved in premetastatic niche formation. If so, resection of 
these lns may yield clinical benefit. Thus, despite the fact that all metastatic lns ex-
pressed frα, the widespread implementation of otl-38 for metastatic ln detection 
remains limited until the role of frβ is elucidated. 
Although no clear intraoperative distinction between uterine tumor and back-
ground tissue could be made using otl-38, this is not relevant in staging or crs 
of ec because all patients undergo a total hysterectomy. Previous studies report on 
constitutive frα expression on normal uterine epithelium, but high expression on 
various ec tumor tissues 12,26. An additional finding observed after histopathologi-
cal analysis of uterine tissues was strong frα expression in adenomyosis cells, which 
has been previously described in 17/18 endometriosis samples27. Since the aim of 
surgery in severe endometriosis patients is to resect all visible lesions, it is plausible 
that otl-38 may enhance intraoperative detection in those patients, enabling better 
patient outcome. 
In conclusion, this study demonstrates the first application of otl-38 for intra-
operative tumor detection during staging and cytoreductive surgery in patients with 
either serous or clear cell ec. Prior to the clinical study, a tma study on tissues from 
high-risk ec patients demonstrated a significant association between frα expres-
sion and tumor type. In the clinical study, all malignant lns and omental metastases 
could be clearly identified using otl-38. However, until the role of frβ in false-
positive lns is unambiguously established, the added value of otl-38 for detection 
of metastatic lns is limited. 
materials and methods
Tissue selection  A  High-risk (stage ib-iii) ec samples were collected from 
collaborating institutions within the Transportec consortium, as previously de-
scribed4. High-risk ec was defined using inclusion criteria for the portec3 study28. 
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by an experienced gynecological oncologist. First the surgical field was searched 
for metastases by usual visual and tactile methods (the latter only in case of open 
surgery). Thereafter, the open or laparoscopic Artemis imaging system was used to 
identify nir fluorescent lesions as described previously30. All tumor tissue identified, 
irrespective of the method, was resected if this was surgically feasible and clinically 
considered important by the operating gynecological oncologist. Each resected le-
sion was marked as fluorescent or non-fluorescent and as clinically suspected or not 
suspected for malignancy. 
analysis  A  All resected lesions were routinely examined by an experienced pa-
thologist for tumor status. A fluorescent tumor positive lesion was considered a true 
positive lesion, a fluorescent tumor negative lesion a false positive lesion and a non-
fluorescent tumor positive lesion a false negative lesion. Additionally, immunohisto-
chemical (ihc) staining for frα was performed. ihc staining of frβ was performed 
to evaluate the cause of false positive fluorescence. Placenta was used as positive 
control for frβ staining. The negative control was assessed by using the secondary 
antibody only, without the primary antibody. 
statistical and image analysis  A  Statistical analysis was performed 
using the ibm spss for Windows 20.0 software. Correlation of patient and tumor 
characteristics, including p53-status, with frα expression was assessed with t-test 
for continuous variables and with χ2 test of Fisher’s exact test for categorical vari-
ables. In all statistical tests, a p-value of <0.05 was considered statistically significant. 
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Figure 1 Representative examples of frα expression status in endometrioid and clear cell endometrial cancer
Shown are tissue cores with respectively weak, moderate and strong intensity of frα staining in endometrioid 
(A) and clear cell carcinoma (B). Magnification: 10x.
Figure 2 Fluorescence imaging of a primary uterine serous adenocarcinoma and of the metastatic lymph 
nodes
A Intraoperative identification of para-aortic, metastatic lymph nodes (dashed arrow), located beneath  
a layer of overlying tissue (patient #1). The normal arrow indicates the f luorescence signal arising from 
the uterus. 
B Ex vivo f luorescence imaging of the resected para-aortal lymph nodes (patient #1), that show a clear 
f luorescence signal. 
c Ex vivo f luorescence imaging of the bisected uterus (patient #1). The f luorescence signal, detected 
during surgery, appears to be mainly arising from normal adjacent background uterine tissue instead  
of the primary tumor. 
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Table 1 Clinicopathologic patient characteristics in relation to frα expression
  Total n (%) frα expression in tumor cells n (%)
  (n=101) absent heterogenous homogeneous P value
Age      
 <60 33 (33%) 15 (45%) 13 (39%) 5 (15%) 0.057
 60-70 26 (26%) 6 (30%) 11 (42%) 9 (35%)  
 >70 42 (42%) 11 (26%) 12 (29%) 19 (45%)  
figo stage 2009      
 I 36 (36%) 15 (42%) 9 (25%) 12 (33%) 0.355
 ii 20 (20%) 5 (25%) 10 (50%) 5 (25%)  
 iii 35 (35%) 9 (26%) 13 (37%) 13 (37%)  
 iv 9 (%) 3 (33%) 4 (44%) 2 (22%)  
Tumor type      
 endometrioid 73 (72%) 27 (37%)  24 (33%) 22 (30%) 0.004
 serous 11 (11%) 2 (18%) 1 (9%) 8 (73%)  
 clear cell 17 (17%) 3 (18%) 11 (65%) 3 (18%)  
Grade      
 1 11 (11%) 3 (27%)  5 (45%) 3 (27%) 0.082
 2 5 (5%) 0 (0%) 1 (20%) 4 (80%)  
 3 85 (84%) 29 (34%) 30 (35%) 26 (31%)  
Depth of myometrial invasion      
 <50% 19 (20%) 4 (21%) 6 (32%) 9 (47%) 0.255
 >50% 76 (80%) 28 (37%) 26 (34%) 22 (29%)  
Lymphovascular space invasion      
 Absent 34 (40%) 15 (44%) 7 (21%) 12 (35%) 0.367
 Present 48 (57%) 15 (31%) 19 (40%) 14 (29%)  
 unknown 2 (2%) 1 (50%) 1 (50%) 0 (0%)  
Distant recurrence status      
 Absent 67 (68%) 29 (43%) 19 (28%) 19 (28%) 0.004
 Present 31 (32%) 3 (10%) 16 (52%) 12 (39%)  
Pelvic recurrence status*      
 Absent 85 (88%) 29 (34%) 30 (35%) 26 (31%) 0.712
 Present 12 (12%) 3 (25%) 4 (33%) 5 (42%)  
p53 status, endometrioid cancer          
 Wildtype 56 (77%) 21 (38%) 20 (36%) 15 (27%) 0.472
 Mutant 17 (23%) 6 (35%) 4 (24%) 7 (41%)  
p53 status, non-endometrioid cancer         
 Wildtype 9 (32%) 3 (33%) 6 (67%) 0 (0%) 0.013
 Mutant 19 (68%) 2 (11%) 6 (32%) 11 (100%)  
Figure 3 Histopathological evaluation of resected lesions
A Immunohistochemical staining for frα of a uterine tumor shows frα expression in cancer cells (black 
arrow, patient #1) and in normal epithelial cells (dashed arrow). Magnification: 5x. 
B Immunohistochemical staining for frα of non-malignant adenomyosis tissue of the uterus (patient #2). 
Magnification: 5x.
c Immunohistochemical staining for frα of a clinically suspect and f luorescent lymph node shows 
positive frα expression in the lymph node follicels (patient #1). The frα expression correlates with the 
presence of tumor cells. Magnification: 0.5x.
d Immunohistochemical staining for frα of a f luorescent omental lesion, that contained tumor cells, 
shows positive frα expression (patient #4). Magnification: 2x.
Figure 4 Histopathological evaluation of a false-positive lymph node
Shown are a nir fluorescence image, haematoxylin & eosin (he) staining, and frα and frβ staining  
of a (fluorescent) ln that did not contain tumor cells. Fluorescence is mainly seen in the sinuses and  
not in the follicles. The magnified images (he, frα and frβ) show the lack of frα staining, while the  








Table 2 Patient and tumor characteristics
Patient
No.








iii Yes Yes, enlarged 
suspect lns














iii Yes Yes, two omental 
lesions
lns = lymph nodes
Table 3 Outcome of fluorescence imaging and histopathology 
Patient Primary tumor Lymph nodest Omentum Other biopsies
No pa Fluo. pa Fluo. pa Fluo. pa Fluo.
1 Malignant Yes* Malignant 
(16/22)**
Yes (all) Benign No Benign No
2 Malignant Yes* Benign Yes (some) Benign No Benign No
3 n/a n/a Benign Yes (some) Benign No Benign No
4 Malignant Yes* n/a n/a Malignant*** Yes (all) n/a n/a
Fluo: Fluorescent; n/a = not applicable;  
* a fluorescence signal arising from the uterus was seen during surgery  
** in 16/22 lymph nodes a macrometastasis was found;  
***  two omental depositions were identified on preoperative imaging, but during surgery a third lesion was identified  
 by nir fluorescence imaging. Final histopathological analysis showed tumor cells in all three omental lesions. 
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dose-escalation cohort and five were reported in three (18%) of 17 patients in the ex-
pansion cohort. Five moderate adverse events were reported in three (18%) patients 
in the expansion cohort, but they were deemed unrelated to sgm-101. No changes 
in vital signs, electrocardiogram, or laboratory results were found after administra-
tion of the maximum dose of 10 mg of sgm-101 in both cohorts. A dose of 10 mg, 
administered 4 days before surgery, showed the highest tbr (mean tbr 6.10 sd 0.42 
in the dose-escalation cohort). In the expansion cohort, 19 (43%) of 43 lesions were 
detected using fluorescence imaging and were not clinically suspected before fluo-
rescent detection, which changed the treatment strategy in six (35%) of 17 patients. 
Sensitivity was 98%, specificity was 62%, and accuracy of fluorescence intensity was 
84% in the expansion cohort.
Interpretation " This study presents the first clinical use of cea-targeted 
detection of colorectal cancer and shows that sgm-101 is safe and can influence 
clinical decision making during the surgical procedure for patients with colorectal 
cancer.
research in context
Evidence before this study  A  Tumour-targeted intraoperative fluores-
cence imaging can provide surgeons with real-time feedback about the location and 
extent of tumours, which might improve patient outcomes. A well-known tumour 
marker for colorectal cancer is carcinoembryonic antigen (cea), which is overex-
pressed in the vast majority of colorectal cancer cells. Involvement of surgical mar-
gins (R+) is reported in up to 28% of primary colorectal cancer resections and up to 
50% of recurrent rectal cancer resections. Moreover, 10% of patients with colorectal 
cancer develop peritoneal metastases, for whom cytoreductive surgery with hyper-
thermic intraperitoneal chemotherapy is the recommended surgical procedure. The 
extent of cytoreduction is directly associated with survival; therefore, maximal cyto-
reduction of small and otherwise undetected tumour lesions is important. cea-tar-
geted fluorescence imaging can be of added value in both locoregional and metasta-
sised colorectal cancer. Our preclinical studies showed that a fluorescent anti-cea 
monoclonal antibody, sgm-101, binds to cea-positive tumours and its metastases 
after intravenous administration.
Added value of this study  A  This study describes the first clinical ap-
plication of sgm-101 in patients with colorectal cancer for intraoperative detec-
tion of primary, recurrent, and peritoneal metastases. We showed that intravenous 
abstract
Background " Tumour-targeted fluorescence imaging has the potential to ad-
vance current practice of oncological surgery by selectively highlighting malignant 
tissue during surgery. Carcinoembryonic antigen (cea) is overexpressed in 90% of 
colorectal cancers and is a promising target for colorectal cancer imaging. We aimed 
to assess the tolerability of sgm-101, a fluorescent anti-cea monoclonal antibody, 
and to investigate the feasibility to detect colorectal cancer with intraoperative fluo-
rescence imaging.
Methods " We did an open-label, pilot study in two medical centres in the 
Netherlands. In the dose-escalation cohort, we included patients (aged>18 years) 
with primary colorectal cancer with increased serum cea concentrations (upper 
limit of normal of >3 ng/mL) since diagnosis, who were scheduled for open or 
laparoscopic tumour resection. In the expansion cohort, we included patients 
(aged>18 years) with recurrent or peritoneal metastases of colorectal cancer, with 
increasing serum concentrations of cea since diagnosis, who were scheduled for 
open surgical resection. We did not mask patients, investigators, or anyone from 
the health-care team. We assigned patients using a 3 + 3 dose design to 5 mg, 
7.5 mg, or 10 mg of sgm-101 in the dose-escalation cohort. In the expansion co-
hort, patients received a dose that was considered optimal at that moment of the 
study but not higher than the dose used in the dose-escalation cohort. sgm-101 
was administered intravenously for 30 min to patients 2 or 4 days before surgery. 
Intraoperative imaging was done to identify near-infrared fluorescent lesions, 
which were resected and assessed for fluorescence. The primary outcome was toler-
ability and safety of sgm-101, assessed before administration and continued up to 
12 h after dosing, on the day of surgery, the first postoperative day, and follow-up 
visits at the day of discharge and the first outpatient clinic visit. Secondary out-
comes were effectiveness of sgm-101 for detection of colorectal cancer, assessed 
by tumour-to-background ratios (tbr); concordance between fluorescent signal 
and tumour status of resected tissue; and diagnostic accuracy in both cohorts. 
This trial is registered with the Nederlands Trial Register, number ntr5673, and 
ClinicalTrials.gov, number nct02973672.
Findings " Between January 2016 and February 2017, 26 patients (nine in the 
dose-escalation cohort and 17 in the expansion cohort) were included in this study. 
sgm-101 did not cause any treatment-related adverse events, although three pos-
sibly related mild adverse events were reported in three (33%) of nine patients in the 
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difficulty in distinction between fibrosis and tumour tissue after neoadjuvant thera-
py10. Globally, 10% of patients with colorectal cancer develop peritoneal metastases, 
for whom cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is 
the recommended therapy, resulting in median overall survival of up to 32 months11. 
The extent of cytoreduction is directly associated with survival; therefore, maximal 
cytoreduction of the numerous and often small tumour lesions is pivotal12. With its 
potential to highlight small tumour lesions, tumour-targeted fluorescence-guided 
surgery can be of added value in both locoregional and metastasized colorectal can-
cer. Moreover, it could aid distinction between fibrosis and malignant tissue, which 
is often challenging in patients with rectal cancer who have had chemotherapy and 
re-irradiation or irradiation therapy.
Carcinoembryonic antigen (cea) is a well known tumour marker and is highly 
expressed in colorectal cancer13,14. Importantly, cea expression in healthy tissue is 
on average 60 times lower than in tumour tissue, and the antigenic concentration 
of cea on the surface of cancer cells is relatively high (105-106 antigens per cell)15. 
In this study, we describe sgm-101, a cea-specific chimeric antibody conjugated 
to a fluorophore that emits near-infrared fluorescence. Preclinical studies showed 
that sgm-101 binds to cea-positive colorectal cancer cells and its metastases after 
intravenous administration16. On the basis of these promising results with sgm-
101, translation in a clinical study in patients with colorectal cancer is a logical next 
step. Therefore, in this study, we aimed to assess the tolerability of ascending doses of 
sgm-101 in patients with primary colorectal cancer, and to determine the best per-
forming dose and dosing time for intraoperative fluorescence imaging. Additionally, 
these parameters were used in an expansion cohort of patients with colorectal cancer 
for intraoperative detection of recurrent tumours, including peritoneal metastases, 
and to assess whether sgm-101 could change patient management.
methods
Study design and patients  A  We did an open-label, pilot study in two 
centres (Leiden University Medical Center, Leiden; and the Catharina Hospital 
Eindhoven, Eindhoven) in the Netherlands. We used a 3 + 3 dose escalating study 
design for those in the dose-escalation cohort only. This study was done in accor-
dance with the Good Clinical Practice guidelines from the International Council 
for Harmonisation of Technical Requirements for Pharmaceuticals for Human 
Use, and the laws and regulations on drug research in humans of the Netherlands. 
The study was approved by a certified medical ethics review board (bebo, Assen, 
Netherlands).
administration of 10 mg of sgm-101 in patients with colorectal cancer is safe and 
tolerable, with the sensitivity needed to detect malignant lesions that would have 
otherwise been missed during surgery. Importantly, sgm-101 allowed detection of 
both superficially and more deeply seeded metastases. This study also suggests that 
intraoperative fluorescence imaging might guide surgeons to identify areas from 
which frozen sections should be obtained for intraoperative decision making.
Implications of all the available evidence  A  Application of 
cea-targeted fluorescence imaging during colorectal cancer surgery can result in 
improved demarcation and detection of otherwise undetected malignant lesions. 
Although investigated in a small pilot study, sgm-101 can influence perioperative 
clinical decision making. Larger studies are needed to assess whether improved 
colorectal cancer detection influences R0 resection rates and results in more com-
plete cytoreductive surgery, which should ultimately improve oncological outcomes.
introduction  
A new era in the field of near-infrared fluorescence-guided oncological surgery has 
commenced with the first clinical studies using tumour-specific fluorescent tracers1. 
Fluorescence imaging can provide surgeons with real-time feedback about the loca-
tion and extent of tumours, which might increase radical resection rates and im-
prove patient outcomes. This technology uses clinically available monoclonal anti-
bodies (eg, bevacizumab or cetuximab) or new tumour-specific ligands that are con-
jugated to a fluorophore and accumulate in tumours after intravenous administra-
tion2. Subsequently, a dedicated near-infrared fluorescence imaging system enables 
detection of tumours in real-time during the procedure. Several tumour-targeted 
tracers have been tested in first-in-human studies, yielding promising results for in-
traoperative fluorescence detection of ovarian cancer, head and neck cancer, breast 
cancer, and peritoneal metastases of colorectal cancer3-6. However, no tracers have 
been investigated for fluorescence imaging of primary and recurrent colorectal can-
cer, although major advantages can be expected from this application.
The primary curative treatment for colorectal cancer is radical resection with 
clear margins (R0). Involvement of surgical margins (R+) is a poor prognostic fac-
tor for disease-free survival and overall survival, but is still reported in up to 28% 
of rectal cancer cases7,8. In surgery for recurrent rectal cancer, an R0 resection is 
equally essential; this is generally achieved in 50-60% of cases, with 5-year survival 
up to 70%9. However, these procedures are challenging because of distorted pelvic 
anatomy after previous resections, the presence of multifocal tumour tissue, and 
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sgm-101 consists of a chimeric monoclonal antibody that targets cea covalent-
ly bound to the fluorophore bm-104. The tracer was manufactured by Novasep 
(Gosslies, Belgium) and supplied by Surgimab (Montpellier, France). Additional 
information about sgm-101 is provided in the appendix (p 1). On the basis of pre-
clinical data16, a dose-escalation scheme of sgm-101 (5 mg, 7.5 mg, or 10 mg) was 
used (appendix p 1). We intravenously infused patients with sgm-101 for 30 min in 
a dedicated clinical research unit at least 2 days before surgery. Following each dose 
level, the collected data (ie, safety data and fluorescence intensity of tumour and 
background tissue using that dose of sgm-101) were reviewed jointly by the investi-
gator and sponsor before ascending the dose level.
All surgical procedures were done by experienced oncological surgeons. First, the 
surgical field was explored using standard visual and tactile methods (for which tac-
tile methods were done only during open surgery). Subsequently, the fluorescence 
imaging, which was done with the Artemis and Spectrum fluorescence imaging sys-
tem (Quest Medical Imaging, Middenmeer, Netherlands; appendix p 1)17 was used 
to identify near-infrared fluorescent lesions. All lesions identified by visual and tac-
tile methods or near-infrared fluorescence imaging were resected if it was surgically 
feasible and supported a clinical purpose (eg, adjustment in staging or treatment). 
If resection included surrounding structures, a frozen section was first assessed by 
an attending pathologist to confirm whether resection was needed. Each resected 
lesion was marked on a case report form as fluorescent or non-fluorescent, and as 
either clinically suspected for malignancy or not.
Following resection, fluorescence imaging of the wound bed was done to iden-
tify any remaining fluorescence. Fluorescence imaging of the resection specimen 
was done in the operating room and the pathology department. All resected speci-
mens were assessed for fluorescence both before and after slicing, and localisation 
of fluorescence signal was recorded on macroscopic photographs. The slice contain-
ing the peak fluorescence signal of each patient undergoing surgery at the Leiden 
University Medical Center was additionally imaged with the Pearl imager (li-cor 
Biosciences, Lincoln, ne, usa) to obtain ex-vivo tumour-to-background ratios 
(tbrs).
Additionally, we did tolerability assessments (ecg, blood pressure, pulse, periph-
eral oxygen saturation, respiratory rate, and temperature) at regular intervals starting 
directly before administration and continued up to 12 h after dosing. We repeated 
these measurements on the day of surgery, the first postoperative day, and the day of 
discharge from the hospital. Follow-up visits coinciding with clinical care took place 
at the day of discharge and the first outpatient clinic visit. Additionally, we recorded 
adverse events and the concomitant use of other medications throughout the study 
We included patients aged 18 years or older with a clinical diagnosis of primary 
colorectal cancer, with increased serum cea concentrations (=upper limit of nor-
mal uln of >3 ng/mL), who were scheduled for either open or laparoscopic sur-
gical resection in the dose-escalation cohort. Additionally, we included patients 
aged 18 years or older who were diagnosed with recurrent or peritoneal metastases 
of colorectal cancer, with increasing serum cea concentrations since diagnosis, and 
who were scheduled for open surgical resection in the expansion cohort. Staging 
of primary colon and rectal cancers was done according to standard protocol and 
included ct or mri, or both. Staging of recurrent colon and rectal cancers, as well 
as peritoneal metastases, was done with use of either ct, mri, or, when considered 
necessary, with pet-ct. No patients were excluded on the basis of preoperative im-
aging, but only patients eligible for surgical resection were included.
We excluded patients who were pregnant or breastfeeding, had a history of ana-
phylactic allergic reactions, had a serum cea concentration of 300 ng/mL or more, 
had a diagnosis of another malignancy within the past 5 years (except adequately 
treated in-situ carcinoma of the cervix and basal or squamous cell skin carcino-
ma), and had anticancer therapy (except for routine preoperative radiotherapy for 
colorectal cancer) within 4 weeks before inclusion. Additionally, we excluded pa-
tients with only colorectal cancer who had abnormal laboratory test values for as-
partate aminotransferase, alanine amino transferase, gamma-glutamyltrans ferase, 
or alkaline phosphatase concentrations that were more than five times the uln; and 
total bilirubin concentrations more than two times the uln. We excluded patients 
who had abnormal laboratory test values for serum creatinine concentrations more 
than 1.5 times the uln, absolute neutrophil counts less than 1.5 × 105 cells per L, 
platelet counts less than 100 × 109 cells per L, or haemoglobin concentrations less 
than 4 mmol/L in women or 5 mmol/L in men. We also excluded patients with a 
known positive test for hiv infection, hepatitis B surface antigen, or hepatitis C virus 
antibody; patients with untreated serious infections; and those who had any condi-
tion that the investigator considered to be potentially compromising to the patients’ 
wellbeing or the study objectives. Participants gave written informed consent to the 
investigators before screening to take part in the study.
Procedures  A  In the dose-escalation cohort, we assigned patients using a 3 
+ 3 dose design to 5 mg, 7.5 mg, or 10 mg of sgm-101. In the expansion cohort, pa-
tients received a dose that was considered optimal at that moment of the study but 
not higher than the dose used in the dose-escalation cohort. We did not mask pa-
tients, investigators, or anyone from the health-care team and did not use placebo 
treatment.
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Fluorescence in tumour and normal tissues, measured on ffpe tissue blocks with 
the Pearl imager, was compared with the paired, non-parametric t test (ie, Wilcoxon 
rank test). A p value of less than 0.05 was considered significant. Data are sum-
marised in a bar chart (mean range) and box plot (median iqr). Patients in the dose-
escalation cohort were included in the primary analysis. Patients in the expansion 
cohort were analysed separately. We did all statistical analyses and generated graphs 
using GraphPad Prism (version 7.0) 
This trial is registered with the prospective Dutch trial registry (Nederlands Trial 
Register), number ntr5673, and ClinicalTrials.gov, number nct02973672.
Role of the funding source  A  The study was designed by the investiga-
tors and approved by the sponsor, Surgimab. The funder of the study had no role in 
data collection, data analysis, data interpretation, or writing of the report. The corre-
sponding author had full access to all the data in the study and had final responsibil-
ity for the decision to submit for publication. 
results
Between January, 2016, and February, 2017, 26 patients were included in this study. 
Nine patients were included in the dose-escalation cohort and 17 patients were 
included in the expansion cohort. In two patients from the expansion cohort, the 
planned surgery was aborted because of unexpected tumour ingrowth in the anal 
sphincter in one of the patients who wanted only sphincter-saving surgery, and a 
high peritoneal carcinomatosis index in the other patient who was planned for cy-
toreductive surgery with hyperthermic intraperitoneal chemotherapy. Despite abor-
tion of the surgical procedures, fluorescence imaging in the first patient was success-
fully done via transanal inspection with a laparoscope and in the second patient dur-
ing exploratory laparotomy. Table 1 summarises the patient characteristics, surgical 
procedures, and histopathology results.
No serious adverse events were reported in the dose-escalation cohort of patients 
with primary colorectal cancer. Three possibly related mild adverse events were 
noted in three (33%) of nine patients in the dose-escalation cohort and five possibly 
related mild adverse events were reported in three (18%) of 17 patients in the expan-
sion cohort. In the expansion cohort, five moderate adverse events were reported in 
three (18%) of 17 patients that were all regarded unrelated to the dosing of sgm-101 
(Table 2). The most common serious adverse events were infections (three 60% of 
five events), paralytic ileus (one 20%), and pyelonephritis (one 20%). No changes in 
period. We also collected blood samples from participating patients before and after 
dosing of sgm-101, and serum cea concentrations were measured in these samples.
An experienced board-certified gastrointestinal pathologist did routine assess-
ment of tumour status on all resected lesions following haematoxylin and eosin 
staining. The histopathological examination was considered the reference standard. 
Tumour status was correlated with the status of fluorescence, and immunohisto-
chemistry staining was done to directly correlate cea expression to fluorescence sig-
nal in formalin-fixed paraffin-embedded (ffpe) blocks with use of the Pearl imager 
(appendix pp 2, 3). A fluorescent lesion that was tumour positive was considered a 
true positive, a fluorescent lesion that was tumour negative was considered a false 
positive, and a non-fluorescent lesion that was tumour positive was considered a 
false negative. Using these classifications, we also evaluated sensitivity, which was 
calculated by dividing the number of true-positive lesions by the total number of 
resected tumour lesions; and specificity, which was calculated by dividing the true 
negative lesions by the total number of resected lesions without tumour involve-
ment. Additionally, we evaluated the positive predictive value, which was calculated 
by dividing the number of true positives by the total number of true and false posi-
tives; and the negative predictive value, which was calculated by dividing the true-
negative lesions by the total number of true and false-negative lesions.
Outcomes  A  The primary outcome was tolerability and safety of sgm-101, 
which was assessed with the use of routine clinical measures such as treatment-re-
lated adverse events, blood pressure, heart rate, body temperature, peripheral oxygen 
saturation, respiratory rate, skin examination, and routine laboratory assessments. 
Treatment-related adverse events were defined as any adverse event associated with 
the study procedure but not necessarily related to the study intervention (ie, sgm-
101) for up to 10 days after surgery, using the National Cancer Institute Common 
Terminology Criteria for Adverse Events (version 4.03). Secondary outcomes were 
effectiveness of sgm-101 for detection of colorectal cancer, assessed by tbrs, concor-
dance between fluorescent signal and tumour status of resected tissue, and diagnos-
tic accuracy. Additionally, the amount of injected sgm-101 that was lost by binding 
to serum cea was calculated by measuring serum cea directly and after dosing in 
both cohorts.
Statistical analysis  A  Due to the exploratory nature of this study, sam-
ple size was not based on statistical power considerations. tbr for fluorescence is 
reported as mean and sd. Patient characteristics are reported as median and iqr. 
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of particles of blue ink, caused by perforation of the bowel wall during endoscopic 
marking of the tumour. None of these lesions displayed cea expression with immu-
nohistochemistry staining. The diagnostic accuracy is shown in Figure 1b.
In the expansion cohort, the first patient received a dose of 5 mg of sgm-101 and 
the second patient received a dose of 7.5 mg, administered 2 days before surgery. The 
other 15 patients received a dose of 10 mg, 4 days before surgery. 44 malignant le-
sions were resected in 17 patients, of which 43 were fluorescent with a mean intra-
operative tbr of 1.64 (sd 0.27; Table 3). The non-fluorescent malignant lesion was 
identified with a random biopsy during intraoperative analysis of a resection mar-
gin. Additional histopathological analysis of the part of the rectum where the bi-
opsy was taken showed a microscopic metastasis in the fatty tissue with strong cea 
expression.
In the expansion cohort, 19 (44%) of the 43 malignant lesions were only identi-
fied with fluorescence imaging and were not clinically suspected before fluorescent 
detection. Fluorescent tumour hotspots were located both superficially (eg, tumour 
spots in the bowel mesentery or ovary) and deeply (eg, retroperitoneal lymph nodes; 
Figure 4). 13 (68%) of the 19 lesions were detected in two patients undergoing cytore-
ductive surgery, followed by hyperthermic intraperitoneal chemotherapy. The other 
six (32%) additional malignant fluorescent hotspots were identified in four patients 
undergoing resection of recurrent colorectal cancer, mostly detected after resection 
of the tumour specimen at the pelvic wall. The original treatment strategy was al-
tered in six (35%) of 17 patients because of intraoperative fluorescent detection of 
additional, otherwise undetected, malignant tissue.
Three (18%) of 17 patients had a pathological complete response after preopera-
tive chemoradiotherapy. In two of these three patients, a fluorescent signal was still 
identified at the location of the suspected tumour (mean tbr 1.67, sd 0.19). One 
patient had a tumour mass near the left ovary, which appeared as an abscess during 
surgery. Both the abscess wall and abscess cavity were fluorescent during surgery, but 
did not contain malignant cells and were not cea positive by immunohistochemi-
cal staining. The other patient with a pathological complete response had a tumour 
mass of 24 mm in diameter near the left iliopsoas muscle, which could be clearly 
identified during ex-vivo fluorescence imaging. Histopathological analysis revealed 
extensive necrosis, with mucin-producing cells that were positive for cea, and scar 
tissue. Of the 14 patients with a malignancy, 13 had an intestinal-type adenocarci-
noma. All these malignancies showed co-localisation of fluorescence and cea ex-
pression on the malignant cells, with strong cea staining. One patient had a poorly 
differentiated sarcomatous adenocarcinoma of the sacral bone; although the tumour 
was fluorescent during ex-vivo imaging (tbr 1.68), no cea expression was found.
vital signs, electrocardiogram, or laboratory results were found after administration 
of the maximum dose of 10 mg of sgm-101 in both cohorts.
The molecular weight of cea is 2 × 105 Da and sgm-101 is 1.5 × 105 Da. The big-
gest change in serum cea concentration before and after dosing was 40 µg/L. 
Considering a circulating blood volume of 5 L, this change means a total circulating 
amount of 200 µg (ie, 1.2 × 1020 Da or 6 × 1014 U). The total amount of injected sgm-
101 was 5 mg (ie, 3 × 1021 Da or 2 × 1016 U). Thus, the amount of sgm-101 lost by bind-
ing to circulating cea was 3%.
Of the nine patients in the dose-escalation cohort, the first three patients re-
ceived a dose of 5 mg of sgm-101, administered 2 days before surgery. Because of 
substantial background fluorescence, probably as a consequence of high concentra-
tions of the tracer in the systemic circulation, the interval between dosing and im-
aging was prolonged to 4 days. The next three patients received a dose of 7.5 mg, 
administered 4 days before surgery. The mean tbr of the resected specimens was 
4.70 (sd 0.99) in the 5 mg dose group compared with 5.70 (sd 1.27) in the 7.5 mg 
dose group. Hence, the dose was further increased and the three subsequent patients 
received a dose of 10 mg, resulting in a mean tbr of 6.10 (sd 0.42). Separate tumour 
and background signals per dose group are shown in Figure 1a.
Fluorescence imaging was used to detect malignant lesions in three patients with 
colon adenocarcinomas and six patients with rectal adenocarcinomas, including two 
pathological complete responders. In four of nine patients, a fluorescent signal aris-
ing from the primary tumour could be detected during surgery with a mean tbr of 
1.83 (sd 0.25; Table 3). These signals were all from three colon tumours (figures 2A, 
2c) and one rectal tumour that was located near the anal verge and detected with 
transanal fluorescence imaging (tbr 1.52). The remaining five patients’ rectal tu-
mours could not be detected by intraoperative fluorescence imaging of the surgical 
field. Three of these rectal tumours showed a clear fluorescent signal during ex-vivo 
imaging of the sliced specimen (figures 3a, 3b). The last two specimens showed no 
fluorescence, which were confirmed as pathological complete responses by histo-
pathological analysis.
Six metastases were detected with fluorescence imaging (mean tbr 1.74, sd 0.32): 
four colorectal liver metastases, one lymph node metastasis, and one omental lesion 
(figures 2b, 2d). All thirteen malignant primary and metastatic lesions showed co-
localisation of fluorescence with cea overexpression and tumour cells (Figure 3c). 
Immunohistochemistry staining of tumour tissues showed that cea expression was 
strong in 80-100% of all tumour cells. Two false-positive fluorescent lesions were 
identified during surgery (mean tbr 1.62, sd 0.11): one lesion was classified as dys-
plasia of the urothelial lining of the bladder and one as a peritoneal lesion consisting 
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healthy epithelium could be disadvantageous, this factor did not hinder discrimina-
tion between tumour and healthy tissue.
Histopathological analysis showed that some of the false-positive lesions detect-
ed contained mucin-producing cells, which express cea. These lesions were only de-
tected in patients with rectal cancer who had undergone re-irradiation, suggesting 
a relationship. Future immunohistochemistry studies should clarify the correlation 
between cea expression and the subtype of colorectal cancer that contains mucin-
producing cells or the effect of re-irradiation, or both. There are several hypotheses 
about why false-positive lesions appeared fluorescent during surgery. First, although 
the use of light in the near-infrared spectrum (700-900 nm) is associated with mini-
mal auto fluorescence, it is plausible that collagen-rich structures, calcified spots, or 
the sacral bone could have caused false-positive fluorescence as a consequence of au-
tofluorescence properties. Secondly, the enhanced permeability and retention effect, 
which results in accumulation of macromolecules (eg, sgm-101) as a consequence of 
hypervasculature and impaired lymphatic drainage, could play a part in false positiv-
ity21,22. This effect is also considered the most likely cause for accumulation of indo-
cyanine green in peritoneal metastases. Indocyanine green is a clinically available 
near-infrared fluorescent tracer and has been studied for intraoperative detection 
of peritoneal metastases of colorectal cancer and ovarian cancer23,24. However, this 
tracer does not specifically bind to tumour cells and, importantly, small peritoneal 
metastases (<2 mm) are still avascular and not possible to detect via the enhanced 
permeability and retention effect25. In an attempt to improve specificity, Harlaar and 
colleagues6 did a pilot study using a vegf-A-targeting tracer in seven patients un-
dergoing cytoreductive surgery for peritoneal metastases; although a high sensitivity 
was reported, specificity was only 53%.
The current dose-escalation study was done in patients with primary colorectal 
cancer. However, in both the dose-escalation and expansion cohorts, the time of ad-
ministration of sgm-101 between the dosing groups differed - eg, the 5 mg dosing 
group was done 2 days before surgery, compared with 4 days before surgery in the 
7.5 mg and 10 mg dosing groups in the dose-escalation cohort, possibly hamper-
ing a fair comparison. Moreover, the maximum tested dose was 10 mg of sgm-101, 
which did not cause any related adverse events. Higher dose concentrations need to 
be assessed in upcoming studies to investigate whether higher tbrs can be obtained 
while maintaining the good safety profile. Furthermore, not all tumours could be 
intraoperatively visualised. In three patients with rectal cancer and cT1-2 tumours, 
a fluorescence tumour signal was only visible after slicing of the resected specimen. 
Although use of near-infrared light allows detection of structures up to 1 cm in 
depth, the layer of mesorectum is apparently too thick to penetrate. In our opinion, 
Ten false-positive lesions were identified with a mean tbr of 1.62 (sd 0.27), includ-
ing lymph nodes, tissue adhered to the bowel, and at the rectal wall (marked during 
ex-vivo fluorescence imaging). Some cea positivity was found in histiocytes within 
lymph nodes, as well as in fibrotic and chronic inflamed tissue. However, four (80%) 
of five assessed false-positive lesions did not show cea expression. Ex-vivo analysis 
of ffpe blocks of all resected tissues from the expansion cohort showed a signifi-
cantly higher fluorescence intensity in tumour tissue than in normal tissue (mean 
0.51 sd 0.43 vs 0.24 sd 0.19; p<0.0001; Figure 1c). 
discussion  
This study shows that intravenous administration of the cea-specific near-infrared 
fluorescent tracer sgm-101 is safe, and provides successful detection of primary and 
recurrent colorectal cancer as well as peritoneal metastases. Intraoperative fluores-
cence imaging led to detection of otherwise undetected malignant tissue causing the 
treatment strategy to be altered in about a third of patients. Importantly, sgm-101 
did not only identify superficially located cancer tissues (eg, small metastases in the 
omentum or bowel mesentery) but also identified more deeply seeded metastases 
(eg, retroperitoneal or para-aortic lymph nodes). 
cea is considered a favourable tumor target for colorectal cancer imaging14,18, 
because it is highly expressed on colorectal cancer tissue, and importantly, expression 
patterns in rectal cancer are not modified after preoperative chemoradiotherapy19. 
However, cea has several disadvantages as a tumour target, including expression 
on normal epithelium and the weak anchorage of cea to the cell membrane. This 
weak anchorage results in shedding of soluble cea into the bloodstream, which 
could serve as a scavenger source when injecting a cea-targeted imaging agent. By 
measuring serum cea concentrations in patients before and directly after dosing 
of sgm-101, we could conclude that 3% of the administered dose of sgm-101 was 
lost by binding to circulating cea. Hence, almost all the injected probe was avail-
able for tumour targeting. The upper limit of circulating serum cea concentration 
(300 ng/mL) as an exclusion criterion could therefore be abandoned in future stud-
ies. Assuming that increased concentrations of serum cea represent upregulation 
of this marker in colorectal cancer tissue, serum cea measurements were initially 
thought to benefit patient selection. However, a recent study20 showed that 32 of 
35 rectal cancer tissues showed intense cea expression independent of the concen-
tration of preoperative serum cea. In the expansion cohort, this inclusion criterion 
was therefore adjusted, and patients with increasing serum cea concentrations since 
diagnosis were also considered eligible. Although normal expression of cea on the 
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devices and to determine the minimal amount of tumour cells that can be detected 
using a specific device32. 
In conclusion, we showed that intravenous administration of sgm-101 is safe and 
provides successful detection of primary, recurrent, and metastasised colorectal can-
cer, leading to an altered treatment strategy in about a third of patients. Because 
completeness of tumour resection is associated with increased survival, sgm-101 
could potentially improve the clinical outcome of patients undergoing surgery for 
colorectal cancer, including cytoreductive surgery and hyperthermic intraperito-
neal chemotherapy. However, the results from this study have to be interpreted cau-
tiously because of the small population and heterogeneity in doses and timing of 
fluorescence imaging after dosing. A larger clinical study is needed to assess whether 
these changes in the operative procedure might influence radical resection rates and 
completeness of cytoreductive surgery, which could ultimately result in improved 
local control and overall survival. 
cea-targeted fluorescence imaging during colorectal cancer surgery is therefore 
mainly useful to detect local and distant metastases, as well as locally advanced rec-
tal cancers. Nonetheless, ex-vivo detection of a tumour-specific fluorescent signal 
underlines the potential added value of sgm-101 during transanal endoscopic mi-
crosurgery. Although different optical properties apply to the endoscopic situation 
compared with ex-vivo fluorescence imaging - eg, scattering and absorption of sur-
rounding tissues - our results suggest that fluorescence imaging could improve the 
limited sensitivity of endoscopic assessment for residual tumour detection26. The 
absence of fluorescence in two resected specimens with a pathological complete re-
sponse underlines the role of sgm-101 application during watch-and-wait strategies 
after neoadjuvant treatment27. 
In the expansion cohort, patients with recurrent colorectal cancer and peritoneal 
metastases of colorectal cancer were included. Although a high sensitivity was re-
ported, ten false-positive lesions were detected. An important lesson to bear in mind 
is that before substantial resections are done, frozen sections should be taken to en-
sure that there is no false positivity. sgm-101 can help surgeons to identify areas from 
which frozen sections should be obtained, which is normally very random without 
intraoperative imaging. The high negative predictive value indicates that if there is 
no fluorescence, there is no tumour if it is also clinically unsuspected. However, more 
deeply seeded tumours can be visualised only when the targeted area is first properly 
exposed. Targeted dual-modality imaging is currently being investigated to over-
come the paucity of depth penetration of near-infared light. This technique provides 
preoperative tumour detection through pet or single-photon emission ct imaging 
and intraoperative guidance towards deeper located targets via fluorescence imaging 
and the radioactive label. A recent preclinical study showed accurate preoperative 
and intraoperative detection of pulmonary micrometastases after intravenous ad-
ministration of a dual-labelled cea-targeted antibody 28. 
Although there has been a rapid increase in the number of clinical trials using 
fluorescence imaging for cancer screening and detection, several barriers must be 
overcome before the technique can be widely used in everyday clinical practice2. 
Besides funding and awareness, the translational process of tumour-targeted probes 
such as sgm-101 is a time consuming process with challenging regulatory affairs29. 
Most importantly, not all currently available imaging devices have similar detec-
tion limits, which results in a scarcity of a fair comparison between these different 
systems, hampering reproducibility. A potential method to improve intraoperative 
distinction between malignant and non-malignant tissue might be the use of cutoff 
values - eg, the use of threshold by calculation of fluorescence with use of phantoms 
or reference standards30,31. More research is needed to objectively compare imaging 
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Figure 2 In-vivo and ex-vivo fluorescence imaging of a sigmoid cancer and synchronous liver metastasis
A Intraoperative f luorescence imaging resulted in clear f luorescence detection of the primary tumour  
in the sigmoid. 
b Fluorescence detection of a synchronous liver metastasis. 
c Ex-vivo analysis of the primary sigmoidal cancer. 
d Ex-vivo analysis of the slices containing the liver metastasis, showing co-localisation of f luorescence 
with visual tumour location.
Figure 1 Outcomes of fluorescence imaging in the dose-escalation and expansion cohort
A Mean f luorescence intensity of tumour and background tissue per dose group of sgm-101 in the  
dose-escalation cohort. Error bars are the maximum f luorescence intensity measured. 
B Sensitivity, specificity, ppv, npv, and accuracy of f luorescence imaging in the dose-escalation cohort. 
All resected tissues (either detected with visual inspection or with f luorescence imaging) were included 
in this analysis. 
c Mean f luorescence intensity of all resected lesions in the expansion cohort. On the basis of 
corresponding haematoxylin and eosin and cea staining, regions of interest were drawn on f luorescent 
images and f luorescence between tumour and normal tissues was compared. The horizontal line in  
the box is the median f luorescence signal. The box refers to 50% of scores. Error bars are ranges. 
d Sensitivity, specificity, ppv, npv, and accuracy of f luorescence imaging in the expansion cohort. 
All resected tissues (either with visual inspection or with f luorescence imaging) were included in 
this analysis. au=arbitrary unit. N=total number of resected lesions. ppv=positive predictive value. 
npv=negative predictive value. cea=carcinoembryonic antigen
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Figure 4 Intraoperative fluorescence detection of additional, otherwise undetected, metastases of colorectal 
cancer.  
A Identification of a f luorescent hotspot in the bowel mesentery, which was confirmed to contain 
malignant cells by frozen section analysis. 
B Intraoperative identification of two small additional f luorescent tumour hotspots in the omentum.
c Intense f luorescence signal shown in the right ovary. Although the surgeon doubted if the ovary 
contained tumour cells, histopathological analysis revealed involvement of tumour cells. 
d Intraoperative f luorescence detection of retroperitoneal lymph nodes. Even below a layer of overlying 
tissue, metastasised lymph nodes can still be detected.
Figure 3 Ex-vivo fluorescence imaging of a primary rectal cancer
A In this specimen (pT2), rectal cancer could not be detected during surgery. After cutting of the 
specimen, a clear f luorescent signal appeared. 
B Corresponding tumour slice, showing a f luorescence signal on the inside of the rectal wall. 
c Histopathological analysis of a tumour slice, showing co-localisation of tumour cells, cea expression, 
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5.0 mg of sgm-101
Patient 1
 day 3 Skin and subcutaneous disorders Scar pain Mild No Unrelated Single occasion
 day 6 Gastrointestinal disorders Paralytic ileus Mild No Unrelated Single occasion
 day 8 General disorders and 
administration siteconditions
Pyrexia Mild No Unrelated Single occasion
 day 17 Gastrointestinal disorders Proctalgia Mild No Unrelated Single occasion
Patient 2
 day 4 Gastrointestinal disorders Nausea Mild No Unrelated Single occasion
Patient 3
 day 20 Metabolism Dehydration Mild No Unrelated Single occasion
7.5 mg of sgm-101
Patient 4 
 day 1 Skin and subcutaneous disorders Rash Mild No Possible Intermittent
 day 5 Undetermined sirs Moderate No Unrelated Single occasion
 day 6 Vascular disorders Orthostatic- 
hypotension
Mild No Unrelated Intermittent
Patient 5
 day 6 Gastrointestinaldisorders Nausea Mild No Unrelated Single occasion
10 mg of sgm-101
Patient 7
 day 1 Nervous system disorders Headache Mild No Possible Single occasion
 day 4 Injury, poisoning, and procedural 
complications
Phlebitis Mild No Unrelated Intermittent
 day 6 Gastrointestinal disorders Nausea Mild No Unrelated Single occasion
Patient 8
 day 1 Gastrointestinal disorders Abdominal 
discomfort
Mild No Possible Intermittent




Mild No Unrelated Single occasion
Patient 9




Mild No Unrelated Single occasion
 day 8 Cardiac disorders Atrial-
fibrillation
Mild No Unrelated Single occasion
 day 9 Skin and subcutaneous disorders Decubitus 
ulcer
Mild No Unrelated Single occasion
 day 12 Infections Wound 
infection
Mild No Unrelated Single occasion
(continuation on next page)






 Men 5 (56%) 10 (59%)
 Women 4 (44%) 7 (41%)
Age, median (range) 69 (65 - 72) 62 (55 - 67)
Median preoperative concentration of serum cea (iqr;ng/mL) 4.0 (3.0 - 5.6) 4.3 (1.9 - 19.7)
Neoadjuvant therapy
 Yes 6 (67%) 14 (82%)
 No 3 (33%) 3 (18%)
Type of surgery
 Abdominoperineal resection 2 (22%) n/a
 Low anterior resection 4 (44%) n/a
 Sigmoid resection 2 (22%) n/a
 Hemicolectomy 1 (11%) n/a
Tumour recurrence locations 
 Anastomotic recurrence n/a 2 (12%)
 Lateral recurrence* n/a 3 (18%)
 Unifocal recurrence elsewhere** n/a 4 (24%)
 Multifocal recurrence in small pelvis n/a 4 (24%)
 Peritoneal recurrence n/a 4 (24%)
Method of surgery
 Open 4 (44%) 16 (94%)
 Laparoscopic 4 (44%) 0 
 Transanal inspection 1 (11%) 1 (6%)
Additional intraoperative therapy
 Liver resection 1 (11%) 0
 Intraoperative radiotherapy 0 10 (59%)
 Hyperthermic intraperitoneal chemotherapy 0 4 (24%)
Tumour stage
 T0 2 (22%) n/a
 T1 1 (11%) n/a
 T2 1 (11%) n/a
 T3 5 (56%) n/a
 T4 0 n/a
Nodal stage
 N0 5 (56%) n/a
 N1 2 (22%) n/a
 N2 2 (22%) n/a
Data are n (%), unless otherwise specified. cea = carcinoembryonic antigen; na = not applicable 
 * Tumours defined as a lateral recurrence were located in the obturator compartment or around the iliac vessels.  
** Tumours defined as a unifocal recurrence elsewhere in the abdomen were located near the duodenal curve,  
 between the bladder and prostate, in the rectovaginal septum or near the left iliopsoas muscle
i. introduction
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5.0 mg of sgm-101
Patient 1
   day 3 Injury, poisoning and procedural 
complications
Scratch Mild No Unrelated Single occasion
   day 5 Gastrointestinal  
disorders
Nausea Mild No Unrelated Intermittent
   day 6 Vascular disorders Scrotal  
haematoma
Mild No Unrelated Single occasion
   day 12 Gastrointestinal  
disorders
Paralytic ileus Moderate No Unrelated Single occasion
   day 15 Infections Urinary tract  
infection
Mild No Unrelated Single occasion
   day 23 Injury, poisoning and procedural 
complications
Renal injury Moderate Yes Unrelated Single occasion
7.5 mg of sgm-101
Patient 2
   day 5 General disorders and 
administration site conditions
Flank pain Mild No Unrelated Single occasion
10 mg of sgm-101
Patient 4
   day 6 Infections Urinary tract  
infection
Mild No Unrelated Single occasion
Patient 5
   day 28 Infections Pyelonephritis Moderate No Unrelated Single occasion
Patient 7
   day 1 Nervous system 
disorders
Headache Mild No Possible Single occasion
Patient 9
   day 7 Infections Urinary tract  
infection
Mild No Unrelated Single occasion
Patient 11
   day 8 Infections Pneumonia Moderate Yes Unrelated Single occasion
   day 19 Infections Abscess Moderate Yes Unrelated Single occasion
Patient 13




Mild No Possible Intermittent
   day 1 Vascular disorders Dizziness Mild No Possible Single occasion
   day 1 Gastrointestinal  
disorders
Nausea Mild No Possible Intermittent
Patient 14
   day 1 Nervous system 
disorders
Headache Mild No Possible Single occasion
SIRS = systemic inflammatory response syndrome
Table 3 Malignant lesions detected with use of fluorescence imaging 
Dose-escalation cohort In vivo fluorescence Ex vivo fluorescence 
 Primary tumours 4/7 (57%) 7/7 (100%)
 Metastases 4/7 (57%) 6/7 (86%)
Expansion cohort  
 All lesions 34/44 (77%) 43/44 (98%)
Data are n/n (%), for which n is the total number of resected lesions
chapter 2
part iv  
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Chapter 4 evaluates the use of near-infrared fluorescence guidance during lapa-
roscopic detection and resection of occult liver tumors of various cancer types. 
Recurrence-free survival after radical resection of both primary and secondary 
liver tumors is rather low, suggesting that small malignant lesions are missed dur-
ing surgical resection. We show that a variety of malignant liver tumors, such as 
cholangiocarcinoma, hepatocellular carcinoma and hepatic metastases of colorec-
tal- and breast cancer and uveal melanoma, can be detected intraoperatively using 
icg. Comparing sensitivity of all employed imaging techniques (ct, mri, inspec-
tion, laparoscopic ultrasound and fluorescence imaging), we show that fluorescence 
imaging has the highest sensitivity for detection of small subcapsular located lesions 
(92.3%). Three additional, otherwise undetected, malignant lesions were identified by 
intraoperative fluorescence guidance only. Importantly, deeper located lesions could 
all be detected with laparoscopic ultrasound. All malignant lesions could be detected 
with the combined use of fluorescence imaging and laparoscopic ultrasound. 
Part ii: Preclinical evaluation of tumor targets for 
fluorescence imaging
In Chapter 5 the expression of Folate Receptor α (frα) within biopsies, primary 
tumor specimens and metastases of lung and breast cancer is investigated. The frα 
is a molecular target that is widely investigated for imaging and therapeutic purposes 
due to its high expression in several tumor types. In 2011 the first clinical trial with a 
tumor-specific fluorescent contrast agent was described by van Dam et al. using a frα-
targeting agent for ovarian cancer detection. Following this pioneering work, applica-
tions for frα-targeted tumor detection are evaluated and investigated, among others 
for breast and lung cancer. In order to efficiently apply both frα-targeted therapeutic 
and imaging agents, adequate patient selection regarding frα expression is required. 
Moreover, information about concordance of frα expression between several tumor 
lesions of an individual patient is pivotal to estimate efficacy and usability of these 
approaches. This study describes that false positivity of frα expression on breast and 
lung cancer biopsies is limited to <5%, suggesting that biopsies can be reliably be used 
for patient selection. Moreover, high concordance rates of frα expression between 
primary tumors and corresponding metastases of both tumor types was shown. High 
frα expression was related with molecular subtypes of both cancers: in breast cancer, 
especially triple negative tumors show frα expression, while in lung cancer patients 
adenocarcinoma shows higher expression than squamous cell carcinoma. The provid-
ed results can be used for patient selection, eventually leading to optimal personalized 
medicine and tailored tumor detection using fluorescent or nuclear agents. 
summary
Near-infrared fluorescence imaging is a technique that can be used to selectively 
highlight certain structures during surgery. This includes structures that need to be 
spared (bile ducts, ureters) as well as structures that need to be resected (tumor tis-
sue, sentinel lymph nodes). During the last decades, indications for fluorescence-
guided surgery using the non-targeted fluorescent tracers icg and mb have been ex-
plored. Currently, the focus has shifted towards development and clinical testing of 
novel tumor-specific fluorescent tracers. Several first-in-human studies with tumor-
specific fluorescent tracers have shown promising results for selective tumor detec-
tion and resection. However, not all patients seem to benefit from this application. It 
is therefore of utmost importance to select vulnerable cancer patients prior to inclu-
sion in studies and exposure to potentially harmful tumor-specific tracers. 
This thesis first focuses on exploring indications of fluorescence guidance during 
hepato-pancreatico-biliary (hpb) surgery using icg. Subsequently, novel tumor-tar-
geted tracers are tested in preclinical studies and tailored tumor detection is evalu-
ated. Finally, clinical studies with novel tumor-targeted tracers are presented for de-
tection of colorectal- and endometrial cancer. 
Part I: Fluorescence-guided hepato-pancreato-biliary 
surgery using non-targeted dyes
In Chapter 2 a dose and time optimization study for fluorescence cholangiography 
is described. Literature reveals that over 1000 patients have been included in studies 
investigating fluorescence cholangiography during open, laparoscopic and robotic 
cholecystectomies. The vast majority of studies administrate a dose of 5 or 10mg icg 
thirty minutes prior to fluorescence cholangiography. Yet, the optimal dose of icg 
and timing of fluorescence imaging of bile ducts has never been properly investi-
gated. Optimal would be a high fluorescent signal in bile ducts, while liver tissue 
in the background stains dark. This study shows that a prolonged interval (at least 3 
hours) between icg injection and intraoperative fluorescence cholangiography re-
sults in the highest contrast ratio between liver and bile ducts. This information can 
be applied in future studies aiming to prove the added value of fluorescence cholan-
giography in a randomized clinical trial. 
Chapter 3 describes the application of icg during associating liver partition and 
portal vein ligation for staged hepatectomy (alpps). This study demonstrates that 
fluorescence-imaging during alpps can provide real-time tumor margin assess-
ment and can identify otherwise undetected tumor lesions. 
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Part iii: Clinical translation of tumor-targeted fluores-
cent tracers
In Chapter 9 the first clinical experience with a frα-targeting agent in endome-
trial cancer is described. Detection and resection of all malignant lesions is pivotal in 
staging and in cytoreductive surgery of endometrial and ovarian cancer. In patients 
with high-risk endometrial cancer, application of a frα-targeted imaging agent 
could be especially valuable, because of their relatively high likelihood of extra-uter-
ine disease. First, expression of frα was assessed in a tissue micro array (tma) study 
consisting of tissue derived from high-risk ec patients to select patients who may 
benefit most from this application. A significant association between frα and tumor 
type was seen, and 82% of serous and clear cell carcinomas showed frα expression. 
In the clinical feasibility study, these patients were therefore enrolled. All lymph 
node and omental metastases could be clearly identified using otl-38, but false-
positivity was noticed in 17/50 non-metastatic lymph nodes, caused by otl-38 tar-
geting of frβ, expressed by tumor-associated macrophages. The role of frβ there-
fore needs to be further investigated before widespread implementation of otl-38 
in endometrial cancer patients. 
Chapter 10 describes the clinical evaluation of a cea-targeted near-infrared 
fluorescent tracer for intraoperative detection of primary and recurrent colorectal 
cancer, as well as their metastases. In this first-in-human study the tolerability and 
feasibility of sgm-101, a cea-specific antibody conjugated to a fluorophore, is as-
sessed. The dose escalation study in patients with primary colorectal cancer showed 
that highest tumor-to-background signals were obtained when administering 10mg 
sgm-101 four days prior to surgery and that no treatment-related adverse events oc-
curred using this dose. In the expansion cohort, 17 patients suffering from recurrent 
or peritoneal metastases of crc were included. 19 of 43 malignant lesions were iden-
tified using fluorescence imaging and were not clinically suspect before fluorescent 
detection. These lesions were mostly detected in patients undergoing cytoreductive 
surgery (13 out of 19 lesions). Larger studies are needed to investigate whether the 
use of sgm-101 might influence radical resection rates and completeness of surgery, 
which should ultimately result in improved local control and overall survival. 
discussion and future perspectives 
Fluorescence-enhanced surgical navigation has emerged as a promising technique 
to diminish iatrogenic damage during surgery, decrease morbidity and, potential-
ly mortality rates. Although the technique exists for over twenty years, it is not yet 
Chapter 6 describes the preclinical validation of a novel Epithelial Cell Adhesion 
Molecule (Epcam) targeted antibody fragment (Epcam-F800) for fluorescence-
guided tumor detection. Epcam is considered as one of the most promising tu-
mor-specific proteins due to its high expression on epithelial-derived cancers. 
Epcam-F800 targets Epcam with high specificity in vitro, which was also validated 
using in vivo blocking experiments with a 10x higher dose of unlabeled Fab. The 
optimal dose range for fluorescence tumor detection in mice was 1-5 nmol, which 
corresponds to a human equivalent dose of 0.2-0.8 mg/kg. Breast and colorectal tu-
mors could be clearly visualized within 8h post injection and up to 96h, while the 
agent showed a homogeneous tumor distribution within 4h. Pharmacokinetic stud-
ies showed a blood half-life of 4.5h. Epcam-F800 is currently translated for clinical 
use and first-in-human studies are expected to start in the near future. 
In Chapter 7 the levels of carcino-embryonal antigen (cea) in preoperative 
serum is correlated with the expression of cea on pancreatic- and rectal cancer 
tissue. Early phase clinical trials investigating cea-targeted fluorescence tumor im-
aging are currently executed. It would be beneficial to select tumor patients with 
homogeneous cea expression prior to exposure to a fluorescent labeled cea-tar-
geted tracer. This study demonstrates that most rectal cancer tissues (32/35) show 
homogeneous cea expression, independent of serum cea levels. In a small subset of 
pancreatic cancer patients (n=20), a correlation between serum cea and expression 
in cancer tissue was found suggesting that selection of pancreatic cancer patients via 
serum cea appears adequate. 
In Chapter 8 we investigated the expression of several promising biomarkers for 
rectal cancer and compared their expression before and after neoadjuvant therapy. 
Preoperative biopsies, primary tumor specimens and lymph node metastases of 38 
rectal cancer patients who did not receive chemo-radiotherapy (crt) were compared 
with 34 patients who did. Immunohistochemical analysis of cea, Epcam and c-Met 
expression showed that all were highly expressed on tumor tissue compared with 
normal epithelium. Epcam showed the most homogeneous expression in tumors, 
while cea showed the highest tumor-to-normal ratio. Importantly, cea and Epcam 
expression did not significantly change after crt, whereas levels of c-Met did. These 
data underscore the applicability of c-Met, and especially cea and Epcam as targets 
for fluorescence-guided rectal cancer surgery both before and after crt. 
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Recently the mimic trial has been initiated (Minimally invasive Indocyanin-guided 
Metastasectomy in patients with Colorectal liver metastases), a prospective multi-
center study, aiming to show improved demarcation and hence, higher radical resec-
tion rates using fluorescence-enhanced surgical navigation. Potential other applica-
tions of icg-guided liver tumor detection can be its use during laparoscopic staging 
procedures, for example to identify resectability of pancreatic cancers by identifi-
cation of occult liver metastases9. Important limitations of icg-guided liver tumor 
detection are inherent to the imaging technique. Only subcapsular tumors of maxi-
mally 8mm below the liver surface can be detected and it is therefore recommended 
to consider fluorescence imaging as complementary technique to laparoscopic ul-
trasound (this thesis). A possibly other imaging technique to identify more deeply 
located lesions is intraoperative photo-acoustic tomography, which combines the 
specific uptake of icg with enhanced depth penetration10. This technique appears 
promising. Yet, there need to be technical advancements before it can be used in 
clinical practice. 
A new era in the field of fluorescence-guided oncologic surgery has begun with 
the first clinical study in 2011 of van Dam et al. using a tumor-targeted fluorescent 
agent11. Selection of tumor targets for imaging purposes depends on various charac-
teristics such as (I) the upregulation of the biomarker on malignant cells compared 
to normal cells (ii) localization on the cell membrane (iii) actual number of targeted 
proteins available per cell (iv) percentage and distribution of expressing cells within 
a tumor12. In the past decades, various promising tumor targets have been evalu-
ated for fluorescence-guided tumor detection in preclinical studies of whom some 
have entered clinical trials. Examples are Folate Receptor-α (frα)11,13, Carcino-
Embryonal Antigen (cea)14, Epidermal Growth Factor Receptor (egfr)15 and 
Vascular Endothelial Growth Factor (vegf)16. Most of the tracers tested in clinical 
studies nowadays target membrane-bound proteins on malignant cells. Yet, future 
studies are awaited for showing the results of tracers that target not only malignant 
cells but also tumor-associated tissue at the invasive border of a tumor, e.g. stromal 
tissue. An example is crgd-zw800-1, a fluorescent labeled peptide that targets in-
tegrins associated with neo-angiogenesis. Preclinical evaluation has demonstrated 
real-time detection of multiple tumor types using crgd-zw800-117. Other promis-
ing tracers targeting stromal tissue are cathepsin E, matrix metalloproteinases and 
upar18,19. 
Apart from the variety of targeted tumor molecules, there is also a wide variety of 
tumor-targeting ligands, e.g. peptides, antibodies, antibody fragments, nanobodies 
etc. Each targeting ligand has different properties and characteristics. Antibodies 
are believed to possess superior binding characteristics compared to smaller mol-
ecules, but their relatively large size (~150kDa) might result in heterogeneous tumor 
routine use in daily surgical practice. The question rises what pivotal steps are needed 
to move this field forward1. Obviously, safety risks of fluorescent agents should be 
elucidated and potential benefits over existing practices should be demonstrated. 
The widely used non-targeted fluorescent dye indocyanine green (icg) has an excel-
lent safety profile2. As described in this thesis, fluorescence cholangiography using 
icg could theoretically prevent bile duct injury by highlighting the bile ducts dur-
ing open, laparoscopic or robotic cholecystectomy. Prevention of bile duct injury 
is however a very difficult endpoint that requires huge amount of patients due its 
low incidence of 0.18-1.5%3. In an attempt to show the added value of fluorescence 
cholangiography, alternative endpoints are used in three randomized studies that 
are currently executed4. For example, the falcon trial (clinicaltrials.gov number 
nct02558556) evaluates the time to identification of the critical view of safety with 
and without use of icg and, as secondary endpoint, prevention of bile duct injury. 
The added value of fluorescence imaging during oncologic hepatic surgery is 
twofold: it can detect additional, otherwise undetected small tumors and it can pro-
vide real-time tumor margin assessment. Studies show that application of icg re-
sults in detection of additional tumor lesions (this thesis,5,6). These results are prom-
ising, but the question rises whether detection of these (mostly small) subcapsular 
malignancies influence the oncological outcome. When additional tumors are iden-
tified, these can be indicative of otherwise undetectable widespread metastases of 
the liver, or they can in fact cure the patient when resected. To answer this question, 
a retrospective case-control study was performed comparing long-term follow up 
after near-infrared (nir) fluorescence-guided resection of colorectal liver metastases 
(crlm) using icg (n=86) vs. normal resection of crlm (n=87). Use of nir fluores-
cence guidance during surgical resection resulted in identification of significantly 
more tumors than the control cohort (25% vs 13%, p=0.04), as well as smaller tumors 
than compared with inspection, palpation or intraoperative ultrasound (3.2±1.8mm 
vs 7.4±2.6mm, p<0.001). Separate analysis of the patients in whom additional metas-
tases were found by nir fluorescence imaging revealed that no liver recurrences oc-
curred in 52% of patients within 3 years follow-up. Possibly, use of nir fluorescence 
guidance has resulted in prevention of a recurrence in these patients. But, analysis 
of both cohorts showed that no significant changes in liver-specific recurrence-free 
survival, nor overall survival between were found. This is (most likely) the result of 
the study design; a study powered to show a significant difference of 7% would re-
quire a total of >1500 patients7. Prospective, larger multicenter studies should dem-
onstrate the value of icg-guided tumor detection and demarcation over the con-
ventional techniques. Importantly, future study designs should take into account 
current advances in preoperative imaging modalities, such as gadoxetic acid-en-
hanced mr imaging, leading to improved sensitivity for small sized tumor lesions8. 
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(700-900nm) into the so-called nir-ii optical window (1000-1700nm)25. Using 
light in the nir-ii spectrum enables imaging of structures at centimeters depth due 
to reduced tissue scattering in the nir-ii spectrum26. 
The underlying principle of tumor targeting, combined with fluorescence imag-
ing for tumor visualization can also be applied for therapeutic purposes and poten-
tially, evaluation of therapeutic response. Tumor-targeted photodynamic therapy is 
a promising technique that induces cell death through light activation of a photo-
sensitizer27. Briefly, this technique requires a tumor-targeting ligand, conjugated to 
a fluorescent photosensitizer. After accumulation of the ligand in the tumor-target 
(for example an egfr targeting nanobody) the tumor can be visualized using fluo-
rescence imaging. Subsequently tumor margins can be locally illuminated leading 
to pronounced tumor necrosis and infiltration of immune cells28. The therapeutic 
response can then be evaluated administering a fluorescent probe that targets tumor 
cell death, e.g. hq4-dtpa, which has been recently described by Stammes et al29. 
The proof of principle of intraoperative fluorescence tumor detection has now 
been demonstrated for several tumor-specific fluorescent contrast agents in ovarian 
cancer11,13, lung cancer30, breast cancer31, head-and-neck cancer15, esophageal can-
cer16, pancreatic cancer14 and colorectal cancer patients32. Although all studies show 
promising results, it is important that results are critically evaluated before wide-
spread implementation and/or testing in phase ii/iii studies. Diagnostic accuracy, 
the number of false positive lesions and even more important, false negative tumor 
lesions need to be properly investigated before moving on. This is underscored by 
the increasing interest in the field of fluorescence-guided pathology and elucidated 
by a recently described analytical framework for assessment of tracer uptake at re-
section borders on both a macroscopic and microscopic level33. 
As described in this thesis, application of sgm-101 led to detection of additional 
tumor tissue that resulted in one-third of these patients in a change of treatment 
plan. Obviously, large clinical studies are needed to confirm this finding and to as-
sess whether the changes in the surgical procedure might influence radical resection 
rates and completeness of cytoreductive surgery. Ultimately this should result in im-
proved local control and overall survival.
Clearly, not all tumors are amenable for application of fluorescence-guided sur-
gery18. Solid tumors with high rates of positive resection margins as well as small 
tumor deposits that are easily missed by the naked eye are useful indications for this 
technique. The added value of tumor specific imaging during cytoreductive surgery 
(crs) has been demonstrated in this thesis for colorectal cancer and in other stud-
ies for ovarian cancer11,13. For both indications, literature suggests that the com-
pleteness of crs is one of the most important prognostic factors for survival34,35.
distribution, complex pharmacokinetics, and long imaging lead-times (up to 72 
h)20. Antibody fragments (Fab fragments) are three times smaller and show more 
homogeneous tumor penetration. Moreover, they display shorter half-life times, a 
decreased immunotoxicity potential while they are large enough to maintain high 
plasma levels for optimal (tumor) distribution21,22. Although smaller vehicles like 
nanobodies or peptides may result in even better pharmacokinetic properties (e.g. 
faster clearance)13, they can have lower stability and affinity than antibodies/Fab and 
more compromised by conjugation.
The idea that one target can be used for detection of all malignant cells in one 
tumor and in one patient appears too optimistic. It is therefore pivotal to under-
stand the tumor landscape before exposing vulnerable cancer patients to (potentially 
harmful) novel agents in first-in-human studies. Different manners are performed 
to select patients and tumor tissue, such as analyzing biomarker expression on bi-
opsy specimens or in preoperative obtained serum (this thesis). The work-up also in-
cludes determination of the effect of neoadjuvant therapy on biomarker expression, 
as well as the differences in biomarker expression between biopsies, local and distant 
metastases of tumors (this thesis). Current preclinical research focuses on address-
ing the difficulty of tumor heterogeneity. Combining multiple targets within one 
compound (bi-specific) may be a solution. Studies show that a so-called bi-para-
topic target, e.g. an agent that targets two different epitopes on a biomarker, show 
considerably high specificity and sensitivity23. Another way to address this problem 
is to simultaneously administer different fluorescent agents that fluoresce at various 
wavelengths. For example to combine administration of icg (fluorescent at 700nm) 
and sgm-101 (fluorescent at 700nm) for detection of crlm. Or, maybe even more 
interesting, combine the administration of a tumor-specific agent that targets mem-
brane-bound malignant cells with the administration of an agent that targets stro-
mal tissue at the invasive border. 
One of the most important limitations of the technique of fluorescence-guid-
ed surgery is the limited depth penetration of nir light of approximately 10mm. 
Tumor-specific multimodal imaging could overcome this issue. By conjugating a 
tumor-specific ligand with both a nuclear and fluorescent label, the location of the 
tumor can be preoperatively determined using spect/ct or pet imaging and in-
traoperatively by fluorescence and in case of a spect tracer, by a handheld Geiger 
counter. Proof-of-principle of this technique has been recently demonstrated by 
Hekman et al. showing clear pre- and intraoperative detection of renal cell carci-
noma using an 111Indium and fluorescent labeled antibody targeting carbonic anhy-
drase (111In-dota-girentuximAb-irdye800cw)24. Another potential resolution for 
the limited depth penetration of nir light is the extension beyond the nir window 
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Only recently, Quenet et al. announced the first results of the randomized phase iii 
Prodige 7 trial, investigating the added benefit on survival of hyperthermic intraper-
itoneal chemoperfusion (hipec) to complete debulking, i.e. cytoreductive surgery, in 
patients with stage iv colorectal cancer36. Surprisingly, median overall survival was 
not different between patients treated by crs + hipec and patients treated by crs 
alone (respectively 41.7 vs 41.2 months respectively). Importantly, the 60-day mortal-
ity rate was nearly double in the hipec + crs patient group compared with the crs 
group alone (24.1% vs. 13.6%). These results emphasize the potential importance of 
detection and resection of (often small sized) tumor lesions during crs and the po-
tential role of fluorescence guidance. Novel indications for fluorescence-enhanced 
tumor navigation also arise at the horizon. For example, application of rectal cancer 
detection during transanal endoscopic microsurgery or detection of residual/recur-
rent tumor tissue during surveillance colonoscopy of patients with a complete clini-
cal response after neoadjuvant therapy37. Response evaluation of neoadjuvant thera-
py is another promising application for multimodal tracers, for example in breast- or 
esophageal cancer. 
Along with the increase of the number of clinically available fluorescent agents, 
numerous fluorescence imaging systems have been developed and are now clinically 
used38. The increasing number of clinical studies, and more importantly, multicenter 
studies, require standards for quantification of the performance of clinically avail-
able imaging systems. Not all imaging systems share similar sensitivity (eg detection 
limits), which clearly hampers proper comparison between different centers and also 
progress of the research field. The Food and Drug Administration (fda) and European 
Medicines Agency (ema) have therefore expressed their preference that fluorescent 
tracers with imaging systems should be submitted as one package before market au-
thorization39. A resolution can be to use phantoms40 or other performance tests like 
described by our research group to compare sensitivity between imaging systems41. 
In conclusion, fluorescence-enhanced surgical navigation can revolutionize current 
surgical standards by highlighting structures during surgery and hence decrease iatro-
genic damage and morbidity. The indications for icg-guided surgery are still expand-
ing, although the true added value is awaited from its application in large multicenter 
studies. Since the first clinical study with a tumor-targeted tracer, the research field 
really moved forward. Various tumor-targeted tracers already showed promising find-
ings, resulting in detection and resection of otherwise undetected tumor tissue. Focus 
should now further be pointed to more intensive collaboration between fluorescence-
guided research groups, standardization of the procedure and quality assurance.
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Hoofdstuk 3 beschrijft de toepassing van ICG tijdens associating liver partition and 
portal vein ligation for staged hepatectomy (ALPPS). Deze studie toont aan dat het 
gebruik van fluorescentiebeeldvorming tijdens ALPPS kan helpen in identificatie van 
tumorbegrenzing en van anderszins niet-gedetecteerde (kleine) tumoren. 
Hoofdstuk 4 evalueert het gebruik van nabij-infrarode (NIR) fluorescentiebeeld-
vorming tijdens laparoscopische detectie en resectie van occulte levertumoren. De 
recidief-vrije overleving na radicale resectie van zowel primaire als secundaire lever-
tumoren is relatief kort wat suggereert dat kleine maligne tumoren worden gemist 
ten tijde van operatie. Deze studie toont dat verschillende maligne levertumoren, 
zoals cholangiocarcinoom, hepatocellulair carcinoom en metastasen van colorectaal 
carcinoom, mamma carcinoom en oogmelanoom, gedurende de operatie gedetec-
teerd kunnen worden met behulp van ICG. Fluorescentiebeeldvorming heeft, verge-
leken met alle andere gebruikte beeldvormende technieken zoals CT, MRI, inspectie 
en laparoscopische echografie, de hoogste sensitiviteit voor detectie van kleine sub-
capsulaire tumoren (92.3%). Drie additionele tumoren werden alleen gedetecteerd 
met behulp van fluorescentiebeeldvorming. Alle maligniteiten konden gedetecteerd 
worden door het gecombineerde gebruik van fluorescentiebeeldvorming en laparo-
scopische echografie. Deze bevinding suggereert dat beeldvorming tijdens de opera-
tie kan bijdragen aan een meer radicale verwijdering van maligne laesies in de lever.
Deel II: Preklinische evaluatie van tumor-specifieke 
fluorescente contraststoffen
In hoofdstuk 5 wordt de expressie van Folaat Receptor α (FRα) onderzocht in biop-
ten, primair tumorweefsel en metastasen van mamma- en longcarcinoom. FRα is 
een molecuul dat veelvuldig wordt onderzocht voor beeldvormende- en therapeuti-
sche doeleinden vanwege de hoge expressie op verschillende tumoren.  In 2011 werd 
door van Dam et al. de eerste klinische studie beschreven met een tumor-specifieke 
fluorescente stof (een fluorescente stof aangrijpend op FRα) voor detectie van ovari-
umcarcinoom. Vervolgens zijn andere toepassingen voor FRα-doelgerichte tumor-
detectie geëvalueerd en onderzocht, onder andere in mamma- en longcarcinoom. 
Om zo efficiënt mogelijk zowel FRα-doelgerichte therapeutische als beeldvormende 
stoffen toe te passen, is adequate selectie van patiënten met betrekking tot FRα ex-
pressie nodig. Bovendien is informatie over de correlatie van FRα expressie tussen 
verschillende tumorweefsels van een individuele patiënt noodzakelijk om effecti-
viteit en bruikbaarheid van een stof aan te kunnen tonen. Deze studie beschrijft dat 
vals-positiviteit van FRα expressie op mamma- en longcarcinoom biopten beperkt 
is tot <5%. Dit suggereert dat biopten betrouwbaar kunnen worden gebruikt voor 
Nabij-infrarode (NIR) fluorescentiebeeldvorming is een techniek die gebruikt kan 
worden om op een selectieve en specifieke manier anatomische structuren tijdens 
operatie op te laten lichten. Dit kunnen structuren zijn die gespaard moeten worden 
(galwegen, ureteren) of structuren die gereseceerd (tumoren, schildwachtklieren) 
dienen te worden. De afgelopen decennia zijn de indicaties voor fluorescentie-gelei-
de chirurgie met behulp van de niet-tumor specifieke fluorescente stoffen indocya-
nine groen (ICG) en methyleen blauw (MB) uitgebreid onderzocht. Momenteel ver-
schuift de aandacht in toenemende mate  naar de ontwikkeling en het klinisch tes-
ten van tumor-specifieke fluorescente stoffen. Verscheidene first-in-human studies 
met tumor-specifieke fluorescente stoffen tonen hoopvolle resultaten voor selectieve 
tumor detectie. Echter, niet alle patiënten lijken baat te hebben bij deze toepassing. 
Het is daarom belangrijk om voorafgaand aan deelname in deze studies kwetsbare 
oncologische patiënten te selecteren om onnodige blootstelling aan potentieel scha-
delijke stoffen te voorkomen. 
In dit proefschrift worden allereerst indicaties voor fluorescentiebeeldvorming 
met behulp van ICG onderzocht binnen de hepato-pancreatico-biliaire (HPB) chi-
rurgie. Vervolgens wordt een aantal preklinische onderzoeken beschreven waar-
in tumor-specifieke fluorescente stoffen worden onderzocht en gepersonaliseerde 
tumordetectie wordt geëvalueerd. Tenslotte worden klinische studies beschreven 
waarin nieuwe tumor-specifieke fluorescente stoffen zijn onderzocht voor detectie 
van colorectaal- en endometrium carcinoom. 
Deel I: Fluorescentie-geleide hepato-pancreatico-
biliaire chirurgie met behulp van niet-specifieke 
fluorescente stoffen
In hoofdstuk 2 wordt een onderzoek beschreven waarin de optimale dosis en de 
optimale tijd tussen toediening van ICG en fluorescentie cholangiografie wordt on-
derzocht. In de huidige literatuur is beschreven dat er meer dan 1000 patiënten zijn 
geïncludeerd in studies naar fluorescentie cholangiografie tijdens open, laparoscopi-
sche en robot cholecystectomie. De grote meerderheid van deze studies gebruikt een 
dosis van 5 of 10 mg ICG 30 min voorafgaand aan fluorescentie cholangiografie. De 
rationale voor de dosis en het tijdsinterval zijn nog niet onderzocht. In de optimale 
situatie zouden de galwegen een intens fluorescent signaal bevatten, terwijl de lever 
(achtergrond) donker zou zijn. De huidige studie toont dat een verlengd interval 
(ten minste 3 uur) tussen ICG toediening en intraoperatieve fluorescentie cholangio-
grafie resulteert in de hoogste contrast ratio tussen lever en galwegen. Deze infor-
matie kan worden toegepast in toekomstige gerandomiseerde studies die de meer-
waarde van deze techniek moeten aantonen. 
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pasbaarheid van c-Met, en vooral van CEA en EpCAM, als targets voor fluorescentie- 
geleide rectumchirurgie, zowel voor als na neoadjuvante chemoradiatie. 
Deel III: klinische translatie van tumor-specifieke 
fluorescente stoffen
Hoofdstuk 9 beschrijft de eerste klinische studie met een FRα-specifieke stof voor 
detectie van endometriumcarcinoom. Een cruciale stap in stagerings- en cytoreduc-
tieve chirurgie bij patiënten met endometrium- en ovarium carcinoom is de detectie 
en resectie van alle maligne tumoren. Met name in patiënten met een hoog-risico en-
dometriumcarcinoom kan toepassing van een tumor-specifieke fluorescente stof van 
toegevoegde waarde zijn, aangezien zij relatief veel kans hebben op extra-uteriene 
ziekte. In de huidige studie werd allereerst expressie van FRα onderzocht in een tissue 
microarray (TMA) met weefsel van patiënten met hoog-risico endometriumcarci-
noom. Een significante associatie tussen FRα en tumor type werd gezien; 82% van se-
reus en heldercellig carcinoom toonde FRα expressie. In de klinische haalbaarheids-
studie werden vervolgens patiënten met deze tumor karakteristieken geïncludeerd. 
Alle lymfklier en omentale metastasen konden peroperatief worden geïdentificeerd 
met behulp van OTL-38 (een fluorescente stof aangrijpend op FRα). Echter, er werd 
ook een fluorescent signaal gezien in 17/50 lymfklieren die geen metastasen bevatten. 
Dit bleek te worden veroorzaakt door OTL-38 targeting van FRβ; deze receptor wordt 
tot expressie gebracht door tumor-geassocieerde macrofagen. De rol van FRβ dient 
daarom eerst verder te worden onderzocht voorafgaand aan brede implementatie 
van OTL-38 tijdens chirurgie van patiënten met een endometriumcarcinoom. 
Hoofdstuk 10  beschrijft de klinische evaluatie van een CEA-specifiek fluores-
cent antilichaam voor intraoperatieve detectie van primair-, recidief- en metastasen 
van colorectaal carcinoom. In deze first-in-human studie is de tolerabiliteit en haal-
baarheid van SGM-101, een CEA-specifiek fluorescent antilichaam, onderzocht. De 
dosis-escalatie studie in patiënten met primair colorectaal carcinoom toonde dat de 
hoogste tumor-tot-normaal ratio werd behaald na toediening van 10 mg SGM-101 
vier dagen voorafgaand aan operatie, en dat hierbij geen treatment-related adverse 
events (TRAE) optraden. In het tweede cohort werden 17 patiënten geïncludeerd met 
recidief of peritoneaal metastasen van colorectaal carcinoom. Negentien van de 43 
maligne tumoren, die niet klinisch verdacht waren voorafgaand aan fluorescente de-
tectie, werden eerst gedetecteerd met behulp van fluorescentiebeeldvorming. Deze 
tumoren waren vooral aanwezig in patiënten die cytoreductieve chirurgie ondergin-
gen (13 van de 19 tumoren). Onderzoeken met grotere aantallen patiënten zijn nodig 
om te onderzoeken of het gebruik van SGM-101 kan leiden tot toename van het aan-
tal radicale resecties, wat uiteindelijk kan resulteren in verbeterde lokale controle en 
algehele overleving.
patiënt selectie.  Er werd eveneens een hoge correlatie aangetoond van FRα expres-
sie tussen primaire tumoren en overeenkomende metastasen van beide tumortypes. 
Hoge FRα expressie bleek gecorreleerd aan moleculair subtype: in mammacarci-
noom bleken met name triple negatieve tumoren FRα expressie te tonen, terwijl in 
niet-kleincellig longcarcinoom adenocarcinoom een hogere expressie toonde dan 
plaveiselcelcarcinoom. 
Hoofstuk 6 beschrijft de preklinische validatie van een nieuw Epithelial Cell 
Adhesion Molecule (EpCAM)-gericht antilichaam fragment (EpCAM-F800) voor 
fluorescentie-geleide tumordetectie. EpCAM wordt beschouwd als een van de meest 
veelbelovende tumor-specifieke eiwitten door de hoge expressie in epitheliale tu-
moren. EpCAM-F800 bindt aan EpCAM met hoge specificiteit in vitro, wat ook werd 
bevestigd door in vivo blocking experimenten met een 10x hogere dosering van onge-
labeld antilichaam fragment. De optimale dosering voor fluorescente tumordetectie 
in muizen lag tussen 1-5 nmol, wat correspondeert met een humaan equivalente dosis 
van 0.2-0.8 mg/kg. Mamma- en colorectale tumoren konden duidelijk worden gevi-
sualiseerd binnen 8u en tot 96u na injectie van EpCAM-F800, terwijl de stof al een ho-
mogene tumordistributie toonde binnen 4u. Farmacokinetische studies toonden een 
halfwaarde tijd in bloed van 4.5h. Momenteel wordt EpCAM-F800 gereed gemaakt 
voor klinisch gebruik en first-in-human studies zullen binnenkort van start gaan.
In hoofdstuk 7 wordt de waarde van carcino-embryonaal antigen (CEA) in 
preoperatief serum vergeleken met expressie van CEA op pancreas- en rectumcar-
cinoom weefsel. Het zou gunstig zijn om oncologische patiënten met homogene 
CEA expressie voorafgaand aan inclusie met een fluorescent anti-CEA antilichaam 
te kunnen selecteren op basis van serum CEA. Deze studie toont dat de grote meer-
derheid van de rectumcarcinoom weefsels (32/35) homogene CEA expressie toont, 
onafhankelijk van serum CEA waarde. In een kleine groep van pancreascarcinoom 
patiënten (n=20) werd een correlatie gevonden tussen serum CEA en expressie op 
carcinoom weefsel, wat suggereert dat patiënt selectie voor deze ziekte via serum 
CEA wel adequaat zou zijn. 
In hoofdstuk 8 wordt de expressie van een aantal biomarkers voor rectumcarci-
noom onderzocht waarbij ook de invloed van neoadjuvante therapie op deze expres-
sie werd geëvalueerd. Preoperatieve biopten, primair tumorweefsel en lymfklierme-
tastasen van 38 patiënten die geen neoadjuvante chemoradiatie ondergingen werden 
vergeleken met weefsels van 34 patiënten die dit wel ondergingen. Immunohistoche-
mische analyse van CEA, EpCAM en c-Met expressie toonde dat allen tot overexpres-
sie kwamen op tumorweefsel ten opzichte van normaal epitheel. EpCAM toonde de 
meest homogene expressie in tumoren, terwijl CEA de hoogste tumor-tot-normaal 
ratio toonde. CEA en EpCAM expressie veranderde niet significant na neoadjuvante 
therapie, terwijl dit wel het geval was voor c-Met. Deze data benadrukken de toe-
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